<SEC-DOCUMENT>0001144204-19-014455.txt : 20190318
<SEC-HEADER>0001144204-19-014455.hdr.sgml : 20190318
<ACCEPTANCE-DATETIME>20190318072017
ACCESSION NUMBER:		0001144204-19-014455
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20190318
DATE AS OF CHANGE:		20190318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		19686803

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q/A
<SEQUENCE>1
<FILENAME>tv515433_10qa.htm
<DESCRIPTION>10-Q/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM
10-Q/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>For the quarterly period ended September 30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PROTALIX
BIOTHERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><B><U>Delaware</U></B></TD>
    <TD STYLE="width: 50%; text-align: center"><B><U>65-0643773</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>of incorporation or organization)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S. Employer</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>2 Snunit Street</B><BR>
<B>Science Park</B><BR>
<B>POB 455</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B><U>Carmiel, Israel</U></B></TD>
    <TD STYLE="text-align: center"><B><U>20100</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Large accelerated filer</P></TD>
    <TD STYLE="width: 5%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 5%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Emerging growth company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On November 1, 2018, approximately 148,374,921
shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms &ldquo;we,&rdquo;
 &ldquo;us,&rdquo; &ldquo;our&rdquo; and &ldquo;the Company&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Explanatory Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment No. 1 to Form 10-Q, or this Amendment, amends
the Quarterly Report on Form 10-Q for the quarterly period ended September&nbsp;30, 2018 we originally filed with the Securities
and Exchange Commission, or the Commission, on November&nbsp;7, 2018, or the Original Filing, in connection with the recognition in this Amendment of revenues from  license agreements that were not
recognized previously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All amendments and restatements to the financial statements
are non-cash in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Restatement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As further discussed in Note 1 to our unaudited condensed consolidated
financial statements in Part I, Item 1, &ldquo;Financial Statements&rdquo; of this Amendment, on March 14, 2019, we concluded that
we would restate our previously issued consolidated financial statements as of and for the three and nine months ended September&nbsp;30,
2018, as set forth in the Original Filing in connection with the recognition in this Amendment of revenues from license agreements
that were not recognized previously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management has reassessed its evaluation of the effectiveness
of the design and operation of its disclosure controls and procedures as of September&nbsp;30, 2018. As a result of that reassessment,
management has concluded that we did not maintain effective disclosure controls and procedures due to the material weakness in
internal control over financial reporting which existed at that date. For a description of the material weakness in internal control
over financial reporting and actions taken, and to be taken, to address the material weakness, see Part 1, Item 4 &ldquo;Controls
and Procedures&rdquo; of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purpose of this Amendment is to restate our previously issued
unaudited condensed consolidated financial statements and related disclosures as of and for the three and nine months ended September&nbsp;30,
2018 in connection with the recognition in this Amendment of revenues from  license agreements that were not
recognized previously. This Amendment also includes (a) an amended Part I, Item 2 &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; to reflect the correction of the errors described above, and (b) an amended Part I,
Item 4 &ldquo;Controls and Procedures&rdquo; to restate the conclusion on the effectiveness of disclosure controls and procedures.
Disclosure controls and procedures were deemed effective in the Original Filing on November&nbsp;7, 2018 and are deemed ineffective
as a result of the material weakness described in Part I, Item 4 &ldquo;Controls and Procedures&rdquo; of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as expressly set forth herein, including in
the notes to the consolidated financial statements, this Amendment does not reflect events occurring after the date of
the Original Filing or modify or update any of the other disclosures contained therein in any way other than as required
to reflect the amendment discussed above. Accordingly, this Amendment should be read in conjunction with the Original Filing
and our other filings with the Commission. Information not affected by the restatement is unchanged and reflects disclosures
made at the time of the filling of the Original Filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Items Amended in this Filing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For reasons discussed above, we are filing this Amendment in
order to amend the following items in our Original Filing to the extent necessary to reflect the adjustments discussed above and
make corresponding revisions to our financial data cited elsewhere in this Amendment in connection with the recognition in this Amendment of revenues from  license agreements that were not
recognized previously:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Part I, Item 1. Financial Statements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Part I, Item 2. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Part I, Item 4. Controls and Procedures</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with applicable Commission rules, this Amendment
includes new certifications required by Rule 13a-14 under the Securities Exchange Act of 1934, as amended, or the Exchange Act,
from our Chief Executive Officer and Chief Financial Officer dated as of the date of filing of this Amendment.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 83%">&nbsp;</TD>
    <TD STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_001"><B>PART I &ndash; FINANCIAL INFORMATION</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><A HREF="#a_002"><B>Cautionary Statement Regarding Forward-Looking Statements</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center"><A HREF="#a_002">iii</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003">Item&nbsp;1.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_003">Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_004">Condensed Consolidated Balance Sheets &ndash; As of September 30, 2018 (as
restated) (Unaudited) and December 31, 2017</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_004">1</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_005">Condensed Consolidated Statements of Operations (Unaudited) &ndash;&nbsp;For the Nine and Three Months Ended September 30, 2018 (as
restated) and 2017</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_005">2</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_006">Condensed Consolidated Statements of Changes in Capital Deficiency (Unaudited) &ndash;&nbsp;For the Nine Months Ended September 30, 2018 (as
restated) and 2017</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_006">3</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_007">Condensed Consolidated Statements of Cash Flows (Unaudited) &ndash;&nbsp;For the Nine Months Ended September 30, 2018 (as
restated) and 2017</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_007">4</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.375in; text-indent: -0.125in"><A HREF="#a_008">Notes to Condensed Consolidated Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_008">6</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009">Item&nbsp;2.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_009">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_009">14</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010">Item 3.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_010">20</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011">Item&nbsp;4.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_011">Controls and Procedures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_011">21</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#a_012"><B>PART II &ndash; OTHER INFORMATION</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_013">Item&nbsp;1.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_013">Legal Proceedings</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_013">23</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_014">Item&nbsp;1A.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_014">Risk Factors</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_014">23</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_015">Item&nbsp;2.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_015">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_015">23</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_016">Item&nbsp;3.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_016">Defaults Upon Senior Securities</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_016">23</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_017">Item&nbsp;4.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_017">Mine Safety Disclosures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_017">23</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_018">Item&nbsp;5.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_018">Other Information</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_018">23</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_019">Item&nbsp;6.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#a_019">Exhibits</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_019">23</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_020">Signatures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center"><A HREF="#a_020">26</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the caption &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; and other statements included elsewhere in this
Quarterly Report on Form&nbsp;10-Q, which are not historical, constitute &ldquo;forward-looking statements&rdquo; within the meanings
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, including statements regarding expectations,
beliefs, intentions or strategies for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo;
 &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases of similar import, as they relate to the Company or our management,
are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor
provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect
our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation
to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances
after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under
applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several
factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues;
lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards
to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient
funding to finance our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the results of our clinical trials will not support the applicable claims of superiority, safety or efficacy
and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to manage our relationship with Chiesi Farmaceutici S.p.A., or Chiesi, and any other collaborator,
distributor or partner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance or satisfy
conversions of our outstanding convertible notes or any other indebtedness;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to the compliance by Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health,
or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material
adverse effect on us and may also result in the termination of such agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial
services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our activities and research programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in preparing and filing applications for regulatory approval of our product candidates in the United States, the European
Union and elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, one or more of our product candidate may become be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our supply of drug product to Pfizer Inc., or Pfizer, pursuant to our amended and restated exclusive license
and supply agreement with Pfizer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in Brazil;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third-party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property
rights against third-parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application
filed by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to numerous risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under
the heading <FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>
in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, and are described from time to time in the reports
we file with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_003"></A>Item&nbsp;1. Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)<BR>
 &nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>(Unaudited)<BR> (as restated)</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-size: 1pt; border-bottom: Black 1pt solid"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">41,868</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">51,163</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts receivable &ndash; Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,934</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt; padding-bottom: 1pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7,959</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7,833</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,651</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,887</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">65,747</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.35in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,521</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.35in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Contracts liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; padding-bottom: 1pt">Convertible notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">5,921</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,337</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">47,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">46,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Contracts liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,493</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,386</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,586</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Other long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,154</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,051</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,353</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,919</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">101,671</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 45pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">CAPITAL DEFICIENCY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(47,943</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,457</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.35in">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">65,747</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">72,214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="a_005"></A>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except per share data) </FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018<BR> (as restated)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018<BR> (as restated)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font-weight: bold; text-align: left">REVENUES FROM SELLING GOODS</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">7,222</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">16,773</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">663</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">7,526</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">REVENUES FROM LICENSE AND R&amp;D SERVICES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">16,665</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">11,672</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF GOODS SOLD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,024</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,917</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,066</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,565</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,389</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,803</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,118</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Less &ndash; grants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,810</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,545</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">732</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">729</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(23,755</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(19,844</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(10,071</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(6,389</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,744</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,187</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,088</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,836</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(15,636</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(24,935</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(3,741</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(7,765</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">FINANCIAL EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,824</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,809</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,811</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,680</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">FINANCIAL INCOME</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">437</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,670</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,387</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(45,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(21,023</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(70,135</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,322</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,437</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">NET LOSS PER SHARE OF COMMON STOCK BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.55</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">WEIGHTED
    AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE &ndash; BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">146,752,355</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">128,223,722</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">148,187,513</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">132,549,001</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in; padding-bottom: 1pt">(1) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">54</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">163</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">14</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">43</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">(2) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CHANGES IN </B><BR>
<B>CAPITAL DEFICIENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid&ndash;In</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance at December 31, 2016</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">124,134,085</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">124</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">202,575</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(212,656</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(9,957</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Changes during the nine-month period ended September 30, 2017:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">291</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">291</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Reclassification of embedded derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,634</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Convertible notes conversions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,711,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,771</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,781</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Conversion component related to convertible notes issuance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,315</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,135</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,135</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance at September 30, 2017</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">133,845,320</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">134</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">256,586</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(282,791</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(26,071</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance at December 31, 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">143,728,797</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">144</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">266,495</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(296,096</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(29,457</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Changes during the nine-month period ended September 30, 2018:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation related to restricted stock award</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Convertible notes conversions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,928,907</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,289</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,291</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Convertible notes exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,613,636</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,148</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period (as restated)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,023</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21,023</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance at September 30, 2018 (as restated)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">148,301,238</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">269,028</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(317,119</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(47,943</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Represents an amount less than $1.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Common Stock, $0.001 par value; Authorized &ndash; as
of September 30, 2018 and 2017 - 250,000,000.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2018<BR> (as restated)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.25pt">CASH FLOWS FROM OPERATING ACTIVITIES: </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; text-indent: 0.25pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">(21,023</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">(70,135</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Adjustments required to reconcile net loss to net cash used in operating activities: </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0.25pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">291</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0.25pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,469</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Financial (income) expenses, net (mainly exchange differences) </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Gain on amounts funded in respect of employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Net loss in connection with conversions of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">587</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Change in fair value of convertible notes embedded derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,061</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Amortization of debt issuance costs and debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of shares for interest payment in connection with conversions of convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">205</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,111</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Increase (decrease) in contracts liability (including non-current
    portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(837</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Increase in accounts receivable and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,467</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Increase in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(126</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,234</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Increase (decrease) in accounts payable and accruals</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,805</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,698</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Increase in other long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,103</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in continuing operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(3,738</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(27,700</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash provided by discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">116</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,738</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(27,584</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.25pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(498</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(681</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Increase in restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(247</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(336</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt; padding-bottom: 1pt">Amounts funded in respect of employee rights upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">70</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(68</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(675</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,085</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.25pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt">Net payment for convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,752</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,961</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0.25pt; padding-bottom: 1pt">Net proceeds from issuance of convertible notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">9,542</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0.25pt; padding-bottom: 1pt">Net cash used in financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(4,752</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,419</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-bottom: 1pt; padding-left: 0.125in">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(130</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">289</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.25pt">NET DECREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,295</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,799</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING
    OF PERIOD</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">51,163</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">63,281</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0.25pt; padding-bottom: 2.5pt">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">41,868</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">33,482</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">September 30, 2018</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">(as restated)</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 2.5pt double; text-align: right">237</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 2.5pt double; text-align: right">666</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Convertible notes conversions</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,236</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,668</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Interest paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,411</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,613</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Protalix BioTherapeutics, Inc.
(collectively with its subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix
B.V. (the &ldquo;Subsidiaries&rdquo;), are biopharmaceutical companies focused on the development and commercialization of recombinant
therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&ldquo;ProCellEx&rdquo;).
To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain
other Latin American countries and Elelyso<SUP>&reg;</SUP> in the rest of the territories) for the treatment of Gaucher disease
that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product
candidates in varying stages of the clinical development process. The Company&rsquo;s strategy is to develop proprietary recombinant
proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">The Company&rsquo;s product pipeline
currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">(1) pegunigalsidase alfa, or PRX-102,
a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">(2) alidornase alfa, or PRX-110,
a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis,
to be administered by inhalation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">(3) OPRX-106, the Company&rsquo;s
oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as
a natural capsule for the expressed protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Obtaining marketing approval with
respect to any product candidate in any country is dependent on the Company&rsquo;s ability to implement the necessary regulatory
steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">On October&nbsp;19, 2017, Protalix
Ltd. and Chiesi Farmaceutici S.p.A. (&ldquo;Chiesi&rdquo;) entered into an Ex-US license agreement (the &ldquo;Chiesi Ex-U.S. Agreement&rdquo;)
pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase
alfa. On July&nbsp;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &ldquo;Chiesi
U.S. Agreement&rdquo;), with respect to the development and commercialization of pegunigalsidase alfa in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Under each of the Chiesi Ex-U.S.
Agreement and the Chiesi U.S. Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&nbsp;million in connection with
the execution of the agreement. In addition, under the Chiesi Ex-U.S. Agreement, Protalix Ltd. is entitled to additional payments
of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million per year and to receive additional
payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi U.S.
Agreement, Protalix Ltd. <FONT STYLE="font-family: Times New Roman, Times, Serif">is entitled to payments of up to a maximum of
$20.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million to cover development costs for </FONT>pegunigalsidase
alfa<FONT STYLE="font-family: Times New Roman, Times, Serif">, subject to a maximum of $7.5</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
per year, and to receive an additional up to a maximum of $760.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, in regulatory and commercial milestone payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Under the terms of both of the
Chiesi agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain
exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi
Ex-U.S. Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual
sales outside of the United States, as consideration for product supply. Under the Chiesi U.S. Agreement, Chiesi is required to
make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales outside of the United States, as consideration
for product supply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Since its approval by the FDA,
taliglucerase alfa has been marketed by Pfizer Inc. (&ldquo;Pfizer&rdquo;), in accordance with the exclusive license and supply
agreement between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered
into an Amended and Restated Exclusive License and Supply Agreement with Pfizer (the &ldquo;Amended Pfizer Agreement&rdquo;) which
amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer
its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment
equal to $36.0&nbsp;million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while
gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible
for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">On June&nbsp;18, 2013, the Company
entered into a Supply and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo
Cruz (&ldquo;Fiocruz&rdquo;), an arm of the Brazilian Ministry of Health (the &ldquo;Brazilian MoH&rdquo;), for taliglucerase alfa.
Fiocruz&rsquo;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and,
accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is,
at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated
with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase.
The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based
on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">In 2017, the Company received a
purchase order from the Brazilian MoH for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for
consideration of approximately $24.3&nbsp;million. Shipments started in June 2017. The Company recorded revenues of $7.1&nbsp;million
for sales of alfataliglicerase to Fiocruz in 2017, and $2.6&nbsp;million during the nine months ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Based on its current cash resources
and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding
level of expenditures for at least 12&nbsp;months from the date of approval of the September 30, 2018 financial statements, although
no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general
and administrative expenses or research and development expenses, the Company may need to seek additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Restatement of previously issued condensed consolidated
financial statements</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company has restated these financial
statements to correct an error in the revenue recognition from the agreements with Chiesi. Previously, the Company had
identified a single performance obligation with regard to its promises under each of the agreements. The Company subsequently
concluded that there are two performance obligations under each of the agreements as follows: (i) the license together with
research and development services and (ii) a contingent performance obligation regarding future manufacturing. As such, the
Company has recognized revenue for the combined performance obligations (the license and the research and development
services) for the three and nine months ended September&nbsp;30, 2018 for the satisfaction of the performance obligation that
occurred during the three and nine months ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company&rsquo;s decision to restate the financial
statements previously reported on its Quarterly Reports on Form 10-Q, was approved by, and with the continuing oversight of, the
Company&rsquo;s Audit Committee.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Impacts of restatement</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The effects of the restatement
on the line items within the Company&rsquo;s condensed consolidated balance sheets as of September&nbsp;30, 2018 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 88%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>(<I>U.S. dollars in thousands)</I></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As<BR> originally<BR> reported</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As restated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-weight: bold; text-align: left">CONTRACTS ASSET</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">1,450</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">(1,450</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES: </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Contracts liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,337</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contracts liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,780</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,287</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,493</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total long term liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,287</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,501</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(64,994</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(47,943</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The effects of the restatement
on the line items within the Company&rsquo;s condensed consolidated statements of operations for the three and nine months ended
September 30, 2018 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt">(<I>U.S. dollars in thousands,</I><BR>
    <I>except per share data)</I></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As<BR> originally<BR> reported</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As<BR> restated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As<BR> originally<BR> reported</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As<BR> restated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; font-weight: bold; text-align: left">REVENUES FROM LICENSE AGREEMENTS</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">11,672</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">11,672</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">16,665</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">16,665</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,638</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,450</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,088</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,450</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(8,744</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(13,963</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,741</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(30,851</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(15,636</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LOSS FOR THE PERIOD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(15,544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,322</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(36,238</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(21,023</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share of common stock-basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.10</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.04</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.25</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The effects of the restatement
on the line items within the Company&rsquo;s condensed consolidated statements of changes in capital deficiency for the nine months
ended September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2018 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 10pt"><B>(<I>U.S. dollars in thousands, except per share data)</I></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As<BR> originally<BR> reported</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">As restated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font-weight: bold">Net loss for the nine months ended September&nbsp;30, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(36,238</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,215</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(21,023</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balances as of September&nbsp;30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(317,119</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total capital deficiency</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(64,994</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(47,943</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Although there was with no impact
to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the
effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended
September 30, 2018 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(<I>U.S.
    dollars in thousands)</I></B></FONT></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>originally
                                         <BR>
                                         reported</B></P> </DIV></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Adjustments</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>As restated</B></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(36,238</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">15,215</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(21,023</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in contracts liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,665</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,264</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Increase in contract asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,450</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,738</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3,738</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The impacts of the restatement have been reflected
throughout the financial statements, including the applicable footnotes, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition, in connection with the Chiesi Ex-U.S.
Agreement, the Company should have recognized $1.8&nbsp;million of revenue in the last quarter of 2017 and accordingly has revised
certain items in its consolidated financial statements for December&nbsp;31, 2017 presented herein. The Company evaluated the
materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&rsquo;s
prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated
financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company
revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for
December&nbsp;31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(<I>U.S. dollars in thousands)</I></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>originally <BR>
reported</B></P> </DIV></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Adjustments</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As revised</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Contracts liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">26,851</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,836</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">25,015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(297,932</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,836</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(296,096</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for
the year ended December&nbsp; 31, 2017, filed by the Company with the Commission. The comparative balance sheet at December&nbsp;
31, 2017 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s common stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;), outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS is calculated in continuing operations.
The calculation of diluted LPS does not include 76,195,921 and 73,310,911 shares of Common Stock underlying outstanding options
and restricted shares of Common Stock and shares of Common Stock issuable upon conversion of the convertible notes for the nine
months ended September&nbsp;30, 2017 and 2018, respectively, and 80,696,070 and 73,280,977 shares of Common Stock for the three
months ended September&nbsp;30, 2017 and 2018, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD><B>Revenue recognition (as restated)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Revenue from supply agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company recognizes revenues from supply agreements
and from selling products when control is transferred to the customer and collectability is probable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Revenue from Chiesi Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">According to Accounting Standard Codification Topic
606, Revenue from contracts with customers (&ldquo;ASC 606&rdquo;), a <FONT STYLE="background-color: white">performance obligation
is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not
distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created.
A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or
together with other resources that are readily available to the customer and the entity&rsquo;s promise to transfer the good or
service to the customer is separately identifiable from other promises in the contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company has identified two performance obligations
in each of the Chiesi agreements as follows: (1) the license and research and development services and (2) <FONT STYLE="background-color: white">a
contingent performance obligation regarding future </FONT>manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company determined that the licenses granted to
Chiesi together with the research and development services should be combined into a single performance obligation under each agreement
since <FONT STYLE="background-color: white">Chiesi cannot benefit from a license without the <FONT STYLE="color: #222222">research
and development services.</FONT></FONT> The research and development services are highly specialized and are dependent on the supply
of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The future manufacturing <FONT STYLE="background-color: white">is
contingent on regulatory approvals of the drug and</FONT> the Company deems these services to be separately identifiable from other
performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated
with the license and research and development services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The transaction price was comprised of fixed consideration
and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company
would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are
a form of variable consideration. The Company estimates variable consideration using the most likely method. <FONT STYLE="background-color: white">Amounts
included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will
not occur, usually upon achievement of a specific milestone.</FONT> The Company used significant judgment when it determined variable
consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Since the customer benefits from the research and development
services as the entity performs, revenue from granting the license and the research and development services is recognized over
time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred
upon satisfying the identified performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="color: #222222; background-color: white">Revenue
from additional</FONT> research and development <FONT STYLE="color: #222222; background-color: white">services ordered by Chiesi,
is recognized over time using the cost-to-cost method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company accounted for the Chiesi U.S.
agreement as a modification of the Chiesi Ex-U.S. Agreement. As such, the Company recorded revenue through a cumulative
catch-up adjustment in the amount of $6.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="background-color: white">The
Company&rsquo;s revenue recognition accounting policy prior to January 1, 2018, was materially the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD><B>Recently adopted standards</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In May 2014, the <FONT STYLE="font-family: Times New Roman, Times, Serif">Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) </FONT>issued guidance on revenues from contracts with customers that will supersede
most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue
to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity
expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to
determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration
of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies
are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and
uncertainty of revenues and cash flows arising from an entity&rsquo;s contracts with customers. The guidance is effective for the
interim and annual periods beginning on or after December&nbsp;15, 2017. On January&nbsp;1, 2018, the Company adopted the new accounting
standard, ASC 606, Revenue from Contracts with Customers, and all the related amendments, using the modified retrospective method.
The implementation of this Accounting Standards Update (ASU) did not have a material impact on the Company&rsquo;s consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In January 2016, the FASB issued ASU, No. 2016-01,
Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects
the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements
of financial instruments. The guidance is effective for annual reporting periods beginning after December&nbsp;15, 2017. The implementation
of this ASU did not have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company&rsquo;s inventory at September&nbsp;30,
2018 and December&nbsp;31, 2017 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left"><B><i>(U.S. dollars in thousands)</I></B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">3,201</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">3,838</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,482</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,959</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,833</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 - FAIR VALUE MEASUREMENT</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the convertible notes derivative
is based on Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the remaining $58.0&nbsp;million
in aggregate principal amount of the Company&rsquo;s outstanding 7.50% secured convertible promissory notes due 2021 (the &ldquo;2021
Notes&rdquo;) is approximately $78.0&nbsp;million, based on a Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company prepared a valuation of the fair value of the</FONT> Company&rsquo;s <FONT STYLE="font-family: Times New Roman, Times, Serif">2021
Notes (a Level 3 valuation) as of September</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">30, 2018. The
value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach.
The following parameters were used:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021 Notes</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-indent: -10pt; padding-left: 10pt">Stock price (USD)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">0.73</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Expected term (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.87</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75.56</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.50</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; CONVERTIBLE NOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All of our outstanding convertible notes are accounted
for using the guidance set forth in the FASB Accounting Standards Codification (ASC) 815 which requires that the Company determine
whether the embedded conversion option must be separated and accounted for separately. ASC 470-20, regarding debt with conversion
and other options, requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately
account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&rsquo;s
nonconvertible debt borrowing rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2021 Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract
with an embedded derivative resulting from the conversion feature. During the year ended December</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">31,
2017, the embedded derivative was reclassified to additional paid in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Issuance costs regarding the issuance of the 2021
Notes are amortized using the effective interest rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; CONVERTIBLE NOTES</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">During the nine months ended
September&nbsp;30, 2018, note holders converted $1.1&nbsp;million aggregate principal amount of the 2021 Notes into a total
of 1,456,354 shares of Common Stock, and cash payments of approximately $14,439, in the aggregate. An additional 14,860
shares of Common Stock were issued after September&nbsp;30, 2018 in connection with the make-whole premium associated with
certain of the converted notes that were converted during the third quarter of 2018. In addition, in June 2018, the Company
exchanged $3.42&nbsp;million aggregate principal amount of the Company&rsquo;s outstanding 4.50% convertible promissory notes
due 2018 (the &ldquo;2018 Notes&rdquo;) for 2,613,636 shares of Common Stock and approximately $2.2&nbsp;million in cash and
delivered the necessary funds under the indenture governing the 2018 Notes, which was $2.5&nbsp;million. On
September&nbsp;15, 2018, the 2018 Notes matured and have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">As of September&nbsp;30, 2018, a
total of $58.0&nbsp;million aggregate principal amount of the 2021 Notes were outstanding. In addition, as of September&nbsp;30,
2018, none of the 2018 Notes were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 &ndash; REVENUES (AS RESTATED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table summarizes the
Company&rsquo;s disaggregation of revenues:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-style: italic"><B>(U.S. dollars in thousands)</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-left: 0.25in">Pfizer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">4,649</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">10,198</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">Brazil</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,573</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,575</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">Total revenues from selling goods </TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,222</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,773</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">Revenues from license and R&amp;D services</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,665</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 6 &ndash; STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On September&nbsp;13, 2018, the
Company&rsquo;s compensation committee approved the grant of 10-year options to purchase, in the aggregate, 6,360,000 shares of
Common Stock, of which options to purchase 4,000,000 shares of Common Stock were granted to the Company&rsquo;s executive officers
and options to purchase 2,360,000 shares of Common Stock were granted to other employees with an exercise price equal to $0.56
per share and $0.51 per share, respectively, under the Company&rsquo;s 2006 Employee Stock Incentive Plan, as amended (the &ldquo;Plan&rdquo;).
The options vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the executive officers
is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan,
and are subject to certain other terms and conditions. The Company estimated the fair value of the options on the date of grant
using the Black-Scholes option-pricing model to be approximately $1.9&nbsp;million based on the following weighted average assumptions:
share price equal to $0.51; dividend yield of 0% for all years; expected volatility of 64.3%; risk-free interest rates of 2.9%;
and expected life of six years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_009"></A>Item&nbsp;2. Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESTATEMENT OF THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Explanatory Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Amendment amends and restates our unaudited condensed
consolidated financial statements and related disclosures in Part I, Item 1. &ldquo;Financial Statements&rdquo; for the three
and nine months ended and as of September&nbsp;30, 2018 to recognize certain revenue from a license agreement that was not
recognized previously. Accordingly, the Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations set forth below reflects the effects of this restatement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended
December</I>&nbsp;<I>31, 2017. Some of the information contained in this discussion and analysis, particularly with respect to
our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties.
You should read &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December</I>&nbsp;<I>31, 2017 for
a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system. We developed our first commercial drug product, Elelyso<SUP>&reg;</SUP>, using our ProCellEx system and we are now focused
on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins
that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of
action. With our experience to date, we believe ProCellEx will enable us to develop additional proprietary recombinant proteins
that are therapeutically superior to existing recombinant proteins currently marketed for the same indications including applying
the unique properties of our ProCellEx system for the oral delivery of therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">19, 2017, Protalix Ltd., our wholly-owned subsidiary,
and Chiesi entered into the Chiesi Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside
of the United States to commercialize pegunigalsidase alfa. </FONT>Pegunigalsidase alfa is our chemically modified version of the
recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase III clinical trials for the treatment
of Fabry disease<FONT STYLE="font-family: Times New Roman, Times, Serif">. Under the terms and conditions of the Chiesi Agreement,
Protalix Ltd. retained the right to commercialize pegunigalsidase alfa in the United States. Under the Chiesi Agreement, Chiesi
made an upfront payment to Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in development costs, capped at $10.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million per year. Protalix
Ltd. is also eligible to receive an additional up to $320.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed
for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix,
subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on
the amount of annual sales, as consideration for the supply of pegunigalsidase alfa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">23, 2018, Protalix Ltd. entered into an Exclusive License
and Supply Agreement with Chiesi, or the Chiesi U.S. Agreement, with respect to the development and commercialization of pegunigalsidase
alfa in the United States. Under the terms of the Chiesi U.S. Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights
for the commercialization of PRX-102 in the United States. Protalix Ltd. is entitled to an upfront, non-refundable, non-creditable
payment of $25.0 million from Chiesi and additional payments of up to a maximum of $20.0 million to cover development costs for
PRX-102, subject to a maximum of $7.5 million per year. Protalix Ltd. is also eligible to receive an additional up to a maximum
of $760.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million, in the aggregate, in regulatory and commercial
milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net sales to Protalix Ltd., depending on the amount
of annual sales, subject to certain terms and conditions, as consideration for product supply.</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2017, the European Commission granted Orphan Drug
Designation for pegunigalsidase alfa for the treatment of Fabry disease. The designation was granted after the European Medicine
Agency&rsquo;s Committee for Orphan Medicinal Products, or the COMP, issued a positive opinion supporting the designation noting
that we had established that there was medically plausible evidence that pegunigalsidase alfa will provide a significant benefit
over existing approved therapies in the European Union for the treatment of Fabry disease. The COMP cited clinical and non-clinical
justifications we provided to establish the significant benefit of pegunigalsidase alfa, noting that the COMP considered the justifications
to constitute a clinically relevant advantage. Orphan Drug Designation for pegunigalsidase alfa qualifies Protalix Ltd. for access
to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the
orphan drug designation is maintained at the time pegunigalsidase alfa is approved for marketing in the European Union, if at all,
we expect that PRX-102 will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will
not have any effect on Fabry disease treatments already approved at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2018, the FDA granted Fast Track designation to PRX-102.
Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious
conditions that fill an unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">1, 2012, the FDA approved for sale our
first commercial product, taliglucerase alfa for injection, an enzyme replacement therapy (ERT) for the long-term treatment
of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently, taliglucerase alfa was approved for
marketing by the regulatory authorities of other countries. Taliglucerase alfa is marketed under the name alfataliglicerase
in Brazil and certain other Latin American countries, and under the name Elelyso in other territories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
its approval by the FDA, taliglucerase alfa has been marketed by Pfizer, as provided in the Pfizer Agreement. In </FONT>October
2015, we entered into the Amended Pfizer Agreement which amends and restates the Pfizer Agreement in its entirety. Pursuant to
the Amended Pfizer Agreement, we sold to Pfizer our share in the collaboration created under the initial Pfizer Agreement for the
commercialization of Elelyso in exchange for a cash payment equal to $36.0&nbsp;million. As part of the sale, we agreed to transfer
our rights to Elelyso in Israel to Pfizer, while gaining full rights to Elelyso in Brazil. We will continue to manufacture drug
substance for Pfizer, subject to certain terms and conditions. Under the Amended Pfizer Agreement, Pfizer is responsible for 100%
of expenses, and entitled to all revenues globally for Elelyso, excluding Brazil, where we are responsible for all expenses and
retain all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the first 10-year period after the execution of the Amended
Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right
to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. Any failure to comply
with our supply commitments may subject us to substantial financial penalties, which will have a material adverse effect on our
business, results of operations and financial condition. The Amended Pfizer Agreement also includes customary provisions regarding
cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">18, 2013, we entered into the Brazil Agreement with </FONT>Fiocruz,
an arm of the Brazilian MoH, <FONT STYLE="font-family: Times New Roman, Times, Serif">for taliglucerase alfa. </FONT>Fiocruz&rsquo;s
purchases of <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> to date have been significantly
below certain agreed upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement. Notwithstanding
our termination right, we are, at this time, continuing to supply <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
to Fiocruz under the Brazil Agreement, and patients continue to be treated with <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil. We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and,
based on such discussions, we will determine what we believe to be the course of action that is in our best interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are developing an innovative product pipeline using our ProCellEx
protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein
candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in an ongoing phase III clinical
trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant
human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, or CF, to be administered by inhalation. We recently
completed a phase IIa efficacy and safety study of alidornase alfa for the treatment of CF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
OPRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein. We
released final data generated in our phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis in March 2018<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT>
Additional data was released in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have licensed the rights to commercialize taliglucerase alfa
worldwide (other than Brazil) to Pfizer, and the rights to commercialize pegunigalsidase alfa worldwide to Chiesi. Otherwise, we
hold the worldwide commercialization rights to our other proprietary development candidates. In addition, we continuously evaluate
potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and
academic research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to
our significant accounting policies since we filed our Annual Report on Form 10-K for the year ended December&nbsp;31, 2017, except
for recognition of revenue from license agreements that was not recognized previously. We used a significant estimate
in order to determine the cost expected to be incurred upon satisfying the identified performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Convertible Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our 2021 Notes are accounted for using the guidance set forth
in FASB ASC 815 which requires that we determine whether the embedded conversion option must be separated and accounted for separately.
ASC 470-20, regarding debt with conversion and other options, requires the issuer of a convertible debt instrument that may be
settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the
instrument in a manner that reflects the issuer&rsquo;s nonconvertible debt borrowing rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
</FONT>2021 Notes <FONT STYLE="font-family: Times New Roman, Times, Serif">were accounted for partially as liability and equity
components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature.
During the year ended December</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">31, 2017, the embedded derivative
was reclassified to additional paid in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuance costs regarding the issuance of the 2021 Notes are
amortized using the effective interest rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended September&nbsp;30, 2018, note holders
converted $1.1&nbsp;million aggregate principal amount of the 2021 Notes into a total of 1,456,354 shares of our common stock,
and cash payments of approximately $14,439, in the aggregate. An additional 14,860 shares of common stock were issued after September
30, 2018 in connection with the make-whole premium associated with certain of the converted notes that were converted during the
third quarter of 2018. On September 15, 2018, our 2018 Notes matured and the outstanding principal amount for such notes was paid
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As of September&nbsp;30, 2018, a total of
$58.0&nbsp;million aggregate principal amount of the <FONT STYLE="font-family: Times New Roman, Times, Serif">2021 Notes</FONT>
were outstanding, and no 2018 Notes were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended September 30, 2018 compared to the
three months ended September 30, 2017</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from Selling Goods</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $663,000 during the three months ended
September&nbsp;30, 2018, a decrease of $6.9&nbsp;million from revenues of $7.5&nbsp;million for the three months ended September&nbsp;30,
2017. The decrease resulted from decreased sales of drug substance to Pfizer and drug product to Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from License and R&amp;D Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $11.7&nbsp;million for the three months
ended September&nbsp;30, 2018. Revenues from the license agreements represent the revenues we recognized in connection with the
Chiesi agreements including a cumulative catch-up adjustment in the amount of $6.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of goods sold was $1.9&nbsp;million for the three
months ended September&nbsp;30, 2018, a decrease of $4.2&nbsp;million, from cost of revenues of $6.1&nbsp;million for the
three months ended September&nbsp;30, 2017. The decrease resulted primarily from decreased sales of drug substance to Pfizer
and drug product to Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $10.1&nbsp;million for
the three months ended September&nbsp;30, 2018, an increase of $3.6&nbsp;million from $6.4&nbsp;million for the three months ended
September&nbsp;30, 2017. The increase resulted primarily from an increase in clinical trial activity during 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and
administrative expenses were $4.1&nbsp;million for the three months ended September&nbsp;30, 2018, an increase of $1.3
million, or 46%, from $2.8&nbsp;million for the three months ended September&nbsp;30, 2017. The increase resulted primarily
from costs incurred in connection with the Chiesi U.S. Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial expenses, net were $1.6&nbsp;million for the three
months ended September&nbsp;30, 2018, a decrease of $2.1&nbsp;million compared to financial expenses, net of $3.7&nbsp;million
for the three months ended September&nbsp;30, 2017. Financial expenses are comprised primarily from interest expense on our outstanding
convertible notes of $1.2&nbsp;million for the period ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nine months ended September 30, 2018 compared to the nine
months ended September 30, 2017</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from Selling Goods</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $7.2&nbsp;million during the nine months
ended September&nbsp;30, 2018, a decrease of $9.6&nbsp;million, or 57%, from revenues of $16.8&nbsp;million for the nine months
ended September&nbsp;30 2017. The decrease resulted from a decrease of $5.6&nbsp;million in sales of drug substance to Pfizer and
$4.0&nbsp;million in sales of drug product to Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from License and R&amp;D Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $16.7&nbsp;million for the nine months
ended September&nbsp;30, 2018. Revenues from the license agreements represent the revenues we recognized in connection with the
Chiesi agreements including a cumulative catch-up adjustment in the amount of $6.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Goods Sold</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of goods sold was $7.0&nbsp;million for the nine
months ended September&nbsp;30, 2018, a decrease of $6.7&nbsp;million, or 49%, from cost of revenues of $13.7&nbsp;million
for the nine months ended September 30, 2017. The decrease resulted primarily from costs related to the production of drug
substance sold to Pfizer and drug product sold to Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses was $23.8&nbsp;million for
the nine months ended September&nbsp;30, 2018, an increase of $4.0&nbsp;million, or 20%, from $19.8&nbsp;million for the nine months
ended September&nbsp;30, 2017. The increase resulted primarily from an increase in clinical trial activity during 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect research and development expenses for our various
development programs to continue to be our primary expense for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and
administrative expenses were $8.7&nbsp;million for the nine months ended September&nbsp;30, 2018, an increase of $557,000, or
6%, from $8.2&nbsp;million for the nine months ended September&nbsp;30, 2017. The increase resulted primarily from costs
incurred in connection with the Chiesi U.S. Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses, net were $5.4&nbsp;million
for the nine months ended September&nbsp;30, 2018, compared to financial expenses net of $45.2&nbsp;million for the nine months
ended September&nbsp;30, 2017. During the nine months ended September&nbsp;30, 2017, financial expenses included a charge of $38.1&nbsp;million
as a result of the re-measurement of the fair value of the 7.5% convertible notes embedded derivative. In addition, financial expenses
are comprised primarily from interest expense on our outstanding convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have incurred operating losses
from our continuing operations since our inception. To date, we have funded our operations primarily with proceeds equal to $31.3&nbsp;million
from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd., and an additional $14.1&nbsp;million in
connection with the exercise of warrants issued in connection with the sale of such shares, through December&nbsp;31, 2008. In
addition, on October&nbsp;25, 2007, we generated gross proceeds of $50.0&nbsp;million in connection with an underwritten public
offering of our common stock and on each of March&nbsp;23, 2011 and February&nbsp;22, 2012, we generated gross proceeds of $22.0&nbsp;million
and $27.2&nbsp;million, respectively, in connection with underwritten public offerings of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September&nbsp;18, 2013, we
completed a private placement of $69.0&nbsp;million in aggregate principal amount of 4.50% convertible notes due 2018, including
$9.0&nbsp;million aggregate principal amount of the of 4.50% convertible notes related to the offering&rsquo;s initial purchaser&rsquo;s
over-allotment option, which was exercised in full. In December 2016, we completed a private placement of $22.5&nbsp;million in
aggregate principal amount of 7.50% convertible notes due 2021. Finally, on July&nbsp;25, 2017, we completed a private placement
of an additional $10.0&nbsp;million in aggregate principal amount of 7.50% convertible notes due 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million as an upfront payment in
connection with the execution of the Pfizer Agreement and subsequently paid to Protalix Ltd. an additional $5.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
upon Protalix Ltd.&rsquo;s meeting a milestone. Protalix Ltd. also received a milestone payment of $25.0</FONT>&nbsp;million <FONT STYLE="font-family: Times New Roman, Times, Serif">in
connection with the FDA&rsquo;s approval of taliglucerase alfa in May 2012. </FONT>Pfizer has also paid Protalix Ltd. $8.3&nbsp;million
in connection with the successful achievement of milestones under a clinical development agreement between Pfizer and Protalix
Ltd. In connection with the execution of the Amended Pfizer Agreement, we received a $36.0&nbsp;million payment from Pfizer, and
Pfizer purchased 5,649,079 shares of our common stock for $10.0&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the fourth quarter of 2017, Chiesi made an upfront payment to Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in connection with the execution of the Chiesi Ex-U.S. Agreement and in the third quarter of 2018, Chiesi made an upfront payment
to Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million in connection with the execution
of the Chiesi U.S. Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations
was $3.7&nbsp;million for the nine months ended September 30, 2018. The net loss for the nine months ended
September&nbsp;30, 2018 of $21.0&nbsp;million was partially offset by an increase of $18.3&nbsp;million in contracts
liabilities representing an upfront payment and certain expense reimbursements actually received from Chiesi in connection
with our license agreements with Chiesi which we have not yet recognized as revenues. Net cash used in investing activities
for the nine months ended September 30, 2018 was $675,000 and consisted primarily of purchases of property and equipment, and
an increase in restricted deposit. Net cash used in financing activities was $4.8&nbsp;million for the repayment of
convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $27.6&nbsp;million
for the nine months ended September&nbsp;30, 2017. The net loss for the nine months ended September 30, 2017 of $70.1&nbsp;million
was partially offset by a change of $38.1&nbsp;million in the fair value of convertible notes embedded derivative and increase
of $8.7&nbsp;million in accounts payable. Net cash used in investing activities for the nine months ended September&nbsp;30, 2017
was $1.1&nbsp;million and consisted primarily of purchases of property and equipment and an increase in restricted deposit. Net
cash used in financing activities for the nine months ended September&nbsp;30, 2017 was $1.4&nbsp;million and consisted primarily
of cash settlement of $11.0&nbsp;million for certain conversions of our convertible notes which was partially offset by $9.5&nbsp;million
of net proceeds from the issuance of our 2021 Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in the
near future, including significant research and development expenses related primarily to the clinical trials of pegunigalsidase
alfa. We believe that our existing cash and cash equivalents and commitments will be sufficient for at least 12 months. We have
based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required to use our available
capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development
and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating
expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many other factors, including our progress in commercializing <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT>
in Brazil, the progress and results of our clinical trials, particularly our clinical trials of pegunigalsidase alfa, the duration
and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates, conversions
of our outstanding 2021 Notes from time to time, the timing and outcome of regulatory review of our product candidates, the costs
involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property
rights, the number and development requirements of other product candidates that we pursue and the costs of commercialization activities,
including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need to finance our future cash needs through corporate
collaboration, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not
have any commitments for future external funding, except with respect to the development-related payments and milestone payments
that may become payable under our agreements with Chiesi. We may need to raise additional funds more quickly if one or more of
our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently
anticipate. We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable.
Any sale of additional equity or debt securities will likely result in dilution to our stockholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity
or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at
all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development
programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may
require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the nine months ended September&nbsp;30, 2018 and September&nbsp;30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the nine months ended September&nbsp;30, 2018 and September&nbsp;30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of September&nbsp;30, 2018 and September&nbsp;30, 2017.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_010"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic environment to be the
currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S. dollars, approximately 50%
of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of our financing has been provided
in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are
remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical
exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they
occur. Foreign currency translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A portion of our costs, including salaries, expenses and office
expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in
Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A devaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended<BR>
 December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">3.558</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">3.629</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">3.600</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at period end</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">3.627</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">3.529</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">3.467</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S.&nbsp;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects
due to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures to ensure that the information
required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the Commission&rsquo;s rules and forms, and to ensure that such information is
accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to
allow timely decisions regarding required disclosure. Based on that evaluation, in the Original Filing, our Chief Executive Officer
and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
under the Exchange Act) were effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subsequent to the evaluation made in connection with the
Original Filing, our Chief Executive Officer and Chief Financial Officer re-evaluated the effectiveness of the design and
operation of our disclosure controls and procedures concluding that our disclosure controls and procedures were not effective as of September&nbsp;30, 2018
because of the material weakness in our internal control over financial reporting which existed at that date and is discussed
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Material Weakness in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A material weakness is defined as a deficiency, or combination
of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement
of annual or interim consolidated financial statements will not be prevented or detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our Original Filing, we did not disclose the existence of
any material weaknesses in internal control over financial reporting. Subsequent to that evaluation, the Company determined the
following material weakness existed as of September&nbsp;30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our Original Filing, we did not disclose the existence
of any material weaknesses in internal control over financial reporting. Subsequent to that evaluation, we determined that a
material weakness in our internal control over financial reporting existed as of March&nbsp;31, 2018 in that we did not
maintain effective internal controls related to accounting for complex revenue contracts. Specifically, we did not properly
assess the performance obligations we had with regard to certain of our out-licensing arrangements which became material to
our company in 2018. The foregoing resulted in the restatement of our unaudited condensed consolidated financial statements
for each of the fiscal quarters of 2018 and in a revision to 2017 figures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The foregoing restatements were effected through our
filing of this Amendment and the filing of an amended Quarterly Report on Form 10-Q/A for the quarter ended March&nbsp;31, 2018
and an amended Quarterly Report on Form 10-Q/A for the quarter ended June&nbsp;30, 2018. Our management has concluded that this
deficiency constitutes a material weakness in our internal control over financial reporting as of September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>Remediation Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In response to the identified material weakness, our management,
with the oversight of the Audit Committee of the Board of Directors, has updated our revenue recognition processes and controls
with respect to out-licensing arrangements, and intends to continue to update our revenue recognition processes and controls and
to implement additional control procedures including retaining a globally recognized business and accounting advisory firm to assist
us in improving our internal processes in connection with revenue recognition. While certain remedial actions have been completed
in the first quarter of 2019, we intend to continue to implement additional control procedures as the need to do so is identified
by our management. The remediation efforts are intended both to address the identified material weakness and to enhance our overall
financial control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management, including our Chief Executive Officer and Chief
Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting
will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable,
not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control system must reflect the
fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements
due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur
because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two
or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals
under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to
risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance
with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in Internal Control over Financial Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except with respect to the material weakness described
herein, there were no changes to our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under
the Exchange Act) that occurred during the quarter ended September&nbsp;30, 2018 that have materially affected, or that are
reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B><A NAME="a_012"></A>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_013"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_014"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2017.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_015"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>Unregistered Sales of Equity
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">There
were no unregistered sales of equity securities during the nine months ended September</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">30,
2018. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_016"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_017"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_018"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_019"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="vertical-align: top; border-bottom: Black 1pt solid; text-align: center"><B>Incorporated by Reference</B></TD>
    <TD STYLE="vertical-align: top; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: Black 1pt solid; text-align: center"><B>Exhibit</B><BR>
<B>Number</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 35%; border-bottom: Black 1pt solid; text-align: center"><B>Exhibit Description</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; border-bottom: Black 1pt solid; text-align: center"><B>Form</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 11%"><B>File</B><BR>
<B>Number</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: Black 1pt solid; text-align: center"><B>Exhibit</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%; border-bottom: Black 1pt solid; text-align: center"><B>Date</B></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Filed or</B><BR>
<B>Furnished</B><BR>
<B>Herewith</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of the Company</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">333-48677</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">April 1, 2016</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Amendment to Certificate of Incorporation of the Company</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Def 14A</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Appen. A</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">July 1, 2016</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">3.4</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">Bylaws of the Company</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">April 1, 2016</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Agreement/Notice</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">July 18, 2012</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit">Indenture, dated as of September 18, 2013, between Protalix BioTherapeutics, Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-1.htm" STYLE="-sec-extract: exhibit">September 18, 2013</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit">4.3</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit">Form of 4.50% Convertible Note due 2018</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420413051455/v355360_ex4-2.htm" STYLE="-sec-extract: exhibit">September 18, 2013</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">4.4</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 35%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">Indenture, dated as of December 7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">December 7, 2016</A></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">4.5</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">December 7, 2016</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">4.6</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">4.3</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">December 7, 2016</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.7</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">First Supplemental Indenture, dated as of July 24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">July 25, 2017</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">4.8</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">Second Supplemental Indenture, dated as of November 27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">December 1, 2017</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1&dagger;</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit">Exclusive U.S. License and Supply Agreement dated as of July 23, 2018, made by and between Protalix Ltd. and Chiesi Farmaceutici S.p.A.</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit">10-Q</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit">November 7, 2018</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm" STYLE="-sec-extract: exhibit"></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv515433_ex31-1.htm" STYLE="-sec-extract: exhibit">31.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv515433_ex31-1.htm" STYLE="-sec-extract: exhibit">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv515433_ex31-1.htm" STYLE="-sec-extract: exhibit">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv515433_ex31-2.htm" STYLE="-sec-extract: exhibit">31.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv515433_ex31-2.htm" STYLE="-sec-extract: exhibit">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv515433_ex31-2.htm" STYLE="-sec-extract: exhibit">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv515433_ex32-1.htm" STYLE="-sec-extract: exhibit">32.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv515433_ex32-1.htm" STYLE="-sec-extract: exhibit">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv515433_ex32-1.htm" STYLE="-sec-extract: exhibit">X</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv515433_ex32-2.htm" STYLE="-sec-extract: exhibit">32.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv515433_ex32-2.htm" STYLE="-sec-extract: exhibit">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer </A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="tv515433_ex32-2.htm" STYLE="-sec-extract: exhibit">X</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt">101.INS</TD>
    <TD STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt">XBRL INSTANCE FILE</TD>
    <TD STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.SCH</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL SHEMA FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.CAL</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL CALCULATION FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.DEF</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL DEFINITION FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.LAB</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL LABEL FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">101.PRE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">XBRL PRESENTATION FILE</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&dagger; Portions of this exhibit were omitted and have been
filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&rsquo;s application requesting
confidential treatment under Rule 24b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: March 18, 2019</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Moshe Manor<BR>
President and Chief Executive Officer<BR>
(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: March 18, 2019</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Yossi Maimon<BR>
Vice President and Chief Financial Officer, Treasurer and Secretary<BR>
(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tv515433_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in">I, Moshe Manor, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q/A of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">Date: March 18, 2019</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tv515433_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.4in">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q/A of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">Date: March 18, 2019</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President, Chief Financial Officer, Treasurer </TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tv515433_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q/A for the period ended September&nbsp;30, 2018 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Moshe Manor, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">Date: March 18, 2019</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Moshe Manor</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Moshe Manor</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tv515433_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q/A for the period ended September&nbsp;30, 2018 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">Date: March 18, 2019</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt; width: 50%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President and Chief Financial Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20180930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--DataTracks Rainbow V 3.0 - www.datatracks.com - on 13-March-2019 [08:19:20] {PM}-->
<xbrli:xbrl xmlns:plx="http://www.protalix.com/20180930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2018-01-31">
<link:schemaRef xlink:type="simple" xlink:href="plx-20180930.xsd" />
<xbrli:context id="P01_01_2018To09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_01_2018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-11-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2016">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_FourPointFiveZeroPercentageConvertibleNotes2018MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFiveZeroPercentageConvertibleNotes2018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFiveZeroPercentageConvertibleNotes2021Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_PfizerMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_BRsrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_SellingGoodsMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:SellingGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_BRsrtStatementGeographicalAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_FiocruzMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FiocruzMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFiveZeroPercentageConvertibleNotes2021Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFiveZeroPercentageConvertibleNotes2021Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_FourPointFiveZeroPercentageConvertibleNotes2018MemberusgaapDebtInstrumentAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:FourPointFiveZeroPercentageConvertibleNotes2018Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_BrazilAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:BrazilAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_RestatementAdjustmentMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_PfizerMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_BRsrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_SellingGoodsMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:SellingGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2017To09_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2017-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ProductMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2015To10_31_2015_PfizerAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-10-01</xbrli:startDate>
<xbrli:endDate>2015-10-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_31_2015_AmendedPfizerAgreementMemberusgaapTypeOfArrangementAxis_BRsrtStatementGeographicalAxis_ProtalixBioTherapeuticsIncorporationMemberdeiLegalEntityAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2015-10-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-10-19</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_19_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-10-19</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_19_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-19</xbrli:startDate>
<xbrli:endDate>2017-10-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_19_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-19</xbrli:startDate>
<xbrli:endDate>2017-10-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_19_2017To10_19_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-19</xbrli:startDate>
<xbrli:endDate>2017-10-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_19_2017To10_19_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-19</xbrli:startDate>
<xbrli:endDate>2017-10-19</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-13</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-09-01</xbrli:startDate>
<xbrli:endDate>2018-09-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_ExecutiveOfficersMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:ExecutiveOfficersMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-09-01</xbrli:startDate>
<xbrli:endDate>2018-09-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_ExecutiveMemberusgaapTitleOfIndividualAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">plx:ExecutiveMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-09-01</xbrli:startDate>
<xbrli:endDate>2018-09-13</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2018To10_31_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFiveZeroPercentageConvertibleNotes2021Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-01</xbrli:startDate>
<xbrli:endDate>2018-10-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P01_01_2017To12_31_2017_FiocruzMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FiocruzMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-01-01</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-07-23</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_01_2017To12_31_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-10-01</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<dei:DocumentType id="Factid_4039417" contextRef="P01_01_2018To09_30_2018">10-Q</dei:DocumentType>
<dei:AmendmentFlag id="Factid_4039418" contextRef="P01_01_2018To09_30_2018">true</dei:AmendmentFlag>
<dei:AmendmentDescription id="Factid_4039419" contextRef="P01_01_2018To09_30_2018">This Amendment No. 1 to Form 10-Q, or this Amendment, amends the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 we originally filed with the Securities and Exchange Commission, or the Commission, on November 7, 2018, or the Original Filing.</dei:AmendmentDescription>
<dei:DocumentPeriodEndDate id="Factid_4039420" contextRef="P01_01_2018To09_30_2018">2018-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus id="Factid_4039421" contextRef="P01_01_2018To09_30_2018">2018</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_4039422" contextRef="P01_01_2018To09_30_2018">Q3</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_4039423" contextRef="P01_01_2018To09_30_2018">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_4039424" contextRef="P01_01_2018To09_30_2018">0001006281</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_4039425" contextRef="P01_01_2018To09_30_2018">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory id="Factid_4039426" contextRef="P01_01_2018To09_30_2018">Accelerated Filer</dei:EntityFilerCategory>
<dei:TradingSymbol id="Factid_4039427" contextRef="P01_01_2018To09_30_2018">PLX</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding id="Factid_4039428" contextRef="PAsOn11_01_2018" unitRef="Unit_shares" decimals="0">148374921</dei:EntityCommonStockSharesOutstanding>
<dei:EntityEmergingGrowthCompany id="Factid_4039429" contextRef="P01_01_2018To09_30_2018">false</dei:EntityEmergingGrowthCompany>
<dei:EntitySmallBusiness id="Factid_4039430" contextRef="P01_01_2018To09_30_2018">false</dei:EntitySmallBusiness>
<us-gaap:InventoryDisclosureTextBlock id="Factid_4039435" contextRef="P01_01_2018To09_30_2018">&lt;div style="letter-spacing: 0px; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt;;font-weight:bold;display:inline;"&gt;NOTE 2 - INVENTORIES&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;The Company&amp;#8217;s inventory at September&amp;#160;30, 2018 and December&amp;#160;31, 2017 consisted of the&amp;#160;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;following:&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 64%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Raw materials&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;3,201&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;3,838&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Work in progress&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;276&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;485&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;4,482&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;3,510&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Total inventory&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;7,959&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;7,833&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
<us-gaap:FairValueDisclosuresTextBlock id="Factid_4039436" contextRef="P01_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 3 &amp;#8211; FAIR VALUE MEASUREMENT&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the convertible notes derivative is based on Level 3 measurement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin: 0px 0px 0px 0.49in; background: none; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the remaining $58.0&amp;#160;million in aggregate principal amount of the Company&amp;#8217;s outstanding 7.50% &lt;/div&gt;secured convertible promissory notes due 2021 (the &amp;#8220;2021 Notes&amp;#8221;) is approximately $78.0&amp;#160;million, based on a Level 3&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;measurement.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company prepared a valuation of the fair value of the Company&amp;#8217;s 2021 Notes (a Level 3 valuation) as of September 30, 2018. The value&amp;#160;of these notes was&amp;#160;estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.98in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 39%;;margin : 0px auto;;text-align:left;;margin-left :auto;margin-right :auto;"&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;Notes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; width: 79%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price (USD)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 18%; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.73&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.13&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.87&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;75.56&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.50&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<us-gaap:DebtDisclosureTextBlock id="Factid_4039440" contextRef="P01_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 4 &amp;#8211; CONVERTIBLE NOTES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;All of our outstanding convertible notes are accounted for using the guidance set forth in the FASB Accounting Standards Codification (ASC) 815 which requires that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20, regarding debt with conversion and other options, requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&amp;#8217;s nonconvertible debt borrowing rate.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The 2021&amp;#160;Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&amp;#160;31, 2017, the embedded derivative was reclassified to additional paid in capital.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance costs regarding the issuance of the 2021&amp;#160;Notes are amortized using the effective interest rate.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the nine months ended September 30, 2018, note holders converted $1.1&amp;#160;million aggregate principal amount of the 2021&amp;#160;Notes into a total of 1,456,354 shares of Common Stock, and cash payments of approximately $14,439, in the aggregate. An additional 14,860 shares of Common Stock were issued after September 30, 2018 in connection with the make-whole premium associated with certain of the converted notes that were converted during the third quarter of 2018. In addition, in June 2018, the Company exchanged $3.42&amp;#160;million aggregate principal amount of the Company&amp;#8217;s outstanding 4.50% convertible promissory notes due 2018 (the &amp;#8220;2018&amp;#160;Notes&amp;#8221;) for 2,613,636 shares of Common Stock and approximately $2.2&amp;#160;million in cash and delivered the necessary funds under the indenture governing the 2018&amp;#160;Notes, which was $2.5 million. On September 15, 2018, the 2018&amp;#160;Notes matured and have been paid in full.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September 30, 2018, a total of $58.0&amp;#160;million aggregate principal amount of the 2021&amp;#160;Notes were outstanding. In addition, as of September 30, 2018, none of the 2018 Notes were outstanding.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
<plx:RevenueDisclosureTextBlock id="Factid_4039441" contextRef="P01_01_2018To09_30_2018">&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 5 &amp;#8211; REVENUES (AS RESTATED)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s disaggregation&amp;#160;of revenues:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; margin-left: 0.5in; width: 80%;"&gt;&lt;tr&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; vertical-align: bottom; width: 64%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pfizer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,649&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,198&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Brazil&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,573&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,575&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"&gt;&lt;div style="margin-left: 0.26in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenues from selling goods&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,222&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,773&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none;"&gt;Revenues from license and R&amp;amp;D services&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; text-align: right; line-height: normal; font-size: 10pt;"&gt;16,665&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:RevenueDisclosureTextBlock>
<plx:NatureOfOperationsPolicyTextBlock id="Factid_4039442" contextRef="P01_01_2018To09_30_2018">&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;General&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#8220;Company&amp;#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &amp;#8220;Subsidiaries&amp;#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#8217;s proprietary ProCellEx&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&amp;#160;&lt;/div&gt;protein expression system (&amp;#8220;ProCellEx&amp;#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt;&amp;#160;in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s product pipeline currently includes, among other candidates:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3) OPRX-106, the Company&amp;#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none; text-align: justify;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&amp;#8220;Chiesi&amp;#8221;) entered into an Ex-US license agreement (the &amp;#8220;Chiesi Ex-U.S. Agreement&amp;#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July 23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#8220;Chiesi U.S. Agreement&amp;#8221;), with respect to the development and commercialization of pegunigalsidase alfa in the United States.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;Under each of the Chiesi Ex-U.S. Agreement and the Chiesi U.S. Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&amp;#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-U.S. Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&amp;#160;million in pegunigalsidase alfa development costs, capped at $10.0&amp;#160;million per year and to receive additional payments of up to $320.0&amp;#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi U.S. Agreement, Protalix Ltd.&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;is entitled to payments of up to a maximum of $20.0&lt;/div&gt;&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&lt;/div&gt;&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million per year, and to receive an additional up to a maximum of $760.0&lt;/div&gt;&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of both of the Chiesi agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-U.S. Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi U.S. Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&amp;#8220;Pfizer&amp;#8221;), in accordance with the exclusive license and supply agreement between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement with Pfizer (the &amp;#8220;Amended Pfizer Agreement&amp;#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0&amp;#160;million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#8220;Brazil Agreement&amp;#8221;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#8220;Fiocruz&amp;#8221;), an arm of the Brazilian Ministry of Health (the &amp;#8220;Brazilian MoH&amp;#8221;), for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2017, the Company received a purchase order from the Brazilian MoH for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3&amp;#160;million. Shipments started in June 2017. The Company recorded revenues of $7.1&amp;#160;million for sales of alfataliglicerase to Fiocruz in 2017, and $2.6&amp;#160;million during the nine months ended September&amp;#160;30, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12&amp;#160;months from the date of approval of the September 30, 2018 financial statements, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:NatureOfOperationsPolicyTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Factid_4039443" contextRef="P01_01_2018To09_30_2018">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restatement of previously issued condensed consolidated financial statements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The Company has restated these financial statements to correct an error in the revenue recognition from the agreements with Chiesi. Previously, the Company had identified a single performance obligation with regard to its promises&amp;#160;under each of the agreements. The Company subsequently concluded that there are two performance obligations under each of the agreements as follows: (i) the license together with research and development services and (ii) a contingent performance obligation regarding future manufacturing. As such, the Company has recognized revenue for the combined performance obligations (the license and the research and development services) for the three and nine months ended September&amp;#160;30, 2018 for the satisfaction of the performance obligation that occurred during the three and nine months ended September&amp;#160;30, 2018.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The Company&amp;#8217;s decision to restate the financial statements previously reported on its Quarterly Reports on Form 10-Q, was approved by, and with the continuing oversight of, the Company&amp;#8217;s Audit Committee.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in; text-align: left; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impacts of restatement&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated balance sheets as of September&amp;#160;30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 88%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 764px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CONTRACTS ASSET&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 250px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;1,450&lt;/td&gt;&lt;td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CURRENT LIABILITIES:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;14,551&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;24,337&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LONG TERM LIABILITIES:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;61,780&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(28,287&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;33,493&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Total long term liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;117,640&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(28,287&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;89,353&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;132,191&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(18,501&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;113,690&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CAPITAL DEFICIENCY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(64,994&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(47,943&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated statements of operations for the three and nine months ended September 30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;(&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands,&lt;/div&gt;&lt;br/&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;except per share data)&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 642px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;REVENUES FROM LICENSE AGREEMENTS&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;11,672&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;11,672&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;16,665&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;16,665&lt;/td&gt;&lt;td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SELLING, GENERAL AND ADMINISTRATIVE EXPENSES&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(2,638&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(4,088&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(7,294&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(8,744&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OPERATING LOSS&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(13,963&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;10,222&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(3,741&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(30,851&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;15,215&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(15,636&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LOSS FOR THE PERIOD&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(15,544&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;10,222&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(5,322&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(36,238&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;15,215&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(21,023&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Net loss per share of common stock-basic and diluted&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.06&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.04&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.25&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.14&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated statements of changes in capital deficiency for the nine months ended September&amp;#160;30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands, except per share data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 921px; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(204, 238, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Net loss for the nine months ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(36,238&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;15,215&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(21,023&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balances as of September&amp;#160;30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(334,170&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(317,119&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Total capital deficiency&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(64,994&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(47,943&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;Although there was with no impact to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows from operating activities:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 921px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Net loss&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(36,238&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;15,215&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(21,023&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Increase in contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;34,929&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(16,665&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;18,264&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;Increase in contract asset&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(1,450&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;1,450&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(3,738&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(3,738&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The impacts of the restatement have been reflected throughout the financial statements, including the applicable footnotes, as appropriate.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="margin: 0in 0in 0.0001pt 1in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt;"&gt;In addition, in connection with the Chiesi Ex-U.S. Agreement, the Company should have recognized $1.8&amp;#160;million of revenue in the last quarter of 2017 and accordingly has revised certain items in its consolidated financial statements for December&amp;#160;31, 2017 presented herein. The Company evaluated the materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&amp;#8217;s prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for December&amp;#160;31, 2017:&lt;/div&gt;&lt;div style="margin: 0px 0in 0px 0.75in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="width: 80%; margin-left: 0.75in; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &amp;quot;times new roman&amp;quot;, serif; line-height: normal; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;As revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 61%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;Contracts liability&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;26,851&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(1,836&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;25,015&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;Accumulated deficit&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(297,932&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;1,836&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(296,096&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="margin: 0px 0in 0px 0.75in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2017, filed by the Company with the Commission. The comparative balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock id="Factid_4039444" contextRef="P01_01_2018To09_30_2018">&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss per share (&amp;#8220;LPS&amp;#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), outstanding for each period.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 76,195,921 and 73,310,911 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares of Common Stock issuable upon conversion of the convertible notes for the nine months ended September&amp;#160;30, 2017 and 2018, respectively, and 80,696,070 and 73,280,977 shares of Common Stock for the three months ended September&amp;#160;30, 2017 and 2018, respectively, because the effect would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_4039445" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">41868000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_4039446" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">51163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<plx:SupplementaryIncomeStatementInformationTableTextBlock id="Factid_4039451" contextRef="P01_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&amp;#8217;s disaggregation&amp;#160;of revenues:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; margin-left: 0.5in; width: 80%;"&gt;&lt;tr&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; vertical-align: bottom; width: 64%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pfizer&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,649&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;10,198&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Brazil&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,573&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,575&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"&gt;&lt;div style="margin-left: 0.26in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenues from selling goods&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,222&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;16,773&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none;"&gt;Revenues from license and R&amp;amp;D services&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; text-align: right; line-height: normal; font-size: 10pt;"&gt;16,665&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="Factid_4039452" contextRef="P01_01_2018To09_30_2018">&lt;div style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;The Company&amp;#8217;s inventory at September&amp;#160;30, 2018 and December&amp;#160;31, 2017 consisted of the&amp;#160;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;following:&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September 30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;(U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 64%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Raw materials&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;3,201&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;3,838&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Work in progress&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;276&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;485&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;4,482&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;3,510&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;Total inventory&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;7,959&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;7,833&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_4039458" contextRef="P01_01_2018To09_30_2018">&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue recognition (as restated)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.75in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;1.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;"&gt;Revenue from supply agreements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenues from supply agreements and from selling products when control is transferred to the customer and collectability is probable.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.75in; padding: 0px; text-align: justify;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;"&gt;2.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;"&gt;Revenue from Chiesi Agreements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;According to Accounting Standard Codification Topic 606, Revenue from contracts with customers (&amp;#8220;ASC 606&amp;#8221;), a&amp;#160;performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&amp;#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company has identified two performance obligations in each of the Chiesi agreements as follows: (1) the license and research and development services and (2)&amp;#160;a contingent performance obligation regarding future&amp;#160;manufacturing.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company determined that the licenses granted to Chiesi together with the research and development services should be combined into a single performance obligation under each agreement since&amp;#160;Chiesi cannot benefit from a license without the&amp;#160;research and development services.&amp;#160;The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The future manufacturing&amp;#160;is contingent on regulatory approvals of the drug and&amp;#160;the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method.&amp;#160;Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur, usually upon achievement of a specific milestone.&amp;#160;The Company used significant judgment when it determined variable consideration.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;Since the customer benefits from the research and development services as the entity performs, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;Revenue from additional&amp;#160;research and development&amp;#160;services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company accounted for the Chiesi U.S. agreement as a modification of the Chiesi Ex-U.S. Agreement. As such, the Company recorded revenue through a cumulative catch-up adjustment&amp;#160;in&amp;#160;the&amp;#160;amount&amp;#160;of&amp;#160;$6.2&amp;#160;million.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company&amp;#8217;s revenue recognition accounting policy prior to January 1, 2018, was materially the same.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Factid_4039459" contextRef="P01_01_2018To09_30_2018">&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently adopted standards&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;In May 2014, the&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;)&amp;#160;&lt;/div&gt;issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&amp;#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December&amp;#160;15, 2017. On January&amp;#160;1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers, and all the related amendments, using the modified retrospective method. The implementation of this Accounting Standards Update (ASU) did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-align: justify;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;In January 2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2017. The implementation of this ASU did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock id="Factid_4039460" contextRef="P01_01_2018To09_30_2018">The liability component was valued based on the Income Approach. The following parameters were used:&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.98in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 39%;;margin : 0px auto;;text-align:left;;margin-left :auto;margin-right :auto;"&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; font-family: &amp;quot;times new roman&amp;quot;, times, serif;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;Notes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="white-space: pre-line; font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; width: 79%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price (USD)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 18%; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.73&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.13&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.87&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;75.56&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13.50&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:AccountsReceivableNetCurrent id="Factid_4039461" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">4894000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent id="Factid_4039462" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">1721000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_4039463" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">2619000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_4039464" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">1934000</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_4039467" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">57340000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_4039468" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">62651000</us-gaap:AssetsCurrent>
<us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Factid_4039469" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">1779000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
<us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="Factid_4039470" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">1887000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_4039471" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">6628000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_4039472" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">7676000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets id="Factid_4039473" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">65747000</us-gaap:Assets>
<us-gaap:Assets id="Factid_4039474" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">72214000</us-gaap:Assets>
<us-gaap:AccountsPayableTradeCurrent id="Factid_4039475" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">4388000</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableTradeCurrent id="Factid_4039476" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">7521000</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableOtherCurrent id="Factid_4039477" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">10163000</us-gaap:AccountsPayableOtherCurrent>
<us-gaap:AccountsPayableOtherCurrent id="Factid_4039478" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">9310000</us-gaap:AccountsPayableOtherCurrent>
<us-gaap:ConvertibleDebtCurrent id="Factid_4039479" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:ConvertibleDebtCurrent id="Factid_4039480" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">5921000</us-gaap:ConvertibleDebtCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_4039481" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">24337000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_4039482" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">22752000</us-gaap:LiabilitiesCurrent>
<us-gaap:ConvertibleDebtNoncurrent id="Factid_4039483" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">47320000</us-gaap:ConvertibleDebtNoncurrent>
<us-gaap:ConvertibleDebtNoncurrent id="Factid_4039484" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">46267000</us-gaap:ConvertibleDebtNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_4039485" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">33493000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_4039486" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">25015000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Factid_4039487" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">2386000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
<us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="Factid_4039488" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">2586000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent id="Factid_4039489" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">6154000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent id="Factid_4039490" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">5051000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent id="Factid_4039491" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">89353000</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent id="Factid_4039492" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">78919000</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities id="Factid_4039493" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">113690000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_4039494" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">101671000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies id="Factid_4039495" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_4039496" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:StockholdersEquity id="Factid_4039497" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">-47943000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_4039499" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">65747000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_4039500" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">72214000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:InventoryRawMaterialsNetOfReserves id="Factid_4039519" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">3201000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryRawMaterialsNetOfReserves id="Factid_4039520" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">3838000</us-gaap:InventoryRawMaterialsNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves id="Factid_4039521" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">276000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryWorkInProcessNetOfReserves id="Factid_4039522" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">485000</us-gaap:InventoryWorkInProcessNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves id="Factid_4039523" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">4482000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryFinishedGoodsNetOfReserves id="Factid_4039524" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">3510000</us-gaap:InventoryFinishedGoodsNetOfReserves>
<us-gaap:InventoryNet id="Factid_4039525" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">7959000</us-gaap:InventoryNet>
<us-gaap:InventoryNet id="Factid_4039526" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">7833000</us-gaap:InventoryNet>
<us-gaap:SharePrice id="Factid_4039532" contextRef="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2">0.73</us-gaap:SharePrice>
<plx:UpfrontNonrefundableNoncreditablePaymentReceivable id="Factid_4039536" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
<plx:AdditionalAmountsPayableToCoverDevelopmentCosts id="Factid_4039537" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">25000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
<plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear id="Factid_4039538" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">10000000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
<plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones id="Factid_4039539" contextRef="PAsOn10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">320000000</plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones>
<plx:AdditionalAmountsPayableToCoverDevelopmentCosts id="Factid_4039540" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">20000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
<plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear id="Factid_4039541" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
<plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones id="Factid_4039542" contextRef="PAsOn07_23_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">760000000</plx:AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones>
<plx:PaymentOnNetSalesPercentage id="Factid_4039543" contextRef="P09_19_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
<plx:PaymentOnNetSalesPercentage id="Factid_4039544" contextRef="P09_19_2017To10_19_2017_ChiesiExUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.35</plx:PaymentOnNetSalesPercentage>
<plx:PaymentOnNetSalesPercentage id="Factid_4039545" contextRef="P09_19_2017To10_19_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
<plx:PaymentOnNetSalesPercentage id="Factid_4039546" contextRef="P09_19_2017To10_19_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="1">0.4</plx:PaymentOnNetSalesPercentage>
<plx:ProceedsFromExchangeForRightsToRoyalties id="Factid_4039547" contextRef="P10_01_2015To10_31_2015_PfizerAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">36000000</plx:ProceedsFromExchangeForRightsToRoyalties>
<plx:CollaborativeArrangementRevenuesExpensesSharingPercentage id="Factid_4039548" contextRef="PAsOn10_31_2015_AmendedPfizerAgreementMemberusgaapTypeOfArrangementAxis_BRsrtStatementGeographicalAxis_ProtalixBioTherapeuticsIncorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="1">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
<plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase id="Factid_4039549" contextRef="P01_01_2018To09_30_2018_BRsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="1">0.1</plx:PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase>
<plx:SupplyCommitmentInYear2017 id="Factid_4039550" contextRef="PAsOn12_31_2017_BrazilAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">24300000</plx:SupplyCommitmentInYear2017>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_4039551" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_shares" decimals="0">76195921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_4039552" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_shares" decimals="0">73310911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_4039553" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_shares" decimals="0">80696070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_4039554" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_shares" decimals="0">73280977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_4039555" contextRef="PAsOn12_31_2017" unitRef="Unit_USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<plx:UpfrontNonrefundableNoncreditablePaymentReceivable id="Factid_4039556" contextRef="PAsOn10_19_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
<us-gaap:ConvertibleDebtFairValueDisclosures id="Factid_4039557" contextRef="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-5">78000000</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_4039558" contextRef="P01_01_2018To09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0">1456354</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtInstrumentFaceAmount id="Factid_4039559" contextRef="PAsOn09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">58000000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_4039562" contextRef="P01_01_2018To09_30_2018_FourPointFiveZeroPercentageConvertibleNotes2018MemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0">2613636</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:RepaymentsOfConvertibleDebt id="Factid_4039563" contextRef="P01_01_2018To09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0">14439</us-gaap:RepaymentsOfConvertibleDebt>
<us-gaap:RepaymentsOfConvertibleDebt id="Factid_4039564" contextRef="P01_01_2018To09_30_2018_FourPointFiveZeroPercentageConvertibleNotes2018MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">2200000</us-gaap:RepaymentsOfConvertibleDebt>
<us-gaap:DebtConversionOriginalDebtAmount1 id="Factid_4039565" contextRef="P01_01_2018To09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">1100000</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:DebtInstrumentCarryingAmount id="Factid_4039566" contextRef="PAsOn09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">58000000</us-gaap:DebtInstrumentCarryingAmount>
<us-gaap:Revenues id="Factid_4039567" contextRef="P01_01_2018To09_30_2018_PfizerMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">4649000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039568" contextRef="P01_01_2017To09_30_2017_PfizerMembersrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">10198000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039569" contextRef="P01_01_2018To09_30_2018_BRsrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">2573000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039570" contextRef="P01_01_2017To09_30_2017_BRsrtStatementGeographicalAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">6575000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039571" contextRef="P01_01_2018To09_30_2018_SellingGoodsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">7222000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039572" contextRef="P01_01_2017To09_30_2017_SellingGoodsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">16773000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039573" contextRef="P07_01_2018To09_30_2018_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">663000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039577" contextRef="P07_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">11672000</us-gaap:Revenues>
<us-gaap:CostOfRevenue id="Factid_4039581" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1917000</us-gaap:CostOfRevenue>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_4039583" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">25565000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_4039584" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">22389000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_4039586" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">7118000</us-gaap:ResearchAndDevelopmentExpense>
<plx:GrantsAndReimbursementsReceivedOrReceivable id="Factid_4039587" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1810000</plx:GrantsAndReimbursementsReceivedOrReceivable>
<plx:GrantsAndReimbursementsReceivedOrReceivable id="Factid_4039588" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">2545000</plx:GrantsAndReimbursementsReceivedOrReceivable>
<plx:GrantsAndReimbursementsReceivedOrReceivable id="Factid_4039589" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">732000</plx:GrantsAndReimbursementsReceivedOrReceivable>
<plx:GrantsAndReimbursementsReceivedOrReceivable id="Factid_4039590" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">729000</plx:GrantsAndReimbursementsReceivedOrReceivable>
<plx:ResearchDevelopmentAndEngineeringExpenseNet id="Factid_4039591" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">23755000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
<plx:ResearchDevelopmentAndEngineeringExpenseNet id="Factid_4039592" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">19844000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
<plx:ResearchDevelopmentAndEngineeringExpenseNet id="Factid_4039594" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">6389000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039595" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">8744000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039596" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">8187000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039597" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">4088000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039598" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">2836000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:OperatingIncomeLoss id="Factid_4039599" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-15636000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_4039600" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-24935000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_4039602" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-7765000</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingExpense id="Factid_4039603" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">5824000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense id="Factid_4039604" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">8809000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense id="Factid_4039605" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1811000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense id="Factid_4039606" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">3680000</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingIncome id="Factid_4039607" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">437000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome id="Factid_4039608" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">1670000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome id="Factid_4039609" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">230000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome id="Factid_4039610" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">8000</us-gaap:OtherNonoperatingIncome>
<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet id="Factid_4039611" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-38061000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
<us-gaap:NonoperatingIncomeExpense id="Factid_4039613" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-5387000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_4039614" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-45200000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_4039615" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-1581000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_4039616" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-3672000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss id="Factid_4039617" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-21023000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039619" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-5322000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039620" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-11437000</us-gaap:NetIncomeLoss>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039621" contextRef="P01_01_2018To09_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">54000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039622" contextRef="P01_01_2017To09_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">163000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039623" contextRef="P07_01_2018To09_30_2018_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">14000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039624" contextRef="P07_01_2017To09_30_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">43000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039625" contextRef="P01_01_2018To09_30_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">42000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039626" contextRef="P01_01_2017To09_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">128000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039627" contextRef="P07_01_2018To09_30_2018_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">8000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_4039628" contextRef="P07_01_2017To09_30_2017_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">32000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:StockholdersEquity id="Factid_4039629" contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">124000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039630" contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">202575000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039631" contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-212656000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039632" contextRef="PAsOn12_31_2016" unitRef="Unit_USD" decimals="-3">-9957000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039633" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">144000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039634" contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">266495000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039635" contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-296096000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039636" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">-29457000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_4039637" contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">124134085</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding id="Factid_4039638" contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">143728797</us-gaap:SharesOutstanding>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_4039639" contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_4039640" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_4039641" contextRef="P01_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_4039642" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Factid_4039643" contextRef="P01_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">16000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Factid_4039644" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">16000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Factid_4039645" contextRef="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">29898</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_4039646" contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_4039647" contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">8771000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_4039648" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">8781000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_4039649" contextRef="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_4039650" contextRef="P01_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1289000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="Factid_4039651" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1291000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Factid_4039652" contextRef="P01_01_2017To09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">9711235</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Factid_4039653" contextRef="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">1928907</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:NetIncomeLoss id="Factid_4039654" contextRef="P01_01_2017To09_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-70135000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039656" contextRef="P01_01_2018To09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-21023000</us-gaap:NetIncomeLoss>
<us-gaap:StockholdersEquity id="Factid_4039658" contextRef="PAsOn09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">134000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039659" contextRef="PAsOn09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">256586000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039660" contextRef="PAsOn09_30_2017_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-282791000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039661" contextRef="PAsOn09_30_2017" unitRef="Unit_USD" decimals="-3">-26071000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039662" contextRef="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">148000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039663" contextRef="PAsOn09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">269028000</us-gaap:StockholdersEquity>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039664" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD_per_Share" decimals="2">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039665" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD_per_Share" decimals="2">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039666" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD_per_Share" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039667" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD_per_Share" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_4039668" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_shares" decimals="0">146752355</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_4039669" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_shares" decimals="0">128223722</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_4039670" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_shares" decimals="0">148187513</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_4039671" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_shares" decimals="0">132549001</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="Factid_4039673" contextRef="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="Factid_4039674" contextRef="P10_01_2018To10_31_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0">14860</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:Revenues id="Factid_4039675" contextRef="P01_01_2018To09_30_2018_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">7222000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039676" contextRef="P01_01_2017To09_30_2017_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">16773000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039677" contextRef="P07_01_2017To09_30_2017_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">7526000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039678" contextRef="P01_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">16665000</us-gaap:Revenues>
<us-gaap:CostOfRevenue id="Factid_4039679" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">7024000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue id="Factid_4039680" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">13677000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue id="Factid_4039681" contextRef="P07_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">6066000</us-gaap:CostOfRevenue>
<plx:ResearchDevelopmentAndEngineeringExpenseNet id="Factid_4039682" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">10071000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_4039683" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">10803000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingIncomeLoss id="Factid_4039684" contextRef="P07_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-3741000</us-gaap:OperatingIncomeLoss>
<us-gaap:StockholdersEquity id="Factid_4039685" contextRef="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-317119000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_4039687" contextRef="PAsOn09_30_2017_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">133845320</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding id="Factid_4039688" contextRef="PAsOn09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">148301238</us-gaap:SharesOutstanding>
<us-gaap:NetIncomeLoss id="Factid_4039690" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-70135000</us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensation id="Factid_4039691" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">96000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_4039692" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">291000</us-gaap:ShareBasedCompensation>
<us-gaap:Depreciation id="Factid_4039693" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1257000</us-gaap:Depreciation>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_4039694" contextRef="PAsOn09_30_2018" unitRef="Unit_USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_4039695" contextRef="PAsOn09_30_2018" unitRef="Unit_shares" decimals="0">250000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_4039696" contextRef="PAsOn09_30_2017" unitRef="Unit_USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_4039697" contextRef="PAsOn09_30_2017" unitRef="Unit_shares" decimals="0">250000000</us-gaap:CommonStockSharesAuthorized>
<plx:StockIssuedDuringPeriodValueConvertibleNoteExchange id="Factid_4039698" contextRef="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">2000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
<plx:StockIssuedDuringPeriodValueConvertibleNoteExchange id="Factid_4039699" contextRef="P01_01_2018To09_30_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1148000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
<plx:StockIssuedDuringPeriodValueConvertibleNoteExchange id="Factid_4039700" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1150000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
<plx:StockIssuedDuringPeriodSharesConvertibleNoteExchange id="Factid_4039701" contextRef="P01_01_2018To09_30_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0">2613636</plx:StockIssuedDuringPeriodSharesConvertibleNoteExchange>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="Factid_4039702" contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">43634000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther id="Factid_4039703" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">43634000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:Depreciation id="Factid_4039704" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">1469000</us-gaap:Depreciation>
<us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Factid_4039705" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">37000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
<us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="Factid_4039706" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-13000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
<us-gaap:PensionAndOtherPostretirementBenefitExpense id="Factid_4039707" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-86000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
<us-gaap:PensionAndOtherPostretirementBenefitExpense id="Factid_4039708" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">54000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
<plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Factid_4039709" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">45000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
<plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="Factid_4039710" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">21000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
<plx:IncomeLossOnConversionOfConvertibleNotes id="Factid_4039711" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-204000</plx:IncomeLossOnConversionOfConvertibleNotes>
<plx:IncomeLossOnConversionOfConvertibleNotes id="Factid_4039712" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-587000</plx:IncomeLossOnConversionOfConvertibleNotes>
<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet id="Factid_4039713" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-38061000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
<us-gaap:AmortizationOfFinancingCosts id="Factid_4039714" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1916000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts id="Factid_4039715" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">1710000</us-gaap:AmortizationOfFinancingCosts>
<plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes id="Factid_4039716" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">205000</plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes>
<plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes id="Factid_4039717" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">1111000</plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_4039718" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">18264000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_4039719" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-837000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInAccountsReceivable id="Factid_4039720" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">3661000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable id="Factid_4039721" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">6467000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories id="Factid_4039722" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">126000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories id="Factid_4039723" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">2234000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Factid_4039724" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-1805000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Factid_4039725" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">8698000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Factid_4039726" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-3738000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Factid_4039727" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-27700000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations id="Factid_4039728" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">116000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_4039731" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">498000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_4039732" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">681000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:IncreaseDecreaseInRestrictedCash id="Factid_4039733" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">247000</us-gaap:IncreaseDecreaseInRestrictedCash>
<us-gaap:IncreaseDecreaseInRestrictedCash id="Factid_4039734" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">336000</us-gaap:IncreaseDecreaseInRestrictedCash>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Factid_4039735" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-70000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="Factid_4039736" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">68000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_4039737" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-675000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_4039738" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-1085000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:RepaymentsOfConvertibleDebt id="Factid_4039739" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">4752000</us-gaap:RepaymentsOfConvertibleDebt>
<us-gaap:RepaymentsOfConvertibleDebt id="Factid_4039740" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">10961000</us-gaap:RepaymentsOfConvertibleDebt>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_4039741" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-4752000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_4039742" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-1419000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_4039743" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-130000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_4039744" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">289000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_4039745" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-9295000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Factid_4039746" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-29799000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_4039748" contextRef="PAsOn12_31_2016" unitRef="Unit_USD" decimals="-3">63281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_4039750" contextRef="PAsOn09_30_2017" unitRef="Unit_USD" decimals="-3">33482000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Factid_4039751" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">237000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
<plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="Factid_4039752" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">666000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
<us-gaap:DebtConversionConvertedInstrumentAmount1 id="Factid_4039753" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">2236000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 id="Factid_4039754" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">7668000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:InterestPaidNet id="Factid_4039755" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">2411000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet id="Factid_4039756" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">2613000</us-gaap:InterestPaidNet>
<us-gaap:DebtInstrumentInterestRateStatedPercentage id="Factid_4039759" contextRef="PAsOn09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtConversionConvertedInstrumentAmount1 id="Factid_4039760" contextRef="P01_01_2018To09_30_2018_FourPointFiveZeroPercentageConvertibleNotes2018MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-4">3420000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<plx:RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds id="Factid_4039761" contextRef="P01_01_2018To09_30_2018_SevenPointFiveZeroPercentageConvertibleNotes2021MemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5">2500000</plx:RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds>
<us-gaap:DebtInstrumentInterestRateStatedPercentage id="Factid_4039762" contextRef="PAsOn09_30_2018_FourPointFiveZeroPercentageConvertibleNotes2018MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature id="Factid_4039771" contextRef="P01_01_2017To09_30_2017_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature id="Factid_4039772" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">1315000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="Factid_4039773" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">1103000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
<us-gaap:ProceedsFromConvertibleDebt id="Factid_4039774" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">9542000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_4039784" contextRef="P01_01_2018To09_30_2018">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 6 &amp;#8211; STOCK TRANSACTIONS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 13, 2018, the Company&amp;#8217;s compensation committee approved the grant of 10-year options&amp;#160;to&amp;#160;purchase, in the aggregate, 6,360,000 shares of Common Stock, of which options to purchase 4,000,000 shares &lt;/div&gt; of Common Stock&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;were granted to the Company&amp;#8217;s executive officers and options to purchase 2,360,000 shares &lt;/div&gt; of Common Stock&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;were granted to other employees with an exercise price equal to $0.56 per share and $0.51 per share, respectively, under the Company&amp;#8217;s 2006 Employee Stock Incentive Plan, as amended (the &amp;#8220;Plan&amp;#8221;). The options vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the executive officers is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other&amp;#160;terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.9&amp;#160;million based on the following weighted average&lt;/div&gt; assumptions: share price equal to $0.51; dividend&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;yield of 0% for all years; expected volatility of 64.3%; risk-free interest rates of 2.9%; and expected life of six years.&lt;/div&gt;&lt;/div&gt; &lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Factid_4039785" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_4039786" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">6360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="Factid_4039787" contextRef="PAsOn09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5">1900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="Factid_4039788" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="1">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="Factid_4039789" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3">0.643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="Factid_4039790" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="3">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_4039791" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_ExecutiveOfficersMemberusgaapTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Factid_4039792" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_ExecutiveMemberusgaapTitleOfIndividualAxis" unitRef="Unit_shares" decimals="0">2360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Factid_4039795" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_4039805" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_ExecutiveOfficersMemberusgaapTitleOfIndividualAxis" unitRef="Unit_USD_per_Share" decimals="2">0.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_4039806" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis_ExecutiveMemberusgaapTitleOfIndividualAxis" unitRef="Unit_USD_per_Share" decimals="2">0.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<plx:FairValueAssumptionsTerm id="Factid_4039809" contextRef="P01_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis">P3Y1M17D</plx:FairValueAssumptionsTerm>
<plx:FairValueAssumptionsRiskFreeInterestRates id="Factid_4039810" contextRef="P01_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.0287</plx:FairValueAssumptionsRiskFreeInterestRates>
<plx:FairValueAssumptionsExpectedVolatilityRates id="Factid_4039811" contextRef="P01_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.7556</plx:FairValueAssumptionsExpectedVolatilityRates>
<plx:FairValueAssumptionsExpectedDividendRates id="Factid_4039812" contextRef="P01_01_2018To09_30_2018_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_SevenPointFivePercentageConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4">0.1350</plx:FairValueAssumptionsExpectedDividendRates>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Factid_4039813" contextRef="P09_01_2018To09_13_2018_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">0.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:Revenues id="Factid_4039815" contextRef="P01_01_2017To12_31_2017_FiocruzMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">7100000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039816" contextRef="P01_01_2018To09_30_2018_FiocruzMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">2600000</us-gaap:Revenues>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Factid_4039818" contextRef="P01_01_2018To09_30_2018">&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;General&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &amp;#8220;Company&amp;#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &amp;#8220;Subsidiaries&amp;#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#8217;s proprietary ProCellEx&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&amp;#160;&lt;/div&gt;protein expression system (&amp;#8220;ProCellEx&amp;#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;div style="vertical-align: super;font-size: smaller;display:inline;"&gt;&amp;#174;&lt;/div&gt;&amp;#160;in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s product pipeline currently includes, among other candidates:&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3) OPRX-106, the Company&amp;#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none; text-align: justify;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&amp;#8220;Chiesi&amp;#8221;) entered into an Ex-US license agreement (the &amp;#8220;Chiesi Ex-U.S. Agreement&amp;#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July 23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#8220;Chiesi U.S. Agreement&amp;#8221;), with respect to the development and commercialization of pegunigalsidase alfa in the United States.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;Under each of the Chiesi Ex-U.S. Agreement and the Chiesi U.S. Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&amp;#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-U.S. Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&amp;#160;million in pegunigalsidase alfa development costs, capped at $10.0&amp;#160;million per year and to receive additional payments of up to $320.0&amp;#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi U.S. Agreement, Protalix Ltd.&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;is entitled to payments of up to a maximum of $20.0&lt;/div&gt;&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&lt;/div&gt;&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million per year, and to receive an additional up to a maximum of $760.0&lt;/div&gt;&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of both of the Chiesi agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-U.S. Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi U.S. Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&amp;#8220;Pfizer&amp;#8221;), in accordance with the exclusive license and supply agreement between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement with Pfizer (the &amp;#8220;Amended Pfizer Agreement&amp;#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0&amp;#160;million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#8220;Brazil Agreement&amp;#8221;) with Funda&amp;#231;&amp;#227;o Oswaldo Cruz (&amp;#8220;Fiocruz&amp;#8221;), an arm of the Brazilian Ministry of Health (the &amp;#8220;Brazilian MoH&amp;#8221;), for taliglucerase alfa. Fiocruz&amp;#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In 2017, the Company received a purchase order from the Brazilian MoH for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3&amp;#160;million. Shipments started in June 2017. The Company recorded revenues of $7.1&amp;#160;million for sales of alfataliglicerase to Fiocruz in 2017, and $2.6&amp;#160;million during the nine months ended September&amp;#160;30, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12&amp;#160;months from the date of approval of the September 30, 2018 financial statements, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of presentation&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restatement of previously issued condensed consolidated financial statements&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The Company has restated these financial statements to correct an error in the revenue recognition from the agreements with Chiesi. Previously, the Company had identified a single performance obligation with regard to its promises&amp;#160;under each of the agreements. The Company subsequently concluded that there are two performance obligations under each of the agreements as follows: (i) the license together with research and development services and (ii) a contingent performance obligation regarding future manufacturing. As such, the Company has recognized revenue for the combined performance obligations (the license and the research and development services) for the three and nine months ended September&amp;#160;30, 2018 for the satisfaction of the performance obligation that occurred during the three and nine months ended September&amp;#160;30, 2018.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The Company&amp;#8217;s decision to restate the financial statements previously reported on its Quarterly Reports on Form 10-Q, was approved by, and with the continuing oversight of, the Company&amp;#8217;s Audit Committee.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;&amp;#160;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"&gt;&lt;tr style="vertical-align: top; text-align: justify;"&gt;&lt;td style="width: 0.75in; text-align: left; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impacts of restatement&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated balance sheets as of September&amp;#160;30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 88%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 764px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CONTRACTS ASSET&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 250px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;1,450&lt;/td&gt;&lt;td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CURRENT LIABILITIES:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;14,551&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;24,337&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LONG TERM LIABILITIES:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;61,780&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(28,287&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;33,493&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Total long term liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;117,640&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(28,287&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;89,353&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;132,191&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(18,501&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;113,690&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CAPITAL DEFICIENCY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(64,994&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(47,943&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated statements of operations for the three and nine months ended September 30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;(&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands,&lt;/div&gt;&lt;br/&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;except per share data)&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 642px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;REVENUES FROM LICENSE AGREEMENTS&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;11,672&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;11,672&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;16,665&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;16,665&lt;/td&gt;&lt;td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SELLING, GENERAL AND ADMINISTRATIVE EXPENSES&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(2,638&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(4,088&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(7,294&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(8,744&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OPERATING LOSS&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(13,963&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;10,222&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(3,741&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(30,851&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;15,215&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(15,636&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LOSS FOR THE PERIOD&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(15,544&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;10,222&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(5,322&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(36,238&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;15,215&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(21,023&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Net loss per share of common stock-basic and diluted&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.06&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.04&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.25&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.14&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated statements of changes in capital deficiency for the nine months ended September&amp;#160;30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands, except per share data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 921px; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(204, 238, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Net loss for the nine months ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(36,238&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;15,215&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(21,023&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balances as of September&amp;#160;30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(334,170&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(317,119&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Total capital deficiency&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(64,994&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(47,943&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;Although there was with no impact to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows from operating activities:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 921px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Net loss&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(36,238&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;15,215&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(21,023&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Increase in contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;34,929&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(16,665&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;18,264&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;Increase in contract asset&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(1,450&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;1,450&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(3,738&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(3,738&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The impacts of the restatement have been reflected throughout the financial statements, including the applicable footnotes, as appropriate.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="margin: 0in 0in 0.0001pt 1in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt;"&gt;In addition, in connection with the Chiesi Ex-U.S. Agreement, the Company should have recognized $1.8&amp;#160;million of revenue in the last quarter of 2017 and accordingly has revised certain items in its consolidated financial statements for December&amp;#160;31, 2017 presented herein. The Company evaluated the materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&amp;#8217;s prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for December&amp;#160;31, 2017:&lt;/div&gt;&lt;div style="margin: 0px 0in 0px 0.75in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="width: 80%; margin-left: 0.75in; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &amp;quot;times new roman&amp;quot;, serif; line-height: normal; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;As revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 61%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;Contracts liability&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;26,851&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(1,836&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;25,015&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;Accumulated deficit&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(297,932&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;1,836&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(296,096&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="margin: 0px 0in 0px 0.75in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2017, filed by the Company with the Commission. The comparative balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss per share (&amp;#8220;LPS&amp;#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Common Stock&amp;#8221;), outstanding for each period.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 76,195,921 and 73,310,911 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares of Common Stock issuable upon conversion of the convertible notes for the nine months ended September&amp;#160;30, 2017 and 2018, respectively, and 80,696,070 and 73,280,977 shares of Common Stock for the three months ended September&amp;#160;30, 2017 and 2018, respectively, because the effect would be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;d.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue recognition (as restated)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.75in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;1.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;"&gt;Revenue from supply agreements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"&gt;&lt;div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenues from supply agreements and from selling products when control is transferred to the customer and collectability is probable.&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.75in; padding: 0px; text-align: justify;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;"&gt;2.&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;"&gt;Revenue from Chiesi Agreements&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; text-align: justify; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;According to Accounting Standard Codification Topic 606, Revenue from contracts with customers (&amp;#8220;ASC 606&amp;#8221;), a&amp;#160;performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&amp;#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company has identified two performance obligations in each of the Chiesi agreements as follows: (1) the license and research and development services and (2)&amp;#160;a contingent performance obligation regarding future&amp;#160;manufacturing.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company determined that the licenses granted to Chiesi together with the research and development services should be combined into a single performance obligation under each agreement since&amp;#160;Chiesi cannot benefit from a license without the&amp;#160;research and development services.&amp;#160;The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The future manufacturing&amp;#160;is contingent on regulatory approvals of the drug and&amp;#160;the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method.&amp;#160;Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur, usually upon achievement of a specific milestone.&amp;#160;The Company used significant judgment when it determined variable consideration.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;Since the customer benefits from the research and development services as the entity performs, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;Revenue from additional&amp;#160;research and development&amp;#160;services ordered by Chiesi, is recognized over time using the cost-to-cost method.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company accounted for the Chiesi U.S. agreement as a modification of the Chiesi Ex-U.S. Agreement. As such, the Company recorded revenue through a cumulative catch-up adjustment&amp;#160;in&amp;#160;the&amp;#160;amount&amp;#160;of&amp;#160;$6.2&amp;#160;million.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in"&gt;The Company&amp;#8217;s revenue recognition accounting policy prior to January 1, 2018, was materially the same.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;&lt;div style="background: none; letter-spacing: 0px; font-size: 10pt; text-decoration: none; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="background-color: initial; letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="vertical-align:top"&gt;&lt;td style="width: 0.5in; padding: 0px;"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;e.&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently adopted standards&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; background: none; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"&gt;&lt;div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;In May 2014, the&amp;#160;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;)&amp;#160;&lt;/div&gt;issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&amp;#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December&amp;#160;15, 2017. On January&amp;#160;1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers, and all the related amendments, using the modified retrospective method. The implementation of this Accounting Standards Update (ASU) did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-align: justify;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;In January 2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2017. The implementation of this ASU did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<us-gaap:ContractWithCustomerLiabilityCurrent id="Factid_4039819" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">9786000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent id="Factid_4039820" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:ContractWithCustomerAssetNetNoncurrent id="Factid_4039826" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">1450000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
<us-gaap:ContractWithCustomerAssetNetNoncurrent id="Factid_4039827" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-1450000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
<us-gaap:ContractWithCustomerAssetNetNoncurrent id="Factid_4039828" contextRef="PAsOn09_30_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent id="Factid_4039832" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent id="Factid_4039833" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">9786000</us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_4039835" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">14551000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_4039836" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">9786000</us-gaap:LiabilitiesCurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_4039838" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">61780000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_4039839" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-28287000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:StockholdersEquity id="Factid_4039847" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-64994000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039848" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">17051000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesNoncurrent id="Factid_4039850" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">117640000</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent id="Factid_4039851" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-28287000</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities id="Factid_4039853" contextRef="PAsOn09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">132191000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_4039854" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-18501000</us-gaap:Liabilities>
<us-gaap:Revenues id="Factid_4039856" contextRef="P07_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039857" contextRef="P07_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">11672000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039859" contextRef="P01_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_4039860" contextRef="P01_01_2018To09_30_2018_LicenseAndServiceMembersrtProductOrServiceAxis_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">16665000</us-gaap:Revenues>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039862" contextRef="P07_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">2638000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039863" contextRef="P07_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">1450000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039865" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">7294000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense id="Factid_4039866" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">1450000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:OperatingIncomeLoss id="Factid_4039874" contextRef="P07_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-13963000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_4039875" contextRef="P07_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">10222000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_4039877" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-30851000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_4039878" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">15215000</us-gaap:OperatingIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039880" contextRef="P07_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-15544000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039881" contextRef="P07_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">10222000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039883" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-36238000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_4039884" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">15215000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039886" contextRef="P07_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039887" contextRef="P07_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2">0.06</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039889" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_4039890" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD_per_Share" decimals="2">0.11</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:StockholdersEquity id="Factid_4039895" contextRef="PAsOn09_30_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-334170000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_4039896" contextRef="PAsOn09_30_2018_RestatementAdjustmentMembersrtRestatementAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">17051000</us-gaap:StockholdersEquity>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_4039904" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">34929000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability id="Factid_4039905" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-16665000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_4039913" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">-3738000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_4039914" contextRef="P01_01_2017To09_30_2017" unitRef="Unit_USD" decimals="-3">-27584000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_4041889" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-3738000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_4041891" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:Revenues id="Factid_4041922" contextRef="P10_01_2017To12_31_2017_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">1800000</us-gaap:Revenues>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_4041968" contextRef="PAsOn12_31_2017_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">26851000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent id="Factid_4041969" contextRef="PAsOn12_31_2017_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-1836000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_4041971" contextRef="PAsOn12_31_2017_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-297932000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_4041972" contextRef="PAsOn12_31_2017_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">1836000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_4041973" contextRef="PAsOn12_31_2017" unitRef="Unit_USD" decimals="-3">-296096000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:IncreaseDecreaseInContractWithCustomerAsset id="Factid_4047223" contextRef="P01_01_2018To09_30_2018_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">-1450000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
<us-gaap:IncreaseDecreaseInContractWithCustomerAsset id="Factid_4047224" contextRef="P01_01_2018To09_30_2018_RestatementAdjustmentMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3">1450000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
<us-gaap:IncreaseDecreaseInContractWithCustomerAsset id="Factid_4047225" contextRef="P01_01_2018To09_30_2018" unitRef="Unit_USD" decimals="-3">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
<us-gaap:Revenues id="Factid_4099674" contextRef="P01_01_2018To09_30_2018_ChiesiUSAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5">6200000</us-gaap:Revenues>
<us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock id="Factid_4103517" contextRef="P01_01_2018To09_30_2018">&lt;div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated balance sheets as of September&amp;#160;30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 88%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 764px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CONTRACTS ASSET&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 250px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;1,450&lt;/td&gt;&lt;td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CURRENT LIABILITIES:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Total current liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;14,551&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;9,786&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;24,337&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LONG TERM LIABILITIES:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;61,780&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(28,287&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;33,493&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Total long term liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;117,640&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(28,287&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;89,353&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;132,191&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(18,501&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;113,690&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CAPITAL DEFICIENCY&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(64,994&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(47,943&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated statements of operations for the three and nine months ended September 30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;(&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands,&lt;/div&gt;&lt;br/&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;except per share data)&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 642px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;REVENUES FROM LICENSE AGREEMENTS&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;11,672&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;11,672&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;16,665&lt;/td&gt;&lt;td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;16,665&lt;/td&gt;&lt;td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SELLING, GENERAL AND ADMINISTRATIVE EXPENSES&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(2,638&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(4,088&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(7,294&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(1,450&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(8,744&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OPERATING LOSS&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(13,963&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;10,222&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(3,741&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(30,851&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;15,215&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(15,636&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LOSS FOR THE PERIOD&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(15,544&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;10,222&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(5,322&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(36,238&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;15,215&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(21,023&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Net loss per share of common stock-basic and diluted&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.06&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.04&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.25&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(0.14&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;The effects of the restatement on the line items within the Company&amp;#8217;s condensed consolidated statements of changes in capital deficiency for the nine months ended September&amp;#160;30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands, except per share data)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="width: 921px; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-indent: 0px;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(204, 238, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Net loss for the nine months ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(36,238&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;15,215&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(21,023&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balances as of September&amp;#160;30, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:#cceeff"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(334,170&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(317,119&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom; background-color:white"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;Total capital deficiency&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(64,994&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;17,051&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;(47,943&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;"&gt;Although there was with no impact to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 are as follows:&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended September&amp;#160;30, 2018&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:bottom"&gt;&lt;td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows from operating activities:&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 921px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;Net loss&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(36,238&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;15,215&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;&lt;td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;(21,023&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;Increase in contracts liability&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;34,929&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;(16,665&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;18,264&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;Increase in contract asset&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(1,450&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;1,450&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;Net cash used in operating activities&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(3,738&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal; font-size: 10pt;"&gt;(3,738&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="color: rgb(0, 0, 0); font: 10pt &amp;quot;times new roman&amp;quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="margin: 0in 0in 0.0001pt 1in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt;"&gt;In addition, in connection with the Chiesi Ex-U.S. Agreement, the Company should have recognized $1.8&amp;#160;million of revenue in the last quarter of 2017 and accordingly has revised certain items in its consolidated financial statements for December&amp;#160;31, 2017 presented herein. The Company evaluated the materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&amp;#8217;s prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for December&amp;#160;31, 2017:&lt;/div&gt;&lt;div style="margin: 0px 0in 0px 0.75in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;table style="width: 80%; margin-left: 0.75in; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&amp;#160;31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;U.S. dollars in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &amp;quot;times new roman&amp;quot;, serif; line-height: normal; font-size: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;originally&lt;br/&gt;reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;times new roman&amp;quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;As revised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: rgb(204, 238, 255); width: 61%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;Contracts liability&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;26,851&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(1,836&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;$&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;25,015&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;Accumulated deficit&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(297,932&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;1,836&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin: 0px 0in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; line-height: normal; background: none;"&gt;&amp;#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;(296,096&lt;/div&gt;&lt;/td&gt;&lt;td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; font-family: &amp;quot;times new roman&amp;quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="margin: 0px 0in 0px 0.75in; font-family: &amp;quot;times new roman&amp;quot;, serif; font-size: 10pt; background: none;"&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="#Factid_4039583" xlink:type="locator" xlink:label="loc_1" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_15602">Includes share-based compensation</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039584" xlink:type="locator" xlink:label="loc_2" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039586" xlink:type="locator" xlink:label="loc_3" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039595" xlink:type="locator" xlink:label="loc_4" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039596" xlink:type="locator" xlink:label="loc_5" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039597" xlink:type="locator" xlink:label="loc_6" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039598" xlink:type="locator" xlink:label="loc_7" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039683" xlink:type="locator" xlink:label="loc_8" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15602" order="1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039637" xlink:type="locator" xlink:label="loc_9" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_15603">Common Stock, $0.001 par value; Authorized &#8211; as of September 30, 2018 and 2017 - 250,000,000.</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039638" xlink:type="locator" xlink:label="loc_10" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039645" xlink:type="locator" xlink:label="loc_11" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039652" xlink:type="locator" xlink:label="loc_12" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039653" xlink:type="locator" xlink:label="loc_13" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039687" xlink:type="locator" xlink:label="loc_14" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039688" xlink:type="locator" xlink:label="loc_15" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039701" xlink:type="locator" xlink:label="loc_16" />
<link:footnoteArc xlink:type="arc" xlink:to="FN_15603" order="1" xlink:from="loc_16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
<link:loc xlink:href="#Factid_4039673" xlink:type="locator" xlink:label="loc_17" />
<link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_15604">Represents an amount less than $1.</link:footnote>
<link:footnoteArc xlink:type="arc" xlink:to="FN_15604" order="1" xlink:from="loc_17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--DataTracks Rainbow V 3.0 - www.datatracks.com - on 13-March-2019 [08:19:20] {PM}-->
<schema targetNamespace="http://www.protalix.com/20180930" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20180930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2018-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>1001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="CondensedConsolidatedStatementsOfOperationsParenthetical">
<link:definition>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency" id="CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency">
<link:definition>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" id="CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical">
<link:definition>1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>1008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/Inventories" id="Inventories">
<link:definition>1009 - Disclosure - INVENTORIES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1010 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotes" id="ConvertibleNotes">
<link:definition>1011 - Disclosure - CONVERTIBLE NOTES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/Revenues" id="Revenues">
<link:definition>1012 - Disclosure - REVENUES</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/StockTransactions" id="StockTransactions">
<link:definition>1013 - Disclosure - STOCK TRANSACTIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
<link:definition>1015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="InventoriesTables">
<link:definition>1016 - Disclosure - INVENTORIES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1017 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/RevenuesTables" id="RevenuesTables">
<link:definition>1018 - Disclosure - REVENUES (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails" id="SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails">
<link:definition>1019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated balance sheets) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails" id="SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails">
<link:definition>1020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated income statement) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails" id="SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails">
<link:definition>1021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated statements of changes in capital deficiency) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails" id="SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails">
<link:definition>1022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated of cash flows) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesReportedAndAsAdjustedDetails" id="SignificantAccountingPoliciesReportedAndAsAdjustedDetails">
<link:definition>1023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES  Reported and as adjusted (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" id="SignificantAccountingPoliciesNarrativeDetails">
<link:definition>1024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/InventoriesDetails" id="InventoriesDetails">
<link:definition>1025 - Disclosure - INVENTORIES (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" id="FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails">
<link:definition>1026 - Disclosure - FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" id="FairValueMeasurementNarrativeDetails">
<link:definition>1027 - Disclosure - FAIR VALUE MEASUREMENT (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails" id="ConvertibleNotesNarrativeDetails">
<link:definition>1028 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails" id="RevenuesStatementsOfOperationsDetails">
<link:definition>1029 - Disclosure - REVENUES (Statements of operations) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.protalix.com/role/StockTransactionsNarrativeDetails" id="StockTransactionsNarrativeDetails">
<link:definition>1030 - Disclosure - STOCK TRANSACTIONS (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="plx-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
<import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
<element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="GrantsAndReimbursementsReceivedOrReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_GrantsAndReimbursementsReceivedOrReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockIssuedDuringPeriodValueConvertibleNoteExchange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesConvertibleNoteExchange" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" substitutionGroup="xbrli:item" />
<element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncomeLossOnConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncomeLossOnConversionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_RevenueDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="SupplementaryIncomeStatementInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_SupplementaryIncomeStatementInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
<element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
<element name="BrazilAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_BrazilAgreementMember" substitutionGroup="xbrli:item" />
<element name="PfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_PfizerAgreementMember" substitutionGroup="xbrli:item" />
<element name="FiocruzMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_FiocruzMember" substitutionGroup="xbrli:item" />
<element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
<element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
<element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" substitutionGroup="xbrli:item" />
<element name="CollaborativeArrangementRevenuesExpensesSharingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" substitutionGroup="xbrli:item" />
<element name="SupplyCommitmentInYear2017" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_SupplyCommitmentInYear2017" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromExchangeForRightsToRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ProceedsFromExchangeForRightsToRoyalties" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontNonrefundableNoncreditablePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionalAmountsPayableToCoverDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
<element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsRiskFreeInterestRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsRiskFreeInterestRates" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsExpectedVolatilityRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedVolatilityRates" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsTerm" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsExpectedDividendRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedDividendRates" substitutionGroup="xbrli:item" />
<element name="SevenPointFiveZeroPercentageConvertibleNotes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" substitutionGroup="xbrli:item" />
<element name="FourPointFiveZeroPercentageConvertibleNotes2018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" substitutionGroup="xbrli:item" />
<element name="RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_PfizerMember" substitutionGroup="xbrli:item" />
<element name="SellingGoodsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SellingGoodsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExecutiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ExecutiveMember" substitutionGroup="xbrli:item" />
<element name="ExecutiveOfficersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ExecutiveOfficersMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--DataTracks Rainbow V 3.0 - www.datatracks.com - on 13-March-2019 [08:19:20] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" use="optional" order="130" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="110" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="70" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="90" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="100" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="280" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="210" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="180" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" use="optional" order="190" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleDebtCurrent" use="optional" order="200" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="3374980" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" use="optional" order="270" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent" use="optional" order="230" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="240" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" use="optional" order="250" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="260" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="310" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="300" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="270" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash" use="optional" order="280" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" use="optional" order="290" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="2553200" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt" use="optional" order="320" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="330" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="3382500" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="240" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="230" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" use="optional" order="90" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" use="optional" order="100" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" use="optional" order="110" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" use="optional" order="120" weight="-1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncomeLossOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeLossOnConversionOfConvertibleNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_plx_IncomeLossOnConversionOfConvertibleNotes" use="optional" order="130" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" use="optional" order="150" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="160" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" use="optional" order="170" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" use="optional" order="180" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="200" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="210" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="220" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" use="optional" order="2554980" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" use="optional" order="340" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="60" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="160" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingExpense" use="optional" order="130" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="140" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" use="optional" order="150" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="120" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" use="optional" order="100" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="80" weight="1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" use="optional" order="90" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="110" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="60" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="50" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves" use="optional" order="60" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" use="optional" order="70" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--DataTracks Rainbow V 3.0 - www.datatracks.com - on 13-March-2019 [08:19:20] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurementTables" roleURI="http://www.protalix.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesReportedAndAsAdjustedDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesReportedAndAsAdjustedDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurementNarrativeDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#ConvertibleNotesNarrativeDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#RevenuesStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#StockTransactionsNarrativeDetails" roleURI="http://www.protalix.com/role/StockTransactionsNarrativeDetails" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_StatementTable_38" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38" xlink:to="loc_us-gaap_StatementClassOfStockAxis_39" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39" xlink:to="loc_us-gaap_ClassOfStockDomain_48" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_48_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39" xlink:to="loc_us-gaap_ClassOfStockDomain_48_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_AssetsAbstract_41" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_AssetsCurrentAbstract_42" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_50" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_OtherAssetsCurrent_51" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_InventoryNet_52" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_AssetsCurrent_53" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_54" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_55" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_Assets_56" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_63" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_62" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_61" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_44" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44" xlink:to="loc_us-gaap_LiabilitiesCurrent_60" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_59" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_59" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_58" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337498" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_65" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_Liabilities_66" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_CommitmentsAndContingencies_67" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_StockholdersEquity_68" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_187" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_StatementTable_185" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_185" xlink:to="loc_us-gaap_StatementClassOfStockAxis_186" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_186" xlink:to="loc_us-gaap_ClassOfStockDomain_188" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_188_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_186" xlink:to="loc_us-gaap_ClassOfStockDomain_188_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_337511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_185" xlink:to="loc_srt_ProductOrServiceAxis_337511" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_337511" xlink:to="loc_srt_ProductsAndServicesDomain_337512" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_337511" xlink:to="loc_srt_ProductsAndServicesDomain_337512_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_337513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_337512" xlink:to="loc_us-gaap_ProductMember_337513" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_337514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_337512" xlink:to="loc_us-gaap_LicenseAndServiceMember_337514" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_Revenues_189" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_CostOfRevenue_190" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_192" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_193" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_194" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_195" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_OperatingIncomeLoss_196" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_OtherNonoperatingExpense_197" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_OtherNonoperatingIncome_198" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_199" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_202" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_203" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_200" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_NetIncomeLoss_201" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_209" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_209" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_207" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_207" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_208" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_207" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_208_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_208" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_210" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_208" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_211" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_209" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_212" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_218" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockholdersEquity_222" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StatementTable_215" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_215" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_216" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_216" xlink:to="loc_us-gaap_EquityComponentDomain_217" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_216" xlink:to="loc_us-gaap_EquityComponentDomain_217_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_217" xlink:to="loc_us-gaap_CommonStockMember_219" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_217" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_220" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_217" xlink:to="loc_us-gaap_RetainedEarningsMember_221" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:label="loc_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_223337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_223337" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:label="loc_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_223338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_223338" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_228" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_NetIncomeLoss_229" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_SharesOutstanding_223" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_224" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_225" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_226" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_227" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_223091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_223091" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_255319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_255319" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_236" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_236" xlink:to="loc_us-gaap_StatementTable_234" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_AwardTypeAxis_235" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_236" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_236" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_239" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_244" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_StatementTable_242" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_242" xlink:to="loc_us-gaap_StatementClassOfStockAxis_243" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_243" xlink:to="loc_us-gaap_ClassOfStockDomain_252" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_252_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_243" xlink:to="loc_us-gaap_ClassOfStockDomain_252_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_NetIncomeLoss_253" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_ShareBasedCompensation_254" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_Depreciation_255" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_256" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_257" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_258" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncomeLossOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeLossOnConversionOfConvertibleNotes_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_plx_IncomeLossOnConversionOfConvertibleNotes_259" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_260" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_261" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_262" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_263" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_264" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_265" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_266" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_267" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_268" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_269" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338250" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_277" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_275" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_276" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_255320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_255320" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_271" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_272" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_273" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_251" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_251" xlink:to="loc_us-gaap_InterestPaidNet_283" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_278" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_279" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_282" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" xlink:to="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_281" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_StatementTable_25" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_StatementClassOfStockAxis_26" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26" xlink:to="loc_us-gaap_ClassOfStockDomain_30" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_30_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26" xlink:to="loc_us-gaap_ClassOfStockDomain_30_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_DebtInstrumentAxis_27" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_27" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_28" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_28_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_27" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_28_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_32" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337634" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337624" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337624" xlink:to="loc_srt_RestatementAxis_337626" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_337626" xlink:to="loc_srt_RestatementDomain_337627" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337627_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_337626" xlink:to="loc_srt_RestatementDomain_337627_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337627" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337628" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337627" xlink:to="loc_srt_RestatementAdjustmentMember_337632" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_337635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_us-gaap_AssetsAbstract_337635" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_337636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_337635" xlink:to="loc_us-gaap_AssetsCurrentAbstract_337636" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_337637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_337636" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_337637" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_337640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_337640" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_337660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_337640" xlink:to="loc_us-gaap_LiabilitiesAbstract_337660" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_337661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_337660" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_337661" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_337661" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337644" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_337646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_337661" xlink:to="loc_us-gaap_LiabilitiesCurrent_337646" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_337660" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337654" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_337657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_337657" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_337673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_337660" xlink:to="loc_us-gaap_Liabilities_337673" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_337674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_us-gaap_StockholdersEquity_337674" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337728" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337703" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337703" xlink:to="loc_srt_RestatementAxis_337718" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_337718" xlink:to="loc_srt_RestatementDomain_337719" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337719_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_337718" xlink:to="loc_srt_RestatementDomain_337719_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337719" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337722" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337719" xlink:to="loc_srt_RestatementAdjustmentMember_337723" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_337736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337703" xlink:to="loc_srt_ProductOrServiceAxis_337736" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_337736" xlink:to="loc_srt_ProductsAndServicesDomain_337737" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337737_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_337736" xlink:to="loc_srt_ProductsAndServicesDomain_337737_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_337742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_337737" xlink:to="loc_us-gaap_LicenseAndServiceMember_337742" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_337745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_Revenues_337745" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_337752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_OperatingIncomeLoss_337752" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_NetIncomeLoss_337759" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_337763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_337763" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_337787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_337787" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337826" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337826" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337819" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337819" xlink:to="loc_srt_RestatementAxis_337820" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_337820" xlink:to="loc_srt_RestatementDomain_337822" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337822_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_337820" xlink:to="loc_srt_RestatementDomain_337822_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337822" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337823" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337822" xlink:to="loc_srt_RestatementAdjustmentMember_337824" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_337908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337819" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_337908" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_337909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_337908" xlink:to="loc_us-gaap_EquityComponentDomain_337909" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_337909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_337908" xlink:to="loc_us-gaap_EquityComponentDomain_337909_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_337916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_337909" xlink:to="loc_us-gaap_RetainedEarningsMember_337916" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337826" xlink:to="loc_us-gaap_NetIncomeLoss_337827" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_337834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337826" xlink:to="loc_us-gaap_StockholdersEquity_337834" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337945" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337939" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337939" xlink:to="loc_srt_RestatementAxis_337941" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_337941" xlink:to="loc_srt_RestatementDomain_337942" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337942_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_337941" xlink:to="loc_srt_RestatementDomain_337942_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337942" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337943" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_337942" xlink:to="loc_srt_RestatementAdjustmentMember_337944" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_NetIncomeLoss_337951" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337953" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_344317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_344317" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_345037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_345037" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesReportedAndAsAdjustedDetails">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_344367" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_344360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_344367" xlink:to="loc_plx_SignificantAccountingPoliciesTable_344360" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_344361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_344360" xlink:to="loc_srt_RestatementAxis_344361" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_344362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_344361" xlink:to="loc_srt_RestatementDomain_344362" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_344362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_344361" xlink:to="loc_srt_RestatementDomain_344362_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_344363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_344362" xlink:to="loc_srt_RestatementAdjustmentMember_344363" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_344366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_344362" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_344366" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_344368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_344367" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_344368" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_344369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_344367" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_344369" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_86" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_SignificantAccountingPoliciesTable_72" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_77" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_77_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_77_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_77" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_92" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_73" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_87" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_73" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_87" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_87_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_73" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_87_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_TypeOfArrangementAxis_74" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_AmendedPfizerAgreementMember_90" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_BrazilAgreementMember" xlink:label="loc_plx_BrazilAgreementMember_88" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_BrazilAgreementMember_88" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PfizerAgreementMember" xlink:label="loc_plx_PfizerAgreementMember_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_PfizerAgreementMember_89" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FiocruzMember" xlink:label="loc_plx_FiocruzMember_223594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_FiocruzMember_223594" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ChiesiUSAgreementMember" xlink:label="loc_plx_ChiesiUSAgreementMember_255328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_ChiesiUSAgreementMember_255328" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="loc_plx_ChiesiExUSAgreementMember_255329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_ChiesiExUSAgreementMember_255329" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_srt_RangeAxis_84" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_84" xlink:to="loc_srt_RangeMember_85" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_85_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_84" xlink:to="loc_srt_RangeMember_85_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85" xlink:to="loc_srt_MinimumMember_98" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85" xlink:to="loc_srt_MaximumMember_99" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_srt_CounterpartyNameAxis_78" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_srt_StatementGeographicalAxis_79" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_79" xlink:to="loc_srt_SegmentGeographicalDomain_80" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_79" xlink:to="loc_srt_SegmentGeographicalDomain_80_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80" xlink:to="loc_country_BR_94" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_StatementScenarioAxis_81" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_81" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_95" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_95_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_81" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_95_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_97" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_97_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_97_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_109" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_100" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_101" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_102" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_103" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SupplyCommitmentInYear2017" xlink:label="loc_plx_SupplyCommitmentInYear2017_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_SupplyCommitmentInYear2017_104" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ProceedsFromExchangeForRightsToRoyalties" xlink:label="loc_plx_ProceedsFromExchangeForRightsToRoyalties_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_ProceedsFromExchangeForRightsToRoyalties_105" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_107" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_108" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_110" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_PaymentOnNetSalesPercentage_111" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_223331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_us-gaap_Revenues_223331" use="optional" order="50" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_117" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_121" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryNet_122" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_StatementTable_115" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_115" xlink:to="loc_us-gaap_StatementClassOfStockAxis_116" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_116" xlink:to="loc_us-gaap_ClassOfStockDomain_118" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_116" xlink:to="loc_us-gaap_ClassOfStockDomain_118_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_119" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_120" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_131" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_us-gaap_StatementTable_125" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_135" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementClassOfStockAxis_126" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_126" xlink:to="loc_us-gaap_ClassOfStockDomain_132" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_132_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_126" xlink:to="loc_us-gaap_ClassOfStockDomain_132_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_DebtInstrumentAxis_127" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_127" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_128" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_128_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_127" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_128_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_128" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_134" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_223063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_223063" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223063" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223064" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223064_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223063" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223064_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_plx_FairValueAssumptionsRiskFreeInterestRates_227611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsRiskFreeInterestRates_227611" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_plx_FairValueAssumptionsExpectedVolatilityRates_227612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsExpectedVolatilityRates_227612" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_us-gaap_SharePrice_136" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsTerm" xlink:label="loc_plx_FairValueAssumptionsTerm_223057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsTerm_223057" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_plx_FairValueAssumptionsExpectedDividendRates_227613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsExpectedDividendRates_227613" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_149" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StatementTable_143" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_DebtInstrumentAxis_146" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_146" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_147" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_146" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_147_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_147" xlink:to="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_153" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_154" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_154_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_217481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_217481" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_155" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_156" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_223526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_223526" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_163" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_168" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_StatementTable_159" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_DebtInstrumentAxis_160" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_160" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_161" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_161_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_160" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_161_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_161" xlink:to="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_165" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xlink:label="loc_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_161" xlink:to="loc_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member_164" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_162" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_255332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_162" xlink:to="loc_us-gaap_EquityComponentDomain_255332" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_255332_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_162" xlink:to="loc_us-gaap_EquityComponentDomain_255332_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_256805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_256805" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_256806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_256805" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_256806" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_256806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_256805" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_256806_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_256807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_256806" xlink:to="loc_us-gaap_SubsequentEventMember_256807" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_167" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_169" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_170" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_223354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_223354" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" xlink:label="loc_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds_226978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds_226978" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_227261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_227261" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_178" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_178" xlink:to="loc_us-gaap_Revenues_182" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_178" xlink:to="loc_us-gaap_StatementTable_174" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_175" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_175" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_175" xlink:to="loc_us-gaap_ClassOfStockDomain_179_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_srt_StatementGeographicalAxis_176" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_176" xlink:to="loc_srt_SegmentGeographicalDomain_177" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_177_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_176" xlink:to="loc_srt_SegmentGeographicalDomain_177_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_177" xlink:to="loc_country_BR_181" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_177" xlink:to="loc_plx_PfizerMember_180" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_338180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_srt_ProductOrServiceAxis_338180" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_338181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_338180" xlink:to="loc_srt_ProductsAndServicesDomain_338181" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_338181_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_338180" xlink:to="loc_srt_ProductsAndServicesDomain_338181_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_338182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_338181" xlink:to="loc_us-gaap_ProductMember_338182" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_344304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_338181" xlink:to="loc_us-gaap_LicenseAndServiceMember_344304" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SellingGoodsMember" xlink:label="loc_plx_SellingGoodsMember_344951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_338181" xlink:to="loc_plx_SellingGoodsMember_344951" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/role/StockTransactionsNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_255350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_StatementTable_255350" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_255351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255350" xlink:to="loc_us-gaap_AwardTypeAxis_255351" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_255351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_255351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_255357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354" xlink:to="loc_us-gaap_EmployeeStockOptionMember_255357" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_255404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_255350" xlink:to="loc_us-gaap_TitleOfIndividualAxis_255404" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_255404" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_255404" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ExecutiveMember" xlink:label="loc_plx_ExecutiveMember_255407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" xlink:to="loc_plx_ExecutiveMember_255407" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ExecutiveOfficersMember" xlink:label="loc_plx_ExecutiveOfficersMember_256808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" xlink:to="loc_plx_ExecutiveOfficersMember_256808" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_255362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_255362" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_255373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_255373" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_255376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_255376" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_255379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_255379" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_255381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_255381" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_255401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_255401" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_255403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_255403" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_349131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_349131" use="optional" order="18" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--DataTracks Rainbow V 3.0 - www.datatracks.com - on 13-March-2019 [08:19:20] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_DocumentAndEntityInformationAbstract" xlink:to="lab_plx_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable &#8211; Trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xml:lang="en-US">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">LONG TERM LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xml:lang="en-US">Liability for employee rights upon retirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contracts liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contracts liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible Debt, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xml:lang="en-US">Convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xml:lang="en-US">Convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accounts payable and accruals:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contracts liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long term liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">COMMITMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">CAPITAL DEFICIENCY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">CAPITAL DEFICIENCY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total capital deficiency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities net of capital deficiency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">REVENUES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">REVENUES FROM LICENSE AGREEMENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">COST OF GOODS SOLD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Grants And Reimbursements Received Or Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Less &#8211; grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GrantsAndReimbursementsReceivedOrReceivable" xml:lang="en-US">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">Research Development And Engineering Expense Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ResearchDevelopmentAndEngineeringExpenseNet" xml:lang="en-US">Research and development expenses, net.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">OPERATING LOSS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">OPERATING LOSS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other Nonoperating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">FINANCIAL EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">FINANCIAL INCOME</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xml:lang="en-US">Change in fair value of convertible notes embedded derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">NET LOSS PER SHARE OF COMMON STOCK BASIC AND DILUTED</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share of common stock-basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">LOSS FOR THE PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for the nine months ended September 30, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Goods [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicenseAndServiceMember" xml:lang="en-US">License and Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicenseAndServiceMember" xml:lang="en-US">License and R&amp;D services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:label="loc_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xml:lang="en-US">Stock Issued During Period Value Convertible Note Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xml:lang="en-US">Convertible notes exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:to="lab_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xml:lang="en-US">The value of outstanding notes exchanged with the company for shares.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:label="loc_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xml:lang="en-US">Stock Issued During Period Shares Convertible Note Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xml:lang="en-US">Convertible notes exchange (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:to="lab_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xml:lang="en-US">The numbers of shares issued in exchange for outstanding notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Convertible notes conversions (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation related to stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Share-based compensation related to restricted stock award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share-based compensation related to restricted stock award (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Convertible notes conversions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xml:lang="en-US">Reclassification of embedded derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Conversion component related to convertible notes issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xml:lang="en-US">Financial (income) expenses, net (mainly exchange differences)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitExpense" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncomeLossOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeLossOnConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncomeLossOnConversionOfConvertibleNotes" xml:lang="en-US">Income Loss on conversion of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_plx_IncomeLossOnConversionOfConvertibleNotes" xml:lang="en-US">Net loss in connection with conversions of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncomeLossOnConversionOfConvertibleNotes" xlink:to="lab_plx_IncomeLossOnConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncomeLossOnConversionOfConvertibleNotes" xml:lang="en-US">The amount of income (loss) from conversions of convertible notes.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares for interest payment in connection with conversions of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:to="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares for interest payment regarding conversion of convertible notes,</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase in contracts liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase in accounts receivable and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase in inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xml:lang="en-US">Increase in other long term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Net payment for convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Net proceeds from issuance of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCash" xml:lang="en-US">Increase in restricted deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCash" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Convertible notes conversions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">INVENTORIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">CONVERTIBLE NOTES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="loc_plx_RevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RevenueDisclosureTextBlock" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_RevenueDisclosureTextBlock" xml:lang="en-US">REVENUES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RevenueDisclosureTextBlock" xlink:to="lab_plx_RevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RevenueDisclosureTextBlock" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCK TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="loc_plx_NatureOfOperationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">General</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_NatureOfOperationsPolicyTextBlock" xlink:to="lab_plx_NatureOfOperationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_NatureOfOperationsPolicyTextBlock" xml:lang="en-US">Nature Of Operations Policy</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently adopted standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">Statements of operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SupplementaryIncomeStatementInformationTableTextBlock" xml:lang="en-US">The tabular disclosure for supplemental income statements.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SignificantAccountingPoliciesTable" xlink:to="lab_plx_SignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SignificantAccountingPoliciesTable" xml:lang="en-US">Significant Accounting Policies [Table].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Restatement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Restatement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Restatement Adjustment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems" xlink:to="lab_plx_SignificantAccountingPoliciesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xml:lang="en-US">Contract with Customer, Asset, Net, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xml:lang="en-US">CONTRACTS ASSET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xml:lang="en-US">Increase in contract asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="lab_plx_ProtalixBioTherapeuticsIncorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProtalixBioTherapeuticsIncorporationMember" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AmendedPfizerAgreementMember" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AmendedPfizerAgreementMember" xlink:to="lab_plx_AmendedPfizerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AmendedPfizerAgreementMember" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_BrazilAgreementMember" xlink:label="loc_plx_BrazilAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_BrazilAgreementMember" xml:lang="en-US">Brazil Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_BrazilAgreementMember" xlink:to="lab_plx_BrazilAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_BrazilAgreementMember" xml:lang="en-US">Brazil Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PfizerAgreementMember" xlink:label="loc_plx_PfizerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PfizerAgreementMember" xml:lang="en-US">Pfizer Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PfizerAgreementMember" xlink:to="lab_plx_PfizerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PfizerAgreementMember" xml:lang="en-US">Pfizer Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FiocruzMember" xlink:label="loc_plx_FiocruzMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FiocruzMember" xml:lang="en-US">Fiocruz [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FiocruzMember" xlink:to="lab_plx_FiocruzMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FiocruzMember" xml:lang="en-US">Fiocruz.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ChiesiUSAgreementMember" xlink:label="loc_plx_ChiesiUSAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ChiesiUSAgreementMember" xml:lang="en-US">Chiesi US Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ChiesiUSAgreementMember" xlink:to="lab_plx_ChiesiUSAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ChiesiUSAgreementMember" xml:lang="en-US">Chiesi U.S. Agreement</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="loc_plx_ChiesiExUSAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ChiesiExUSAgreementMember" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ChiesiExUSAgreementMember" xlink:to="lab_plx_ChiesiExUSAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ChiesiExUSAgreementMember" xml:lang="en-US">Chiesi Ex-U.S. Agreement</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BR" xml:lang="en-US">BRAZIL</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_country_BR" xml:lang="en-US">Brazil [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR" xlink:to="lab_country_BR" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xml:lang="en-US">Percentage Of Adult Gaucher Patients Treated With alfataliglicerase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:to="lab_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xml:lang="en-US">Represents the percentage of adult Gaucher patients treated with alfataliglicerase.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SupplyCommitmentInYear2017" xlink:label="loc_plx_SupplyCommitmentInYear2017" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SupplyCommitmentInYear2017" xml:lang="en-US">Supply Commitment In Year 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SupplyCommitmentInYear2017" xlink:to="lab_plx_SupplyCommitmentInYear2017" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SupplyCommitmentInYear2017" xml:lang="en-US">Amount represents an order for supply in year 2017.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ProceedsFromExchangeForRightsToRoyalties" xlink:label="loc_plx_ProceedsFromExchangeForRightsToRoyalties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ProceedsFromExchangeForRightsToRoyalties" xml:lang="en-US">Proceeds From Exchange For Rights To Royalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ProceedsFromExchangeForRightsToRoyalties" xlink:to="lab_plx_ProceedsFromExchangeForRightsToRoyalties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ProceedsFromExchangeForRightsToRoyalties" xml:lang="en-US">Amount received in exchange for rights to royalties.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xml:lang="en-US">Upfront Nonrefundable Noncreditable Payment Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xml:lang="en-US">The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xml:lang="en-US">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PaymentOnNetSalesPercentage" xml:lang="en-US">Payment On Net Sales Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PaymentOnNetSalesPercentage" xlink:to="lab_plx_PaymentOnNetSalesPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_PaymentOnNetSalesPercentage" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xml:lang="en-US">Work in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotesMember" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_SevenPointFivePercentageConvertibleNotesMember" xml:lang="en-US">2021 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="lab_plx_SevenPointFivePercentageConvertibleNotesMember" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_plx_FairValueAssumptionsRiskFreeInterestRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsRiskFreeInterestRates" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsRiskFreeInterestRates" xml:lang="en-US">Risk free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsRiskFreeInterestRates" xlink:to="lab_plx_FairValueAssumptionsRiskFreeInterestRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsRiskFreeInterestRates" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_plx_FairValueAssumptionsExpectedVolatilityRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsExpectedVolatilityRates" xml:lang="en-US">Fair Value Assumptions Expected Volatility Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsExpectedVolatilityRates" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsExpectedVolatilityRates" xlink:to="lab_plx_FairValueAssumptionsExpectedVolatilityRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsExpectedVolatilityRates" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price (USD)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsTerm" xlink:label="loc_plx_FairValueAssumptionsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsTerm" xml:lang="en-US">Fair Value Assumptions Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsTerm" xml:lang="en-US">Expected term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsTerm" xlink:to="lab_plx_FairValueAssumptionsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsTerm" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_plx_FairValueAssumptionsExpectedDividendRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FairValueAssumptionsExpectedDividendRates" xml:lang="en-US">Fair Value Assumptions Expected Dividend Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_FairValueAssumptionsExpectedDividendRates" xml:lang="en-US">Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FairValueAssumptionsExpectedDividendRates" xlink:to="lab_plx_FairValueAssumptionsExpectedDividendRates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FairValueAssumptionsExpectedDividendRates" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xml:lang="en-US">Seven Point Five Zero Percentage Convertible Notes 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xml:lang="en-US">7.50% Convertible Notes 2016 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xml:lang="en-US">2021 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xlink:to="lab_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xml:lang="en-US">Seven Point Five Zero Percentage Convertible Notes 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xlink:label="loc_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xml:lang="en-US">Four Point Five Zero Percentage Convertible Notes 2018 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xml:lang="en-US">2018 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xlink:to="lab_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xml:lang="en-US">Four Point Five Zero Percentage Convertible Notes 2018 [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" xlink:label="loc_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" xml:lang="en-US">Repayments of Remaining Convertible Debt Through Necessary Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" xlink:to="lab_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" xml:lang="en-US">The cash outflow from the repayment of a remaining outstanding of long-term debt instrument through necessary funds during the year.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_PfizerMember" xml:lang="en-US">Pfizer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_PfizerMember" xlink:to="lab_plx_PfizerMember" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SellingGoodsMember" xlink:label="loc_plx_SellingGoodsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_SellingGoodsMember" xml:lang="en-US">Goods [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_SellingGoodsMember" xlink:to="lab_plx_SellingGoodsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_SellingGoodsMember" xml:lang="en-US">Selling Goods Member</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Option to purchase shares of common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ExecutiveMember" xlink:label="loc_plx_ExecutiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ExecutiveMember" xml:lang="en-US">Executive [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ExecutiveMember" xlink:to="lab_plx_ExecutiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_plx_ExecutiveMember" xml:lang="en-US">Employees</label>
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ExecutiveOfficersMember" xlink:label="loc_plx_ExecutiveOfficersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_plx_ExecutiveOfficersMember" xml:lang="en-US">Executive Officers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_plx_ExecutiveOfficersMember" xlink:to="lab_plx_ExecutiveOfficersMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--DataTracks Rainbow V 3.0 - www.datatracks.com - on 13-March-2019 [08:19:20] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#DocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPolicies" roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#Inventories" roleURI="http://www.protalix.com/role/Inventories" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurement" roleURI="http://www.protalix.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#ConvertibleNotes" roleURI="http://www.protalix.com/role/ConvertibleNotes" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#Revenues" roleURI="http://www.protalix.com/role/Revenues" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#StockTransactions" roleURI="http://www.protalix.com/role/StockTransactions" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#InventoriesTables" roleURI="http://www.protalix.com/role/InventoriesTables" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurementTables" roleURI="http://www.protalix.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#RevenuesTables" roleURI="http://www.protalix.com/role/RevenuesTables" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesReportedAndAsAdjustedDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesReportedAndAsAdjustedDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#InventoriesDetails" roleURI="http://www.protalix.com/role/InventoriesDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#FairValueMeasurementNarrativeDetails" roleURI="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#ConvertibleNotesNarrativeDetails" roleURI="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#RevenuesStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="plx-20180930.xsd#StockTransactionsNarrativeDetails" roleURI="http://www.protalix.com/role/StockTransactionsNarrativeDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract_187665" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_187411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentType_187411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_187412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_AmendmentFlag_187412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_187413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_AmendmentDescription_187413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_187421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentPeriodEndDate_187421" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_187422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentFiscalYearFocus_187422" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_187423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_DocumentFiscalPeriodFocus_187423" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_187436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityRegistrantName_187436" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_187437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityCentralIndexKey_187437" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_187453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_CurrentFiscalYearEndDate_187453" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_187458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityFilerCategory_187458" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_187540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_TradingSymbol_187540" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_187547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_187547" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_187659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntityEmergingGrowthCompany_187659" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_187661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="loc_dei_EntitySmallBusiness_187661" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_37" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_37" xlink:to="loc_us-gaap_StatementTable_38" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38" xlink:to="loc_us-gaap_StatementClassOfStockAxis_39" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_39" xlink:to="loc_us-gaap_ClassOfStockDomain_48" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38" xlink:to="loc_us-gaap_StatementLineItems_40" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_AssetsAbstract_41" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_AssetsCurrentAbstract_42" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_50" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_OtherAssetsCurrent_51" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_InventoryNet_52" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_42" xlink:to="loc_us-gaap_AssetsCurrent_53" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_54" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_55" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41" xlink:to="loc_us-gaap_Assets_56" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_44" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_57" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_58" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_45" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337498" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_59" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_44" xlink:to="loc_us-gaap_LiabilitiesCurrent_60" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_61" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_62" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_63" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_46" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_64" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_65" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_Liabilities_66" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_43" xlink:to="loc_us-gaap_CommitmentsAndContingencies_67" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_StockholdersEquity_68" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_40" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_184" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_184" xlink:to="loc_us-gaap_StatementTable_185" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_185" xlink:to="loc_us-gaap_StatementClassOfStockAxis_186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_186" xlink:to="loc_us-gaap_ClassOfStockDomain_188" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_337511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_185" xlink:to="loc_srt_ProductOrServiceAxis_337511" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_337511" xlink:to="loc_srt_ProductsAndServicesDomain_337512" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_337513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_337512" xlink:to="loc_us-gaap_ProductMember_337513" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_337514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_337512" xlink:to="loc_us-gaap_LicenseAndServiceMember_337514" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_185" xlink:to="loc_us-gaap_StatementLineItems_187" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_Revenues_189" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_CostOfRevenue_190" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_192" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_plx_GrantsAndReimbursementsReceivedOrReceivable_193" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_plx_ResearchDevelopmentAndEngineeringExpenseNet_194" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_195" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_OperatingIncomeLoss_196" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_OtherNonoperatingExpense_197" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_OtherNonoperatingIncome_198" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_199" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_200" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_NetIncomeLoss_201" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_202" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_187" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_203" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_205" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_205" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_207" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_207" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_208" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_208" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_210" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_208" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_211" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_206" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_209" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_209" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_212" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_214" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_214" xlink:to="loc_us-gaap_StatementTable_215" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_215" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_216" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_216" xlink:to="loc_us-gaap_EquityComponentDomain_217" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_217" xlink:to="loc_us-gaap_CommonStockMember_219" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_217" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_220" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_217" xlink:to="loc_us-gaap_RetainedEarningsMember_221" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_215" xlink:to="loc_us-gaap_StatementLineItems_218" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockholdersEquity_222" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_SharesOutstanding_223" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_224" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_223091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_223091" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_225" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_226" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_227" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_228" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_255319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_255319" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:label="loc_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_223337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_223337" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:label="loc_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_223338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_223338" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_NetIncomeLoss_229" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_StockholdersEquity_230" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_218" xlink:to="loc_us-gaap_SharesOutstanding_231" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_233" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_233" xlink:to="loc_us-gaap_StatementTable_234" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_AwardTypeAxis_235" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_235" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_237" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_StatementLineItems_236" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_236" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_238" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_236" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_239" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_241" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_241" xlink:to="loc_us-gaap_StatementTable_242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_242" xlink:to="loc_us-gaap_StatementClassOfStockAxis_243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_243" xlink:to="loc_us-gaap_ClassOfStockDomain_252" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_242" xlink:to="loc_us-gaap_StatementLineItems_244" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_NetIncomeLoss_253" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_ShareBasedCompensation_254" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_Depreciation_255" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_256" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitExpense_257" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_258" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncomeLossOnConversionOfConvertibleNotes" xlink:label="loc_plx_IncomeLossOnConversionOfConvertibleNotes_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_plx_IncomeLossOnConversionOfConvertibleNotes_259" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_260" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_261" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_262" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_246" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_263" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_264" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_265" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_266" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_247" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_267" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_268" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_269" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_338250" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_271" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCash_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCash_272" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_273" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_275" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_255320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_255320" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_249" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_276" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_277" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_278" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_279" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_280" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" xlink:to="loc_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_281" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_250" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_282" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_244" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_251" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_251" xlink:to="loc_us-gaap_InterestPaidNet_283" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_285" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_285" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Inventories">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_9" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/Revenues">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_11" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="loc_plx_RevenueDisclosureTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_11" xlink:to="loc_plx_RevenueDisclosureTextBlock_12" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/StockTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_255344" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_255346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_255344" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_255346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_14" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="loc_plx_NatureOfOperationsPolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14" xlink:to="loc_plx_NatureOfOperationsPolicyTextBlock_15" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_16" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_17" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_14" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_19" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_223282" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_344373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_223282" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_344373" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_21" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_22" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_24" xlink:to="loc_us-gaap_StatementTable_25" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_StatementClassOfStockAxis_26" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26" xlink:to="loc_us-gaap_ClassOfStockDomain_30" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_DebtInstrumentAxis_27" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_27" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_28" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25" xlink:to="loc_us-gaap_StatementLineItems_29" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_32" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_34" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_34" xlink:to="loc_plx_SupplementaryIncomeStatementInformationTableTextBlock_35" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_337614" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337614" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337624" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337624" xlink:to="loc_srt_RestatementAxis_337626" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_337626" xlink:to="loc_srt_RestatementDomain_337627" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337627" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337627" xlink:to="loc_srt_RestatementAdjustmentMember_337632" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337624" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_337634" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_337635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_us-gaap_AssetsAbstract_337635" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_337636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_337635" xlink:to="loc_us-gaap_AssetsCurrentAbstract_337636" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_337637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_337636" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_337637" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_337640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_337640" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_337660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_337640" xlink:to="loc_us-gaap_LiabilitiesAbstract_337660" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_337661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_337660" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_337661" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_337661" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_337644" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_337646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_337661" xlink:to="loc_us-gaap_LiabilitiesCurrent_337646" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_337660" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_337654" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_337657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_337663" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_337657" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_337673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_337660" xlink:to="loc_us-gaap_Liabilities_337673" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_337674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337634" xlink:to="loc_us-gaap_StockholdersEquity_337674" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_337700" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337700" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337703" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337703" xlink:to="loc_srt_RestatementAxis_337718" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_337718" xlink:to="loc_srt_RestatementDomain_337719" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337719" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337722" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337719" xlink:to="loc_srt_RestatementAdjustmentMember_337723" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_337736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337703" xlink:to="loc_srt_ProductOrServiceAxis_337736" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_337737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_337736" xlink:to="loc_srt_ProductsAndServicesDomain_337737" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_337742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_337737" xlink:to="loc_us-gaap_LicenseAndServiceMember_337742" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337703" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_337728" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_337745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_Revenues_337745" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_337763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_337763" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_337752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_OperatingIncomeLoss_337752" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_NetIncomeLoss_337759" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_337787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337728" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_337787" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_337812" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337812" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337819" xlink:to="loc_srt_RestatementAxis_337820" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_337820" xlink:to="loc_srt_RestatementDomain_337822" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337822" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337823" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337822" xlink:to="loc_srt_RestatementAdjustmentMember_337824" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_337908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337819" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_337908" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_337909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_337908" xlink:to="loc_us-gaap_EquityComponentDomain_337909" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_337916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_337909" xlink:to="loc_us-gaap_RetainedEarningsMember_337916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337819" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_337826" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337826" xlink:to="loc_us-gaap_NetIncomeLoss_337827" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_337834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337826" xlink:to="loc_us-gaap_StockholdersEquity_337834" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_337937" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_337939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337937" xlink:to="loc_plx_SignificantAccountingPoliciesTable_337939" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_337941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337939" xlink:to="loc_srt_RestatementAxis_337941" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_337942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_337941" xlink:to="loc_srt_RestatementDomain_337942" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_337943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337942" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_337943" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_337944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_337942" xlink:to="loc_srt_RestatementAdjustmentMember_337944" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_337945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_337939" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_337945" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_337951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_NetIncomeLoss_337951" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_337953" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_345037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_345037" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_344317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_337945" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_344317" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesReportedAndAsAdjustedDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_344358" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_344360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_344358" xlink:to="loc_plx_SignificantAccountingPoliciesTable_344360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_344361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_344360" xlink:to="loc_srt_RestatementAxis_344361" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_344362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_344361" xlink:to="loc_srt_RestatementDomain_344362" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_344363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_344362" xlink:to="loc_srt_RestatementAdjustmentMember_344363" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_344366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_344362" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_344366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_344367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_344360" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_344367" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_344368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_344367" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_344368" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_344369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_344367" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_344369" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_71" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="loc_plx_SignificantAccountingPoliciesTable_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_71" xlink:to="loc_plx_SignificantAccountingPoliciesTable_72" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_73" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_87" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_TypeOfArrangementAxis_74" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_BrazilAgreementMember" xlink:label="loc_plx_BrazilAgreementMember_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_BrazilAgreementMember_88" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PfizerAgreementMember" xlink:label="loc_plx_PfizerAgreementMember_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_PfizerAgreementMember_89" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="loc_plx_AmendedPfizerAgreementMember_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_AmendedPfizerAgreementMember_90" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FiocruzMember" xlink:label="loc_plx_FiocruzMember_223594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_FiocruzMember_223594" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ChiesiUSAgreementMember" xlink:label="loc_plx_ChiesiUSAgreementMember_255328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_ChiesiUSAgreementMember_255328" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="loc_plx_ChiesiExUSAgreementMember_255329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75" xlink:to="loc_plx_ChiesiExUSAgreementMember_255329" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_dei_LegalEntityAxis_76" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_76" xlink:to="loc_dei_EntityDomain_77" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="loc_plx_ProtalixBioTherapeuticsIncorporationMember_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_77" xlink:to="loc_plx_ProtalixBioTherapeuticsIncorporationMember_92" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_srt_CounterpartyNameAxis_78" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_78" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_93" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_srt_StatementGeographicalAxis_79" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_79" xlink:to="loc_srt_SegmentGeographicalDomain_80" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80" xlink:to="loc_country_BR_94" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_StatementScenarioAxis_81" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_81" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_95" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_83" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_97" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_srt_RangeAxis_84" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_84" xlink:to="loc_srt_RangeMember_85" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85" xlink:to="loc_srt_MinimumMember_98" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85" xlink:to="loc_srt_MaximumMember_99" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="loc_plx_SignificantAccountingPoliciesLineItems_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesTable_72" xlink:to="loc_plx_SignificantAccountingPoliciesLineItems_86" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase" xlink:label="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase_100" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_101" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_102" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_103" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SupplyCommitmentInYear2017" xlink:label="loc_plx_SupplyCommitmentInYear2017_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_SupplyCommitmentInYear2017_104" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ProceedsFromExchangeForRightsToRoyalties" xlink:label="loc_plx_ProceedsFromExchangeForRightsToRoyalties_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_ProceedsFromExchangeForRightsToRoyalties_105" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_UpfrontNonrefundableNoncreditablePaymentReceivable_107" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_AdditionalAmountsPayableToCoverDevelopmentCosts_108" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_109" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones_110" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="loc_plx_PaymentOnNetSalesPercentage_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_plx_PaymentOnNetSalesPercentage_111" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_223331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_SignificantAccountingPoliciesLineItems_86" xlink:to="loc_us-gaap_Revenues_223331" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/InventoriesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_114" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_114" xlink:to="loc_us-gaap_StatementTable_115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_115" xlink:to="loc_us-gaap_StatementClassOfStockAxis_116" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_116" xlink:to="loc_us-gaap_ClassOfStockDomain_118" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_115" xlink:to="loc_us-gaap_StatementLineItems_117" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_119" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_120" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_121" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_117" xlink:to="loc_us-gaap_InventoryNet_122" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_124" xlink:to="loc_us-gaap_StatementTable_125" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementClassOfStockAxis_126" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_126" xlink:to="loc_us-gaap_ClassOfStockDomain_132" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_DebtInstrumentAxis_127" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_127" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_128" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="loc_plx_SevenPointFivePercentageConvertibleNotesMember_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_128" xlink:to="loc_plx_SevenPointFivePercentageConvertibleNotesMember_134" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_129" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_130" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_135" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_223063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_223063" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_223064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_223063" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_223064" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_125" xlink:to="loc_us-gaap_StatementLineItems_131" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_us-gaap_SharePrice_136" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsTerm" xlink:label="loc_plx_FairValueAssumptionsTerm_223057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsTerm_223057" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="loc_plx_FairValueAssumptionsRiskFreeInterestRates_227611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsRiskFreeInterestRates_227611" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="loc_plx_FairValueAssumptionsExpectedVolatilityRates_227612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsExpectedVolatilityRates_227612" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="loc_plx_FairValueAssumptionsExpectedDividendRates_227613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_131" xlink:to="loc_plx_FairValueAssumptionsExpectedDividendRates_227613" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/FairValueMeasurementNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_142" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_142" xlink:to="loc_us-gaap_StatementTable_143" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_DebtInstrumentAxis_146" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_146" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_147" xlink:to="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_153" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_154" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_217479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_217481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_217480" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_217481" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_143" xlink:to="loc_us-gaap_StatementLineItems_149" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_155" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_156" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_223526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_223526" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/ConvertibleNotesNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_158" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_158" xlink:to="loc_us-gaap_StatementTable_159" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_DebtInstrumentAxis_160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_160" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_161" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_FourPointFiveZeroPercentageConvertibleNotes2018Member" xlink:label="loc_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_161" xlink:to="loc_plx_FourPointFiveZeroPercentageConvertibleNotes2018Member_164" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member" xlink:label="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_161" xlink:to="loc_plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member_165" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_162" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_255332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_162" xlink:to="loc_us-gaap_EquityComponentDomain_255332" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_256805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_256805" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_256806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_256805" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_256806" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_256807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_256806" xlink:to="loc_us-gaap_SubsequentEventMember_256807" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_159" xlink:to="loc_us-gaap_StatementLineItems_163" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_167" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_168" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_169" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_170" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_223354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_223354" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds" xlink:label="loc_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds_226978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds_226978" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_227261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_163" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_227261" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_173" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_173" xlink:to="loc_us-gaap_StatementTable_174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementClassOfStockAxis_175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_175" xlink:to="loc_us-gaap_ClassOfStockDomain_179" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_srt_StatementGeographicalAxis_176" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_176" xlink:to="loc_srt_SegmentGeographicalDomain_177" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_PfizerMember" xlink:label="loc_plx_PfizerMember_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_177" xlink:to="loc_plx_PfizerMember_180" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_177" xlink:to="loc_country_BR_181" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_338180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_srt_ProductOrServiceAxis_338180" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_338181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_338180" xlink:to="loc_srt_ProductsAndServicesDomain_338181" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_338182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_338181" xlink:to="loc_us-gaap_ProductMember_338182" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaap_LicenseAndServiceMember_344304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_338181" xlink:to="loc_us-gaap_LicenseAndServiceMember_344304" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_SellingGoodsMember" xlink:label="loc_plx_SellingGoodsMember_344951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_338181" xlink:to="loc_plx_SellingGoodsMember_344951" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_174" xlink:to="loc_us-gaap_StatementLineItems_178" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_178" xlink:to="loc_us-gaap_Revenues_182" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/role/StockTransactionsNarrativeDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_255348" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_255350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_255348" xlink:to="loc_us-gaap_StatementTable_255350" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_255351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255350" xlink:to="loc_us-gaap_AwardTypeAxis_255351" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_255351" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_255357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_255354" xlink:to="loc_us-gaap_EmployeeStockOptionMember_255357" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_255404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255350" xlink:to="loc_us-gaap_TitleOfIndividualAxis_255404" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_255404" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ExecutiveOfficersMember" xlink:label="loc_plx_ExecutiveOfficersMember_256808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" xlink:to="loc_plx_ExecutiveOfficersMember_256808" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ExecutiveMember" xlink:label="loc_plx_ExecutiveMember_255407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_255405" xlink:to="loc_plx_ExecutiveMember_255407" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_255350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_255362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_255362" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="plx-20180930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_255373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_255373" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_255376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_255376" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_255379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_255379" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_255381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_255381" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_255401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_255401" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_255403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_255403" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_349131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_255353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_349131" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763157424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Amendment No. 1 to Form 10-Q, or this Amendment, amends the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 we originally filed with the Securities and Exchange Commission, or the Commission, on November 7, 2018, or the Original Filing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,374,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763470080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,868<span></span>
</td>
<td class="nump">$ 51,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable &#8211; Trade</a></td>
<td class="nump">4,894<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,619<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">7,959<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">57,340<span></span>
</td>
<td class="nump">62,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">6,628<span></span>
</td>
<td class="nump">7,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">65,747<span></span>
</td>
<td class="nump">72,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">7,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">9,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">9,786<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,921<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,337<span></span>
</td>
<td class="nump">22,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">47,320<span></span>
</td>
<td class="nump">46,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">33,493<span></span>
</td>
<td class="nump">25,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">6,154<span></span>
</td>
<td class="nump">5,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">89,353<span></span>
</td>
<td class="nump">78,919<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">113,690<span></span>
</td>
<td class="nump">101,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(47,943)<span></span>
</td>
<td class="num">(29,457)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 65,747<span></span>
</td>
<td class="nump">$ 72,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763437216">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,917)<span></span>
</td>
<td class="num">$ (6,066)<span></span>
</td>
<td class="num">$ (7,024)<span></span>
</td>
<td class="num">$ (13,677)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(10,803)<span></span>
</td>
<td class="num">(7,118)<span></span>
</td>
<td class="num">(25,565)<span></span>
</td>
<td class="num">(22,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less &#8211; grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">732<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,071)<span></span>
</td>
<td class="num">(6,389)<span></span>
</td>
<td class="num">(23,755)<span></span>
</td>
<td class="num">(19,844)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,088)<span></span>
</td>
<td class="num">(2,836)<span></span>
</td>
<td class="num">(8,744)<span></span>
</td>
<td class="num">(8,187)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,741)<span></span>
</td>
<td class="num">(7,765)<span></span>
</td>
<td class="num">(15,636)<span></span>
</td>
<td class="num">(24,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,811)<span></span>
</td>
<td class="num">(3,680)<span></span>
</td>
<td class="num">(5,824)<span></span>
</td>
<td class="num">(8,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">LOSS FROM CHANGE IN FAIR VALUE OF CONVERTIBLE NOTES EMBEDDED DERIVATIVE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,061)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,581)<span></span>
</td>
<td class="num">(3,672)<span></span>
</td>
<td class="num">(5,387)<span></span>
</td>
<td class="num">(45,200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,322)<span></span>
</td>
<td class="num">$ (11,437)<span></span>
</td>
<td class="num">$ (21,023)<span></span>
</td>
<td class="num">$ (70,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE OF COMMON STOCK BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,187,513<span></span>
</td>
<td class="nump">132,549,001<span></span>
</td>
<td class="nump">146,752,355<span></span>
</td>
<td class="nump">128,223,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 7,526<span></span>
</td>
<td class="nump">$ 7,222<span></span>
</td>
<td class="nump">$ 16,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes share-based compensation</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrantsAndReimbursementsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ResearchDevelopmentAndEngineeringExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763966912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763287536">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th" colspan="2"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,957)<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 202,575<span></span>
</td>
<td class="num">$ (212,656)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,134,085<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Reclassification of embedded derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,781<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,711,235<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Conversion component related to convertible notes issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(70,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70,135)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,071)<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">256,586<span></span>
</td>
<td class="num">(282,791)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,845,320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,457)<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">266,495<span></span>
</td>
<td class="num">(296,096)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,728,797<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange', window );">Convertible notes exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange', window );">Convertible notes exchange (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,023)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (47,943)<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 269,028<span></span>
</td>
<td class="num">$ (317,119)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,301,238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common Stock, $0.001 par value; Authorized &#8211; as of September 30, 2018 and 2017 - 250,000,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than $1.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The numbers of shares issued in exchange for outstanding notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of outstanding notes exchanged with the company for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueConvertibleNoteExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6762991680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Parenthetical] - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763807104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (21,023)<span></span>
</td>
<td class="num">$ (70,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial (income) expenses, net (mainly exchange differences)</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncomeLossOnConversionOfConvertibleNotes', window );">Net loss in connection with conversions of convertible notes</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of convertible notes embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">1,916<span></span>
</td>
<td class="nump">1,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes', window );">Issuance of shares for interest payment in connection with conversions of convertible notes</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="nump">18,264<span></span>
</td>
<td class="num">(837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(3,661)<span></span>
</td>
<td class="num">(6,467)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(1,805)<span></span>
</td>
<td class="nump">8,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase in other long term liabilities</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in continuing operations</a></td>
<td class="num">(3,738)<span></span>
</td>
<td class="num">(27,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,738)<span></span>
</td>
<td class="num">(27,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(498)<span></span>
</td>
<td class="num">(681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted deposit</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="nump">70<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(675)<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="num">(4,752)<span></span>
</td>
<td class="num">(10,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,542<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,752)<span></span>
</td>
<td class="num">(1,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(130)<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(9,295)<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">51,163<span></span>
</td>
<td class="nump">63,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">41,868<span></span>
</td>
<td class="nump">33,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="nump">2,236<span></span>
</td>
<td class="nump">7,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 2,411<span></span>
</td>
<td class="nump">$ 2,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeLossOnConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income (loss) from conversions of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeLossOnConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for interest payment regarding conversion of convertible notes,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6631946736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</div></div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-indent: -0.25in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">a.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">General</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;&#160;</div>protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;</div>&#160;in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s product pipeline currently includes, among other candidates:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3) OPRX-106, the Company&#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none; text-align: justify;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) entered into an Ex-US license agreement (the &#8220;Chiesi Ex-U.S. Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July 23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi U.S. Agreement&#8221;), with respect to the development and commercialization of pegunigalsidase alfa in the United States.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;">Under each of the Chiesi Ex-U.S. Agreement and the Chiesi U.S. Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-U.S. Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi U.S. Agreement, Protalix Ltd.&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">is entitled to payments of up to a maximum of $20.0</div>&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5</div>&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">million per year, and to receive an additional up to a maximum of $760.0</div>&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">million, in the aggregate, in regulatory and commercial milestone payments.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of both of the Chiesi agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-U.S. Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi U.S. Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;), in accordance with the exclusive license and supply agreement between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement with Pfizer (the &#8220;Amended Pfizer Agreement&#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0&#160;million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2017, the Company received a purchase order from the Brazilian MoH for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3&#160;million. Shipments started in June 2017. The Company recorded revenues of $7.1&#160;million for sales of alfataliglicerase to Fiocruz in 2017, and $2.6&#160;million during the nine months ended September&#160;30, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12&#160;months from the date of approval of the September 30, 2018 financial statements, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-indent: -0.25in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">b.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Basis of presentation</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.75in; padding: 0px;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Restatement of previously issued condensed consolidated financial statements</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The Company has restated these financial statements to correct an error in the revenue recognition from the agreements with Chiesi. Previously, the Company had identified a single performance obligation with regard to its promises&#160;under each of the agreements. The Company subsequently concluded that there are two performance obligations under each of the agreements as follows: (i) the license together with research and development services and (ii) a contingent performance obligation regarding future manufacturing. As such, the Company has recognized revenue for the combined performance obligations (the license and the research and development services) for the three and nine months ended September&#160;30, 2018 for the satisfaction of the performance obligation that occurred during the three and nine months ended September&#160;30, 2018.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The Company&#8217;s decision to restate the financial statements previously reported on its Quarterly Reports on Form 10-Q, was approved by, and with the continuing oversight of, the Company&#8217;s Audit Committee.</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.75in; text-align: left; padding: 0px;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2.</div></td><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Impacts of restatement</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;">&#160;&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated balance sheets as of September&#160;30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 88%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 764px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CONTRACTS ASSET</div></div></td><td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 250px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">1,450</td><td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(1,450</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CURRENT LIABILITIES:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Total current liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">14,551</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">24,337</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">LONG TERM LIABILITIES:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">61,780</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(28,287</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">33,493</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Total long term liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">117,640</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(28,287</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">89,353</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Total liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">132,191</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(18,501</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">113,690</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CAPITAL DEFICIENCY</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(64,994</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(47,943</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated statements of operations for the three and nine months ended September 30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">(</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands,</div><br/><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;">except per share data)</div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 642px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">REVENUES FROM LICENSE AGREEMENTS</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">11,672</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">11,672</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">16,665</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">16,665</td><td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(2,638</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(1,450</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(4,088</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(7,294</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(1,450</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(8,744</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">OPERATING LOSS</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(13,963</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">10,222</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(3,741</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(30,851</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">15,215</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(15,636</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;">LOSS FOR THE PERIOD</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(15,544</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">10,222</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(5,322</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(36,238</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">15,215</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(21,023</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Net loss per share of common stock-basic and diluted</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.10</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.06</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.04</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.25</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.11</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.14</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated statements of changes in capital deficiency for the nine months ended September&#160;30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands, except per share data)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 921px; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(204, 238, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Net loss for the nine months ended September&#160;30, 2018</div></td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(36,238</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">15,215</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(21,023</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Balances as of September&#160;30, 2018</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Accumulated deficit</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(334,170</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(317,119</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Total capital deficiency</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(64,994</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(47,943</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">Although there was with no impact to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 921px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Net loss</td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(36,238</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">15,215</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(21,023</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Increase in contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">34,929</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(16,665</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">18,264</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">Increase in contract asset</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">(1,450</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal;">)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">1,450</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal;">-</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr><tr><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">Net cash used in operating activities</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">(3,738</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">-</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">(3,738</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The impacts of the restatement have been reflected throughout the financial statements, including the applicable footnotes, as appropriate.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in;">&#160;</div><div style="margin: 0in 0in 0.0001pt 1in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt;">In addition, in connection with the Chiesi Ex-U.S. Agreement, the Company should have recognized $1.8&#160;million of revenue in the last quarter of 2017 and accordingly has revised certain items in its consolidated financial statements for December&#160;31, 2017 presented herein. The Company evaluated the materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&#8217;s prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for December&#160;31, 2017:</div><div style="margin: 0px 0in 0px 0.75in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none;">&#160;</div><table style="width: 80%; margin-left: 0.75in; border-collapse: collapse; border-spacing: 0px;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="10" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December&#160;31, 2017</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">As</div></div><div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &quot;times new roman&quot;, serif; line-height: normal; font-size: 10pt;"><div style="font-weight:bold;display:inline;">originally<br/>reported</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">As revised</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 61%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">Contracts liability</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">26,851</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(1,836</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">25,015</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">Accumulated deficit</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(297,932</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">1,836</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(296,096</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="margin: 0px 0in 0px 0.75in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2017, filed by the Company with the Commission. The comparative balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">c.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Net loss per share</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), outstanding for each period.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 76,195,921 and 73,310,911 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares of Common Stock issuable upon conversion of the convertible notes for the nine months ended September&#160;30, 2017 and 2018, respectively, and 80,696,070 and 73,280,977 shares of Common Stock for the three months ended September&#160;30, 2017 and 2018, respectively, because the effect would be anti-dilutive.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">d.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Revenue recognition (as restated)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.75in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">1.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;">Revenue from supply agreements</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; background: none; text-align: justify; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenues from supply agreements and from selling products when control is transferred to the customer and collectability is probable.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.75in; padding: 0px; text-align: justify;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;">2.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;">Revenue from Chiesi Agreements</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; background: none; text-align: justify; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">According to Accounting Standard Codification Topic 606, Revenue from contracts with customers (&#8220;ASC 606&#8221;), a&#160;performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company has identified two performance obligations in each of the Chiesi agreements as follows: (1) the license and research and development services and (2)&#160;a contingent performance obligation regarding future&#160;manufacturing.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company determined that the licenses granted to Chiesi together with the research and development services should be combined into a single performance obligation under each agreement since&#160;Chiesi cannot benefit from a license without the&#160;research and development services.&#160;The research and development services are highly specialized and are dependent on the supply of the drug.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The future manufacturing&#160;is contingent on regulatory approvals of the drug and&#160;the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method.&#160;Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur, usually upon achievement of a specific milestone.&#160;The Company used significant judgment when it determined variable consideration.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">Since the customer benefits from the research and development services as the entity performs, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">Revenue from additional&#160;research and development&#160;services ordered by Chiesi, is recognized over time using the cost-to-cost method.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company accounted for the Chiesi U.S. agreement as a modification of the Chiesi Ex-U.S. Agreement. As such, the Company recorded revenue through a cumulative catch-up adjustment&#160;in&#160;the&#160;amount&#160;of&#160;$6.2&#160;million.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company&#8217;s revenue recognition accounting policy prior to January 1, 2018, was materially the same.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;"><div style="background: none; letter-spacing: 0px; font-size: 10pt; text-decoration: none; top: 0px;;display:inline;">&#160;</div><div style="background-color: initial; letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">e.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Recently adopted standards</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;">In May 2014, the&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial Accounting Standards Board (&#8220;FASB&#8221;)&#160;</div>issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December&#160;15, 2017. On January&#160;1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers, and all the related amendments, using the modified retrospective method. The implementation of this Accounting Standards Update (ASU) did not have a material impact on the Company&#8217;s consolidated financial statements.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-align: justify;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">In January 2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective for annual reporting periods beginning after December&#160;15, 2017. The implementation of this ASU did not have a material impact on the Company&#8217;s consolidated financial statements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6751015168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="letter-spacing: 0px; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt;;font-weight:bold;display:inline;">NOTE 2 - INVENTORIES</div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0px 0px 0px 0.5in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;">The Company&#8217;s inventory at September&#160;30, 2018 and December&#160;31, 2017 consisted of the&#160;<div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">following:</div></div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0px 0px 0px 0.5in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 64%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Raw materials</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">3,201</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">3,838</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Work in progress</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">276</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">485</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Finished goods</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">4,482</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">3,510</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Total inventory</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">7,959</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">7,833</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6754488288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 3 &#8211; FAIR VALUE MEASUREMENT</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the convertible notes derivative is based on Level 3 measurement.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; margin: 0px 0px 0px 0.49in; background: none; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the remaining $58.0&#160;million in aggregate principal amount of the Company&#8217;s outstanding 7.50% </div>secured convertible promissory notes due 2021 (the &#8220;2021 Notes&#8221;) is approximately $78.0&#160;million, based on a Level 3&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">measurement.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;">&#160;</div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company prepared a valuation of the fair value of the Company&#8217;s 2021 Notes (a Level 3 valuation) as of September 30, 2018. The value&#160;of these notes was&#160;estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.98in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 39%;;margin : 0px auto;;text-align:left;;margin-left :auto;margin-right :auto;"><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Notes</div></div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; width: 79%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock price (USD)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 18%; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">0.73</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (years)</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">3.13</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">2.87</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;">%</div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">75.56</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;">%</div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Yield</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">13.50</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;">%</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6754403888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 4 &#8211; CONVERTIBLE NOTES</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">All of our outstanding convertible notes are accounted for using the guidance set forth in the FASB Accounting Standards Codification (ASC) 815 which requires that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20, regarding debt with conversion and other options, requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The 2021&#160;Notes were accounted for partially as liability and equity components of the instrument and partially as a debt host contract with an embedded derivative resulting from the conversion feature. During the year ended December&#160;31, 2017, the embedded derivative was reclassified to additional paid in capital.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Issuance costs regarding the issuance of the 2021&#160;Notes are amortized using the effective interest rate.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.49in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the nine months ended September 30, 2018, note holders converted $1.1&#160;million aggregate principal amount of the 2021&#160;Notes into a total of 1,456,354 shares of Common Stock, and cash payments of approximately $14,439, in the aggregate. An additional 14,860 shares of Common Stock were issued after September 30, 2018 in connection with the make-whole premium associated with certain of the converted notes that were converted during the third quarter of 2018. In addition, in June 2018, the Company exchanged $3.42&#160;million aggregate principal amount of the Company&#8217;s outstanding 4.50% convertible promissory notes due 2018 (the &#8220;2018&#160;Notes&#8221;) for 2,613,636 shares of Common Stock and approximately $2.2&#160;million in cash and delivered the necessary funds under the indenture governing the 2018&#160;Notes, which was $2.5 million. On September 15, 2018, the 2018&#160;Notes matured and have been paid in full.</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2018, a total of $58.0&#160;million aggregate principal amount of the 2021&#160;Notes were outstanding. In addition, as of September 30, 2018, none of the 2018 Notes were outstanding.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6751025680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt;"><div style="font-weight:bold;display:inline;">NOTE 5 &#8211; REVENUES (AS RESTATED)</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s disaggregation&#160;of revenues:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; margin-left: 0.5in; width: 80%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended </div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; vertical-align: bottom; width: 64%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pfizer</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4,649</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,198</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Brazil</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,573</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6,575</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"><div style="margin-left: 0.26in; font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">Total revenues from selling goods</div></div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7,222</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">16,773</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none;">Revenues from license and R&amp;D services</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;">$</td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; text-align: right; line-height: normal; font-size: 10pt;">16,665</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6641889088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 6 &#8211; STOCK TRANSACTIONS</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On September 13, 2018, the Company&#8217;s compensation committee approved the grant of 10-year options&#160;to&#160;purchase, in the aggregate, 6,360,000 shares of Common Stock, of which options to purchase 4,000,000 shares </div> of Common Stock&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">were granted to the Company&#8217;s executive officers and options to purchase 2,360,000 shares </div> of Common Stock&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">were granted to other employees with an exercise price equal to $0.56 per share and $0.51 per share, respectively, under the Company&#8217;s 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options vest over a four-year period in 16 equal quarterly increments. Vesting of the options granted to the executive officers is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other&#160;terms and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $1.9&#160;million based on the following weighted average</div> assumptions: share price equal to $0.51; dividend<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;yield of 0% for all years; expected volatility of 64.3%; risk-free interest rates of 2.9%; and expected life of six years.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763184208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">a.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">General</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;), and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;&#160;</div>protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<div style="vertical-align: super;font-size: smaller;display:inline;">&#174;</div>&#160;in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s product pipeline currently includes, among other candidates:</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(1) pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(2) alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(3) OPRX-106, the Company&#8217;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; background: none; text-align: justify;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On October 19, 2017, Protalix Ltd. and Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) entered into an Ex-US license agreement (the &#8220;Chiesi Ex-U.S. Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July 23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi U.S. Agreement&#8221;), with respect to the development and commercialization of pegunigalsidase alfa in the United States.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;">Under each of the Chiesi Ex-U.S. Agreement and the Chiesi U.S. Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement. In addition, under the Chiesi Ex-U.S. Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi U.S. Agreement, Protalix Ltd.&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">is entitled to payments of up to a maximum of $20.0</div>&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5</div>&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">million per year, and to receive an additional up to a maximum of $760.0</div>&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">million, in the aggregate, in regulatory and commercial milestone payments.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of both of the Chiesi agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-U.S. Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi U.S. Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. (&#8220;Pfizer&#8221;), in accordance with the exclusive license and supply agreement between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, the Company entered into an Amended and Restated Exclusive License and Supply Agreement with Pfizer (the &#8220;Amended Pfizer Agreement&#8221;) which amends and restates the Pfizer Agreement in its entirety. Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment equal to $36.0&#160;million. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil. Approximately 10% of adult Gaucher patients in Brazil are currently treated with alfataliglicerase. The Company is discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, the Company will determine what it believes to be the course of action that is in the best interest of the Company.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In 2017, the Company received a purchase order from the Brazilian MoH for the purchase of alfataliglicerase for the treatment of Gaucher patients in Brazil for consideration of approximately $24.3&#160;million. Shipments started in June 2017. The Company recorded revenues of $7.1&#160;million for sales of alfataliglicerase to Fiocruz in 2017, and $2.6&#160;million during the nine months ended September&#160;30, 2018.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least 12&#160;months from the date of approval of the September 30, 2018 financial statements, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align: top;"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">b.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Basis of presentation</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.75in; padding: 0px;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Restatement of previously issued condensed consolidated financial statements</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The Company has restated these financial statements to correct an error in the revenue recognition from the agreements with Chiesi. Previously, the Company had identified a single performance obligation with regard to its promises&#160;under each of the agreements. The Company subsequently concluded that there are two performance obligations under each of the agreements as follows: (i) the license together with research and development services and (ii) a contingent performance obligation regarding future manufacturing. As such, the Company has recognized revenue for the combined performance obligations (the license and the research and development services) for the three and nine months ended September&#160;30, 2018 for the satisfaction of the performance obligation that occurred during the three and nine months ended September&#160;30, 2018.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The Company&#8217;s decision to restate the financial statements previously reported on its Quarterly Reports on Form 10-Q, was approved by, and with the continuing oversight of, the Company&#8217;s Audit Committee.</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">&#160;</div><table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0px; margin-bottom: 0px; width: 100%; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"><tr style="vertical-align: top; text-align: justify;"><td style="width: 0.75in; text-align: left; padding: 0px;"></td><td style="width: 0.25in; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">2.</div></td><td style="text-align: justify; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Impacts of restatement</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;">&#160;&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated balance sheets as of September&#160;30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 88%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 764px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CONTRACTS ASSET</div></div></td><td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 250px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">1,450</td><td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(1,450</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CURRENT LIABILITIES:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Total current liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">14,551</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">24,337</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">LONG TERM LIABILITIES:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">61,780</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(28,287</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">33,493</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Total long term liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">117,640</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(28,287</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">89,353</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Total liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">132,191</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(18,501</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">113,690</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CAPITAL DEFICIENCY</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(64,994</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(47,943</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated statements of operations for the three and nine months ended September 30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">(</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands,</div><br/><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;">except per share data)</div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 642px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">REVENUES FROM LICENSE AGREEMENTS</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">11,672</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">11,672</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">16,665</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">16,665</td><td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(2,638</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(1,450</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(4,088</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(7,294</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(1,450</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(8,744</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">OPERATING LOSS</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(13,963</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">10,222</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(3,741</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(30,851</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">15,215</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(15,636</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;">LOSS FOR THE PERIOD</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(15,544</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">10,222</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(5,322</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(36,238</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">15,215</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(21,023</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Net loss per share of common stock-basic and diluted</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.10</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.06</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.04</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.25</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.11</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.14</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated statements of changes in capital deficiency for the nine months ended September&#160;30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands, except per share data)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 921px; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(204, 238, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Net loss for the nine months ended September&#160;30, 2018</div></td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(36,238</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">15,215</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(21,023</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Balances as of September&#160;30, 2018</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Accumulated deficit</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(334,170</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(317,119</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Total capital deficiency</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(64,994</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(47,943</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">Although there was with no impact to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 921px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Net loss</td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(36,238</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">15,215</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(21,023</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Increase in contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">34,929</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(16,665</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">18,264</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">Increase in contract asset</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">(1,450</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal;">)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">1,450</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal;">-</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr><tr><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">Net cash used in operating activities</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">(3,738</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">-</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">(3,738</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The impacts of the restatement have been reflected throughout the financial statements, including the applicable footnotes, as appropriate.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in;">&#160;</div><div style="margin: 0in 0in 0.0001pt 1in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt;">In addition, in connection with the Chiesi Ex-U.S. Agreement, the Company should have recognized $1.8&#160;million of revenue in the last quarter of 2017 and accordingly has revised certain items in its consolidated financial statements for December&#160;31, 2017 presented herein. The Company evaluated the materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&#8217;s prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for December&#160;31, 2017:</div><div style="margin: 0px 0in 0px 0.75in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none;">&#160;</div><table style="width: 80%; margin-left: 0.75in; border-collapse: collapse; border-spacing: 0px;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="10" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December&#160;31, 2017</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">As</div></div><div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &quot;times new roman&quot;, serif; line-height: normal; font-size: 10pt;"><div style="font-weight:bold;display:inline;">originally<br/>reported</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">As revised</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 61%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">Contracts liability</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">26,851</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(1,836</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">25,015</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">Accumulated deficit</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(297,932</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">1,836</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(296,096</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="margin: 0px 0in 0px 0.75in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2017, filed by the Company with the Commission. The comparative balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">c.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Net loss per share</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), outstanding for each period.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Diluted LPS is calculated in continuing operations. The calculation of diluted LPS does not include 76,195,921 and 73,310,911 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares of Common Stock issuable upon conversion of the convertible notes for the nine months ended September&#160;30, 2017 and 2018, respectively, and 80,696,070 and 73,280,977 shares of Common Stock for the three months ended September&#160;30, 2017 and 2018, respectively, because the effect would be anti-dilutive.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">d.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Revenue recognition (as restated)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.75in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">1.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;">Revenue from supply agreements</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; background: none; text-align: justify; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in; text-align: justify;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenues from supply agreements and from selling products when control is transferred to the customer and collectability is probable.</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; text-indent: -0.25in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.75in; padding: 0px; text-align: justify;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;">2.</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-align: justify;">Revenue from Chiesi Agreements</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; text-align: justify; max-height: 0px;"></div><div style="clear: both; background: none; text-align: justify; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none; text-align: justify;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">According to Accounting Standard Codification Topic 606, Revenue from contracts with customers (&#8220;ASC 606&#8221;), a&#160;performance obligation is a commitment to provide a distinct good or service or a series of distinct goods or services. Goods and services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. A good or service promised to a customer is distinct if the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company has identified two performance obligations in each of the Chiesi agreements as follows: (1) the license and research and development services and (2)&#160;a contingent performance obligation regarding future&#160;manufacturing.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company determined that the licenses granted to Chiesi together with the research and development services should be combined into a single performance obligation under each agreement since&#160;Chiesi cannot benefit from a license without the&#160;research and development services.&#160;The research and development services are highly specialized and are dependent on the supply of the drug.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The future manufacturing&#160;is contingent on regulatory approvals of the drug and&#160;the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method.&#160;Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur, usually upon achievement of a specific milestone.&#160;The Company used significant judgment when it determined variable consideration.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">Since the customer benefits from the research and development services as the entity performs, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">Revenue from additional&#160;research and development&#160;services ordered by Chiesi, is recognized over time using the cost-to-cost method.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company accounted for the Chiesi U.S. agreement as a modification of the Chiesi Ex-U.S. Agreement. As such, the Company recorded revenue through a cumulative catch-up adjustment&#160;in&#160;the&#160;amount&#160;of&#160;$6.2&#160;million.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">&#160;</div><div style="color:#000000; font:10pt 'times new roman', times, serif; letter-spacing:normal; orphans:2; text-align:start; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-style:initial; text-decoration-color:initial; margin:0pt 0px 0pt 1in">The Company&#8217;s revenue recognition accounting policy prior to January 1, 2018, was materially the same.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted standards</a></td>
<td class="text"><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="vertical-align:top"><td style="width: 0.5in; padding: 0px;"></td><td style="width: 0.25in; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">e.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;">Recently adopted standards</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; background: none; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;">In May 2014, the&#160;<div style="font-family: &quot;times new roman&quot;, times, serif; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial Accounting Standards Board (&#8220;FASB&#8221;)&#160;</div>issued guidance on revenues from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions require capitalization of certain contracts costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount timing and uncertainty of revenues and cash flows arising from an entity&#8217;s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December&#160;15, 2017. On January&#160;1, 2018, the Company adopted the new accounting standard, ASC 606, Revenue from Contracts with Customers, and all the related amendments, using the modified retrospective method. The implementation of this Accounting Standards Update (ASU) did not have a material impact on the Company&#8217;s consolidated financial statements.</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in; text-align: justify;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 0.75in;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">In January 2016, the FASB issued ASU, No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective for annual reporting periods beginning after December&#160;15, 2017. The implementation of this ASU did not have a material impact on the Company&#8217;s consolidated financial statements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6754398448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font: 10pt 'times new roman', times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated balance sheets as of September&#160;30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 88%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 764px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CONTRACTS ASSET</div></div></td><td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 250px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">1,450</td><td style="width: 17px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 17px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(1,450</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 249px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CURRENT LIABILITIES:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Total current liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">14,551</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">9,786</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">24,337</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">LONG TERM LIABILITIES:</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">61,780</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(28,287</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">33,493</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Total long term liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">117,640</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(28,287</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">89,353</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Total liabilities</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">132,191</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(18,501</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">113,690</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">CAPITAL DEFICIENCY</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(64,994</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(47,943</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 1in; background: none;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated statements of operations for the three and nine months ended September 30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap; text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">(</div><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands,</div><br/><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-style:italic;display:inline;;font-style:italic;display:inline;">except per share data)</div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 642px; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">REVENUES FROM LICENSE AGREEMENTS</div></td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">11,672</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">11,672</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">-</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">16,665</td><td style="width: 19px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 19px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">16,665</td><td style="width: 18px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(2,638</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(1,450</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(4,088</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(7,294</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(1,450</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(8,744</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">OPERATING LOSS</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(13,963</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">10,222</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(3,741</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(30,851</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">15,215</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(15,636</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="font-weight:bold;display:inline;">LOSS FOR THE PERIOD</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(15,544</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">10,222</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(5,322</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(36,238</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">15,215</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(21,023</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Net loss per share of common stock-basic and diluted</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.10</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.06</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.04</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.25</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">0.11</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(0.14</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px 0px 0px 0.75in;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">The effects of the restatement on the line items within the Company&#8217;s condensed consolidated statements of changes in capital deficiency for the nine months ended September&#160;30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands, except per share data)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="width: 921px; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; text-indent: 0px;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(204, 238, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Net loss for the nine months ended September&#160;30, 2018</div></td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(36,238</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">15,215</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(21,023</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Balances as of September&#160;30, 2018</div></div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align:bottom; background-color:#cceeff"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Accumulated deficit</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(334,170</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(317,119</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr><tr style="vertical-align:bottom; background-color:white"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Total capital deficiency</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(64,994</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">17,051</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">(47,943</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">)</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0in; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0pt 0px 0pt 1in;">Although there was with no impact to net cash provided by operating activities, net cash used in investing activities or net cash used in financing activities, the effects of the restatement on the line items within the condensed consolidated statements of cash flows for the nine months ended September 30, 2018 are as follows:</div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; text-indent: 25.9pt; background: none;">&#160;</div><table style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 80%; margin-left: 0.75in; border-spacing: 0px;"><tr style="vertical-align:bottom"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="10" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Nine Months Ended September&#160;30, 2018</div></td><td style="padding-bottom: 1pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align:bottom"><td style="padding-bottom: 1pt; padding-left: 0px; font-size: 10pt; line-height: 10pt; padding-top: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>originally<br/>reported</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="border-bottom: 1pt solid black; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">As restated</div></div></td><td style="font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="width: 921px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">Net loss</td><td style="width: 16px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 151px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(36,238</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">15,215</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">$</td><td style="width: 150px; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">(21,023</td><td style="width: 15px; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);">)</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">Increase in contracts liability</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">34,929</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">(16,665</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">)</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">18,264</td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr><tr><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">Increase in contract asset</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">(1,450</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal;">)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; font-size: 10pt;">1,450</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal;">-</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(255, 255, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td></tr><tr><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">Net cash used in operating activities</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">(3,738</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">)</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">-</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">$</div></td><td style="text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal; font-size: 10pt;">(3,738</div></td><td style="text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px; background-color: rgb(204, 238, 255);"><div style="line-height: normal;">)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="color: rgb(0, 0, 0); font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin: 0px; background: none;">&#160;</div><div style="margin: 0in 0in 0.0001pt 1in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt;">In addition, in connection with the Chiesi Ex-U.S. Agreement, the Company should have recognized $1.8&#160;million of revenue in the last quarter of 2017 and accordingly has revised certain items in its consolidated financial statements for December&#160;31, 2017 presented herein. The Company evaluated the materiality of the error from quantitative and qualitative perspectives, and concluded that the error was immaterial to the Company&#8217;s prior annual consolidated financial statements. Since the revision was not material to any prior interim period or annual consolidated financial statements, no amendments to previously filed interim or annual periodic reports was required. Consequently, the Company revised the historical consolidated financial information presented herein. Below are amounts as reported and as adjusted for December&#160;31, 2017:</div><div style="margin: 0px 0in 0px 0.75in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none;">&#160;</div><table style="width: 80%; margin-left: 0.75in; border-collapse: collapse; border-spacing: 0px;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="10" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December&#160;31, 2017</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(<div style="font-style:italic;display:inline;;font-style:italic;display:inline;">U.S. dollars in thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td colspan="2" style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">As</div></div><div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: &quot;times new roman&quot;, serif; line-height: normal; font-size: 10pt;"><div style="font-weight:bold;display:inline;">originally<br/>reported</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Adjustments</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;"><div style="color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;, times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: 0px; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: nowrap; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">As revised</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 61%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">Contracts liability</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">26,851</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(1,836</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">25,015</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">Accumulated deficit</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(297,932</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">1,836</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">(296,096</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin-bottom: 0.0001pt; font-family: &quot;times new roman&quot;, serif; margin-right: 0in; margin-left: 0in; font-size: 10pt; line-height: normal;">)</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="margin: 0px 0in 0px 0.75in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; background: none;">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763305056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal;">The Company&#8217;s inventory at September&#160;30, 2018 and December&#160;31, 2017 consisted of the&#160;<div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">following:</div></div><div style="font: 10pt &quot;times new roman&quot;, times, serif; margin: 0px 0px 0px 0.5in; background: none;"><div style="text-decoration: none; color: rgb(0, 0, 0); background: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table style="width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;"><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">December 31,</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td><td colspan="2" style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; padding: 0in; font-size: 10pt; line-height: 10pt; white-space: nowrap;;vertical-align:bottom;"><div style="text-align: center; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;"><div style="font-weight:bold;display:inline;">2017</div></div></td><td style="padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;"><div style="background: none;;font-weight:bold;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); width: 64%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Raw materials</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">3,201</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="background: rgb(204, 238, 255); width: 15%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">3,838</div></td><td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Work in progress</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">276</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">485</div></td><td style="background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Finished goods</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">4,482</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 1pt solid black; background: rgb(204, 238, 255); padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">3,510</div></td><td style="background: rgb(204, 238, 255); padding: 0in 0in 1pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr><tr><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">Total inventory</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">7,959</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">$</div></td><td style="border-top: none; border-right: none; border-left: none; border-image: initial; border-bottom: 2.25pt double black; background: white; padding: 0in; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="text-align: right; margin: 0in 0in 0.0001pt; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal;">7,833</div></td><td style="background: white; padding: 0in 0in 2.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"><div style="margin: 0px 0in; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; line-height: normal; background: none;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6754421008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text">The liability component was valued based on the Income Approach. The following parameters were used:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.98in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; width: 39%;;margin : 0px auto;;text-align:left;;margin-left :auto;margin-right :auto;"><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; font-family: &quot;times new roman&quot;, times, serif;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; background: none; line-height: normal;"><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div><div style="font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;Notes</div></div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; width: 79%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock price (USD)</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 18%; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">0.73</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Expected term (years)</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">3.13</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Risk free rate</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">2.87</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;">%</div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">75.56</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;">%</div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 0px 10pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-indent: -0.14in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Yield</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">13.50</div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;">%</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6754431216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Statements of operations</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.5in; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s disaggregation&#160;of revenues:</div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div><table style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; border-image: initial; border-collapse: collapse; margin-bottom: 0.001pt; margin-left: 0.5in; width: 80%;"><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="6" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended </div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">(U.S. dollars in thousands)</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td colspan="2" style="border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt;;width:;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; vertical-align: bottom; width: 64%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pfizer</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">4,649</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 15%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,198</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0pt 0px; vertical-align: bottom; width: 1%; font-size: 10pt; line-height: 10pt;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding-top: 0px; padding-right: 0px; padding-bottom: 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Brazil</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,573</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); border-bottom: 1pt solid rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6,575</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"><div style="margin-left: 0.26in; font-size: 10pt; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;times new roman&quot;, times, serif; letter-spacing: 0px; top: 0px;;display:inline;">Total revenues from selling goods</div></div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-align: right;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">7,222</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">16,773</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background: none; line-height: normal;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; background: none; color: rgb(0, 0, 0); text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></td></tr><tr><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 64%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin: 0px 0px 0px 0.26in; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none;">Revenues from license and R&amp;D services</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;">$</td><td style="background: rgb(255, 255, 255); border-bottom: 2.5pt double rgb(0, 0, 0); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; border-top: none; padding: 0pt 0px; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; text-align: right; line-height: normal; font-size: 10pt;">16,665</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-left-width: initial; border-left-color: initial; border-right-width: initial; border-right-color: initial; padding: 0pt 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 15%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; font-weight: normal;">&#160;</div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-top-style: none; border-bottom-style: none; border-color: initial; padding: 0px 0px 2.75pt; vertical-align: bottom; font-size: 10pt; line-height: 10pt; width: 1%;"><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; background-image: none; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: normal; text-decoration: none; font-weight: normal;">&#160;</div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental income statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763408000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated balance sheets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">CONTRACTS ASSET</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">9,786<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,337<span></span>
</td>
<td class="nump">22,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">33,493<span></span>
</td>
<td class="nump">25,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">89,353<span></span>
</td>
<td class="nump">78,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">113,690<span></span>
</td>
<td class="nump">101,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(47,943)<span></span>
</td>
<td class="num">(29,457)<span></span>
</td>
<td class="num">$ (26,071)<span></span>
</td>
<td class="num">$ (9,957)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">CONTRACTS ASSET</a></td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">61,780<span></span>
</td>
<td class="nump">26,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">117,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">132,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(64,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">CONTRACTS ASSET</a></td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">9,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="num">(28,287)<span></span>
</td>
<td class="num">$ (1,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="num">(28,287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="num">(18,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="nump">$ 17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6756356864">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated income statement) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (4,088)<span></span>
</td>
<td class="num">$ (2,836)<span></span>
</td>
<td class="num">$ (8,744)<span></span>
</td>
<td class="num">$ (8,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,741)<span></span>
</td>
<td class="num">(7,765)<span></span>
</td>
<td class="num">(15,636)<span></span>
</td>
<td class="num">(24,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,322)<span></span>
</td>
<td class="num">$ (11,437)<span></span>
</td>
<td class="num">$ (21,023)<span></span>
</td>
<td class="num">$ (70,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES FROM LICENSE AGREEMENTS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (15,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (36,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | License and Service [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES FROM LICENSE AGREEMENTS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member] | License and Service [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES FROM LICENSE AGREEMENTS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes share-based compensation</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6756347312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated statements of changes in capital deficiency) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the nine months ended September 30, 2018</a></td>
<td class="num">$ (5,322)<span></span>
</td>
<td class="num">$ (11,437)<span></span>
</td>
<td class="num">$ (21,023)<span></span>
</td>
<td class="num">$ (70,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(47,943)<span></span>
</td>
<td class="num">(26,071)<span></span>
</td>
<td class="num">(47,943)<span></span>
</td>
<td class="num">(26,071)<span></span>
</td>
<td class="num">$ (29,457)<span></span>
</td>
<td class="num">$ (9,957)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the nine months ended September 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,023)<span></span>
</td>
<td class="num">(70,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(317,119)<span></span>
</td>
<td class="num">$ (282,791)<span></span>
</td>
<td class="num">(317,119)<span></span>
</td>
<td class="num">$ (282,791)<span></span>
</td>
<td class="num">$ (296,096)<span></span>
</td>
<td class="num">$ (212,656)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the nine months ended September 30, 2018</a></td>
<td class="num">(15,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(64,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="num">(334,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the nine months ended September 30, 2018</a></td>
<td class="nump">10,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="nump">17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member] | Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
<td class="nump">$ 17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6753156672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated of cash flows) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,322)<span></span>
</td>
<td class="num">$ (11,437)<span></span>
</td>
<td class="num">$ (21,023)<span></span>
</td>
<td class="num">$ (70,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,264<span></span>
</td>
<td class="num">(837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Increase in contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,738)<span></span>
</td>
<td class="num">$ (27,584)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Increase in contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 10,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Increase in contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752999232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES  Reported and as adjusted (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">$ 33,493<span></span>
</td>
<td class="nump">$ 25,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(296,096)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="num">(28,287)<span></span>
</td>
<td class="num">(1,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">$ 61,780<span></span>
</td>
<td class="nump">26,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (297,932)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6765422576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,280,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,696,070<span></span>
</td>
<td class="nump">73,310,911<span></span>
</td>
<td class="nump">76,195,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase', window );">Percentage Of Adult Gaucher Patients Treated With alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember', window );">Brazil Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplyCommitmentInYear2017', window );">Supply Commitment In Year 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember', window );">Pfizer Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromExchangeForRightsToRoyalties', window );">Proceeds From Exchange For Rights To Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FiocruzMember', window );">Fiocruz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Upfront Nonrefundable Noncreditable Payment Receivable</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Upfront Nonrefundable Noncreditable Payment Receivable</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountpayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of adult Gaucher patients treated with alfataliglicerase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfAdultGaucherPatientsTreatedWithAlfataliglicerase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExchangeForRightsToRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount received in exchange for rights to royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExchangeForRightsToRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplyCommitmentInYear2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents an order for supply in year 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplyCommitmentInYear2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront,non refundable and non creditable payment receivable under the agreement for licencing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_BrazilAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6753188016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,201<span></span>
</td>
<td class="nump">$ 3,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,482<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 7,959<span></span>
</td>
<td class="nump">$ 7,833<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6753587168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsTerm', window );">Expected term (years)</a></td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsRiskFreeInterestRates', window );">Risk free rate</a></td>
<td class="nump">2.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">75.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedDividendRates', window );">Yield</a></td>
<td class="nump">13.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6751026784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 78.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member', window );">7.50% Convertible Notes 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member', window );">7.50% Convertible Notes 2016 [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 58.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6763856048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,752,000<span></span>
</td>
<td class="nump">$ 10,961,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,236,000<span></span>
</td>
<td class="nump">$ 7,668,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_FourPointFiveZeroPercentageConvertibleNotes2018Member', window );">2018 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt Conversion, Converted Instrument, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member', window );">2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,456,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds', window );">Repayments of Remaining Convertible Debt Through Necessary Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member', window );">2021 Notes [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">14,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a remaining outstanding of long-term debt instrument through necessary funds during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RepaymentsOfRemainingConvertibleDebtThroughNecessaryFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_FourPointFiveZeroPercentageConvertibleNotes2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_FourPointFiveZeroPercentageConvertibleNotes2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFiveZeroPercentageConvertibleNotes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6753805984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Statements of operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 7,526<span></span>
</td>
<td class="nump">$ 7,222<span></span>
</td>
<td class="nump">$ 16,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 11,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=plx_SellingGoodsMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,222<span></span>
</td>
<td class="nump">16,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=plx_PfizerMember', window );">Pfizer [Member] | Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,649<span></span>
</td>
<td class="nump">10,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member] | Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,573<span></span>
</td>
<td class="nump">$ 6,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_SellingGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_SellingGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6751158448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Narrative) (Details) - Option to purchase shares of common stock [Member]<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 13, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">64.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">6,360,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">2,360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=plx_ExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=plx_ExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (<Z<DX?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ ASIR3B?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MT:*C!+SDP+IY8CB.?0L7P PCC#9]%U OQ%S]$YL[P$[),9DE-0Q#.30Y-^W
MX?WYZ36O6QB72#J%TZ]D!!T#KMEY\EMS_[!Y9%U=\551-06_VU2W@J]$??TQ
MN_[PNPA;K\W6_&/CLV#7PJ^[Z+X 4$L#!!0    ( (<Z<DZ97)PC$ 8  )PG
M   3    >&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&V
MM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X
M>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3
M$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E
M'S/X%<M4C66C 1-702:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(
MX53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T
M;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?
MZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;C
MZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6
M-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[
MR:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3
M<CH<9T)\S_;VD:4E,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>I
MP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^
M",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\T
MJC4LQ=9XE<#QK9P\'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*
MD8]ILR.G=";-Z#,:P4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\D
MCIJMPA$K0CYB&38:<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1
M#A&27C="/F+.BY 1OQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4
M%TKD#R:G/^DR- >CFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[
M ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC
M5W+-R,=4KY,IV#F?P.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH
M9%LE"<M4TV4WBA*>0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#
MMW)+ZK:4OK4F.$KTL<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#
M;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'
MB/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"
M\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*
MWF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15
M.+]%,[82EQB\X^;'<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WM
MU>>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"
M(Y4<!A87,N10[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.
M7M(E$A2*L P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF
M"X7;XE3-NQJ^)F!+PWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>
M^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@
M#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:
M&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+
MOP%02P,$%     @ ASIR3D1_[.%\ @  00D  !@   !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q]5M&.FS 0_!7$!QS8)H&<"%*2JFJE5HJN:OOL)$Y !YC:
M3KC^?6W#46HO?0FVF=GQ>MBL\YZ+5UDRIH*WIF[E-BR5ZIZC2)Y+UE#YQ#O6
MZC=7+AJJ]%3<(MD)1B^6U-01CN-UU-"J#8O<KAU%D?.[JJN6'44@[TU#Q>\]
MJWF_#5'XOO!2W4IE%J(B[^B-?6/J>W<4>A9-42Y5PUI9\380[+H-=^CY@%)#
ML(@?%>OE;!R85$Z<OYK)Y\LVC,V.6,W.RH2@^O%@!U;7)I+>QZ\Q:#AI&N)\
M_![]HTU>)W.BDAUX_;.ZJ'(;9F%P85=ZK]4+[S^Q,:%5&(S9?V$/5FNXV8G6
M./-:VM_@?)>*-V,4O96&O@W/JK7/?GB3D)$&$_!(P!,AB_]+(".!3 24V.2'
MG=E4/U!%BUSP/A"#6QTU'P5Z)OHPSV;1GIU]I[.5>O51Q'GT,&%&Q'Y X!D"
M38A(QYX$,"2PQQX=_RMP\!$$%B!@!L32R8R>P/0$I">6GLSH*^< ?,0:%EB!
M BN/GCH"/B*#!=:@P-JC;QP!'X%B6"$%%5*?CQP) ()AB0R4R'P^<20 R(+3
M&U!BX_-=JP'(@M<HALLI]B.X=D.8!</10M$B/X+K.8#!"Z8CL')W"/L17-LA
MS(+O""Y?1/P(KO,09L%Z!%<Y\HL8N^9#F"7WX5)'?B5CQ_W#B%E93#M^QAE)
MDPU>^%]%<-DCOZIQYJ8$8#8+*G#I([^PB=<A?(RG$LT:4L/$S?9N&9SYO;47
MA]GJ=#_88=O0_L*'R\57*FY5*X,35[HMVN9UY5PQO97X29]KJ>\STZ1F5V6&
MJ1Z+H:D/$\6[\<(23;>FX@]02P,$%     @ ASIR3E?DROB6 P  \P\  !@
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MR3 8U/]JWVWF\#82YV-?9G7W&^QO=5/FPRPNE#S]WO]?BN[_/LS_848;\,&
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M7%POE*XO57YJ+\N\[L9N^C]02P,$%     @ ASIR3FB2GY&_ 0  * 0  !@
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M[90(:*P//[A8Q\,;$ZOZ\5Z2Z>=0_@%02P,$%     @ ASIR3O;-E3V3!
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M[</Q%L]V'+/1\*:;?A";OW'Q 5!+ P04    " "'.G).##P :;4!  #2 P
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M^%J((_] Y^OT[6J&VTC?+J/ODW6!W:K +@KL/BUQ!;/_OTBVZ*D&4\=ILJ3
MOHV3O/#. WO'XYO\@X_3_BA,+5M+SNC\R\;^5X@.?"K)E1^AQG^PV5!0N7"\
M\6<SCMEH..RF'\3F;YS_!5!+ P04    " "'.G).&\//=[8!  #0 P  &0
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M+ASW_FS&,1L-I[OI!Y'Y&Q=_ 5!+ P04    " "'.G).;HA)!;4!  #2 P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6QM4]MNW" 0_17$!X0U=MK5
MRK:4356U4BNM4K5]9NWQ10'&!;Q._[Z '==-_0+,<,Z9"T,^H7FV'8 C+TIJ
M6]#.N>'$F*TZ4,+>X0#:WS1HE'#>-"VS@P%11Y*2C!\.[Y@2O:9E'GT74^8X
M.MEKN!AB1Z6$^7T&B5-!$_KJ>.K;S@4'*_-!M/ -W/?A8KS%5I6Z5Z!MCYH8
M: KZD)S.6<!'P(\>)KLYDU#)%?$Y&)_K@AY"0B"A<D%!^.T&CR!E$/)I_%HT
MZ1HR$+?G5_6/L79?RU58>$3YLZ]=5] C)34T8I3N":=/L-1S3\E2_!>X@?3P
MD(F/4:&T<275:!VJ1<6GHL3+O/<Z[M-\D_*%MD_@"X&OA&.,P^9 ,?,/PHDR
M-S@1,_=^$.&)DQ/WO:F",[8BWOGDK??>RN28Y.P6A!;,><;P+69%,*^^AN![
M(<[\/SK?IZ>[&::1GFZCWV?[ MFN0!8%LG]*Y&]*W,.D;X*P34\5F#9.DR45
MCCI.\L:[#NQ#?$3V%SY/^U=AVEY;<D7G7S;VOT%TX%,YW/D1ZOP'6PT)C0O'
M]_YLYC&;#8?#\H/8^HW+/U!+ P04    " "'.G).E,%^8:H!  "1 P  &0
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MU]'L_Q!O(E?P-A+5QU[F=??K[*]U(POM1852I#_[9U9VSYOV_VZ&&X V@,&
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MXADLFRX$6$^V'EISKR+P6@0CG,!'"?R*P&\U+3":5F.""I-5F"_4(V99$12
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MAYSOI'Z-U'O5+)/-08ICNRA[W;8^_PM02P,$%     @ ASIR3C=W( ,Y @
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M8S7G_2W>!Y*UPPL%QF>R^ M02P,$%     @ ASIR3FOHYPY2!   <18  !D
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MN9@N\60H/LSO$UH>R?PO4$L#!!0    ( (<Z<DX)VAE=Z@$  "@%   9
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M--IN,[.7T^.=#"V&>2ZA93B6?P%02P,$%     @ ASIR3G344/W) 0  I 0
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MKL8;U6KMP..R.]]UYY^,Q1#0NK!E?F^F#V<RG![F-X$L#U/U'U!+ P04
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M :-G95X3_2ZZT[<;*-[T-PMON-[D?P%02P,$%     @ ASIR3O28H A8+
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M"'/FKP*D1MQFV,!RJ]LDSMPP^,H^!O'=HY^X&S_/ B]U@*(]"RUBS"$ E0!
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M_9];KP:WX[O!-;L<78V'X]%D^-/.T5GD@X9] (;:!/AJZ3\$7N!'GB4_:J3
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M9*K7)HF? J1$<#>(BJ@S_+U'WVWB:9<X'8,'/M\E3F]S\*X0)4"  "A, Q2
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M/!Y<@A.9OF>'G2/P"E9Y%*Q /<)3#!2&#RX=3]_._G;<:7>A=]5R]#C*O\]
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M^V&+4>-Q]C?8./4G0MW]#SM^ U!+ P04    " "'.G).:89[.(@!  #4$P
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MK%WLZY/\,V_Z U!+ 0(4 Q0    ( (<Z<DX?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (<Z<DXGZ(<.@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ ASIR3I_YG\CP    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ ASIR3IE<G",0!@  G"<  !,
M         ( !N (  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "'
M.G).1'_LX7P"  !!"0  &               @ 'Y"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ ASIR3E?DROB6 P  \P\  !@
M         ( !JPL  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( (<Z<DZ!'0*"(P0  $T2   8              "  7</  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "'.G).4D-B3CX"   2!P
M&               @ '0$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ ASIR3FU;3'1/!   O1,  !@              ( !1!8  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (<Z<DYHDI^1OP$
M "@$   8              "  <D:  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " "'.G).]LV5/9,$  "E%@  &               @ &^
M'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ASIR3@]0
M^V2S 0  T@,  !@              ( !AR$  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( (<Z<DY/PBF3M $  -(#   8
M  "  7 C  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "'
M.G).R?^P";4!  #2 P  &0              @ %:)0  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (<Z<DX,/ !IM0$  -(#   9
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M970Q-2YX;6Q02P$"% ,4    " "'.G).;HA)!;4!  #2 P  &0
M    @ $>,0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M (<Z<DZ4P7YAJ@$  )$#   9              "  0HS  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ ASIR3IA*:96W 0  T@,  !D
M             ( !ZS0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " "'.G).]=?Y1*4#  "7$   &0              @ '9-@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (<Z<D[*S\&V[@,
M /D1   9              "  ;4Z  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ ASIR3@G]B3EG P  ,P\  !D              ( !
MVCX  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "'.G).
M>OR.N 0#  "Y"P  &0              @ %X0@  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( (<Z<DXW=R #.0(  #('   9
M      "  ;-%  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ ASIR3FOHYPY2!   <18  !D              ( !(T@  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "'.G).'XBLR.P!   P!0
M&0              @ &L3   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( (<Z<DX)VAE=Z@$  "@%   9              "  <].  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ASIR3G344/W)
M 0  I 0  !D              ( !\%   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " "'.G).B#Z.=\X"  ")"@  &0
M@ 'P4@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (<Z
M<DZFAWV^B (  ,P(   9              "  ?55  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ ASIR3FAG%4-G @  Z@@  !D
M         ( !M%@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " "'.G).])B@"%@L  !%\0  %               @ %26P  >&PO<VAA
M<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "'.G).':Q<XT\"  "X"P  #0
M            @ '<AP  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (<Z<DZH
MS2*X @,  *44   /              "  5:*  !X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " "'.G).5: LZ6P!   ?$P  &@              @ &%C0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "'.G).:89[
M.(@!  #4$P  $P              @ $ICP  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     )P G (,*  #BD      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>89</ContextCount>
  <ElementCount>142</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfChangesInShareholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Parenthetical]</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Revenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Inventories</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurement</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/Revenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated balance sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated balance sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated income statement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedIncomeStatementDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated income statement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated statements of changes in capital deficiency) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated statements of changes in capital deficiency) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated of cash flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesCondensedConsolidatedOfCashFlowsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (condensed consolidated of cash flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES  Reported and as adjusted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesReportedAndAsAdjustedDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES  Reported and as adjusted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/InventoriesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementTheLiabilityComponentWasValuedBasedOnTheIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (The liability component was valued based on the Income Approach) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurementTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - FAIR VALUE MEASUREMENT (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/FairValueMeasurementTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - CONVERTIBLE NOTES (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/ConvertibleNotesNarrativeDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/ConvertibleNotes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - REVENUES (Statements of operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/RevenuesStatementsOfOperationsDetails</Role>
      <ShortName>REVENUES (Statements of operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/RevenuesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - STOCK TRANSACTIONS (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactionsNarrativeDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/StockTransactions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20180930.xml</File>
    <File>plx-20180930.xsd</File>
    <File>plx-20180930_cal.xml</File>
    <File>plx-20180930_def.xml</File>
    <File>plx-20180930_lab.xml</File>
    <File>plx-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001144204-19-014455-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-19-014455-xbrl.zip
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MRK-"=7RUD&T#1S/;M'6$:1/R5U\B;(#M&P-",'AI1O'<L8C@-/P#GUAZR77
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MEEYLN>7^^H_KK]^N'S#;"W\\/%X]7B]O&ROTAM#=5:3!IH> !J?<>6>1N3/
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M8@=U!-3QUO"B2CQP#*G#?4?<^(MI)+:J!.Z?0N,?QPUUV&$N5G,:;#T(2M
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M&MCZFF;C"MOZ,BIE_R-!DO\07E=67E3VDZ+)[OF67Y_).YID*2B^:&Y9N$\
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M!FM@XQX%?FJ<"O#9.0YJNC:0=4QUENKC7P\_R\>AJL3W<ML,/(O\Z5*+:$W
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ME]4R;T^FQO/]06PM)]?6Q#?2\B]5P0!=Q)H7RJBD8_;SW%?=1]/04#@@=79
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M(G3VY%HV#WC>-J5OS'GQLEH-7T5$/@F*!W"J<IGV5=2+[RFQ' BFDMRYYRV
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MS7<E,*)G/GS "HYQB"PV<KSBFT0CSMPGP1@=-R"(+^HZQH.-HZ<CR^3]N/,
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M^8"5>]1D; ESKR_'N#\2R'JB%!#TXLZH)PJ,;50HC%0?@[WR0J4 V/?"T?4
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M;#F&8V;;"W;('BB6*8!C&&-$?Y$[:Z*R 8ZN/U0V@,H&6&Y<JFP N8+Y5#;
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M QT1.>:.,1]9Z 4R762MSW]:@T\@@ 3"3/88&63FT9GA<4A,CHE@8/H^0VG
MW^<.P\B<>1:T.;-!.!ZI0SW,Y\#OZ2S@[V+K/QPVKB%VZY/S?Q<H HWZQZ^#
MP??H5_WC.S).Y/WGILS7R"!&:&!I^*]DY#(4 8Y. FRQ[9"N9*X]YLXSC)(H
MIY\\O!(< >M5@ #D8Q=<<T+<&0@"QY. 16 \"EP*[-"(P\3).7QO"(%%<(JY
MYR&O'!;X^([-BC6B. "'FM3W#>^5#X&,#<N+.TY@M\QM 2;!J4H"(_A)%(%H
M_@0S1C5R&P&:KFZ'@0X@'\-!@6J"1T:P@3$0B<Q@&&[$U'B%[@A]F7$4F;#E
M\1Q8\@JJ<P'_16FBO6NB-/#+XGY06#=EN@Q?SYV;Q5ZV4&+%0B65F)S(AN73
M+7<I ?;S@-K'& G@H/^;.QGDH$33:QH4&]. Z_P[EG5(H*DO,&<@21?_%6DR
M5&*$.HB4$Z;NDS!C7Q-0,K"-)#?1&,G(G4XMWV>[%N[7;+?VN#9],&RVH?H3
M2@,"JG2A=08_Q'0Y[!7PRH@#_20)S:6-P?G 7Z,\^"T)U]5)0W$)<W\3V!N)
MU)D$[ R1/7,<#.SPLQD$$&&<O@#=Y,Z!]K'U0D<?/_)1Z_7ZK[$&7%H]$L9S
MMN@N" FOL<-=["E(G1)7U-"LUQK)-S>'.-TZO]%<U!%[10?>>F!A"6TT3T%-
M@G6J7!#JY3?R\J)YK2!OY=K2B^60J2/5VSA2A4)Q[%/5)\.W3.;:&EGV',\$
MZ2TSY6W[]GV8<K;A]W@F8>_!(0;&9S%T7R?<>L7)AF_5B#\)QI#Q2(DS9T<5
M=\Q[R?H1PUX83BCT,(6CE1^XYI\:F @>05A32G[!2PX].51L(3'<2_[B$%],
MCELC8+R!;G'86/&@1@US(KQ853CQ5%WL"^A"Y7-2DB*%@OPLU"+H/F*!,C)L
M4P3+BEJ\EC-'-2+*?KF.+WPUXD'A[A\EFAFYU$]=.'0[FMYO:_V&SC1QMZDU
M];K6U_6$=DPJ,P(23#V;7=LD59D[8P-@C2!>NV<QI_J21O"I)5]9OC]G+H7Y
MS&54@MKV!24!<T0Y[%2+C_ KD=#=Y2"L #043'SA]1KB54X&L;*NQ8#9\$-/
MP^$*@&F\E<'/>W6M@_?MW7K(E 9\U.]VEPTZ'$(P\>@>QO! 36/N<\!I.A[#
M%[ 4A!<1H;(OV)3"PU78,91!7=Y^L87KHB $A/( *@^@!![ ')M9#@_@G:C9
M(.H[L+WXG,'AL^N.D8I)4B^_E9=/SB%856LEOCP/]\^+4'5+:L 4,D:4 7(R
M!DBW5 M$K^W?@ECN-0A-!!8:X<]G,PP_#"M&^<HF4"\?_.4\V92MQ6+^V4J9
M%*?C_U!1FTI,)([:3)2Y$V46_;":HK]DWV5.6?X5M6V>)^".Y@C-^3RAW._N
MN38ZY/EL4 ^CX46Q01/H<J?4$X4*;:Q0*O \\0UHZ@$W[RKX;:LE:]L=<JJN
MJ-3)YY1//JNE\Z#'H>5=-\H[(XGJN@-U1E(OJS.2.B-5R2 Y.=-C04S^4F?_
M"0%A\O$?&;'XCS72D!6&M L^)X(@3S@692,C&EG)6",8*^1BC5ADI2)S(F+,
MCC*"\00QB).3AQA88W@C.,&,K#'+8W4=<N_.+)-TZAV-I'9&,RH?P!*XPE-(
M.F%Y,+S$5]/AB$8\VS/JL8QC3.UR'UBQ$^P3CBT&"X2T6(HP+TCN/EF8K8Q5
M/6"X9D >75[F'";VR<(&,"489YE'RZ2>\Q,/^C7RE7W$0H+$9SP)+,SIC=[%
M#QY MC%OC=$)N@^.6@M-ABER(5<(\M2&\?"7<3R+[[ N@=:H-XRX\BC>U=;(
M8($^8,&4%TYWD3WAL2_5P#A])#0-ASQ0AXZM($Z'R[9++483\AU3W)\=_#)P
M'RG[.$&U1WUW[J68A0F&F/AL/!F6S4X&>:=2%E0$# G2H:Z"(/:*.-?F#C#;
M)%#L4Y8:2#'G&I<ER"OKG1')1RM:7YB:A8.P)+O/20<MY6](FT)O*'V_C;Y/
M.J4P239<,*A)GEV2KX/9LF&!XF&L.C\));U6& =IVTS2SO5W["D;UJOCTS F
M$^Q%:('%V\/>8;LSILXC!8A?G#?>Q1)@B!C31WQLR>;@T4>#;U_C.2)$Q&_#
MH_,QK/ YXD>H9:Z6^9M=YB,*S)B">3WB6W5B:?KD$0@,N!DA%G5ZLQ>P)6O6
M;@PR (;: ^O*<IAEXB/8#%VV?%DP-]<LD2[!5\S$0A;# NL%C;&4 6-$*@;'
MZLX9;?&;:\==BY^]+T0G6CD3.+^"I8'QTC +UC\QM<?A"# C.J-,@M!^0LX)
M[[[0FB-OKC21TD1O3Q/QO9FDMN28\7C0B3=ZOJEC^HCKP5%BAF<]P_:3:PC7
M6_QZD%)U=(H'$H1+B4]6+BJF(H>$Y<9/ZLQ _D@2$G<T<_W@(F?PT4F2@48E
ME(3 Z_(HSZJ)%.Y&AI/2*$JCO#F-PL9N< RCF8=^@6>#I<O"+^@5 6W![L@B
MP+@8QXY5R\65G_[JW(3E2E>L-X]:TX>YY_,#S[L:^<&,%^'5TD(5D6@2% _P
MU)PDTWOC1"KF T%7$DLT8]!$)I@Z3Q%\7:AO$&9I:MG4#V":0!!XFSP!.5*;
M42.NB9AYE.FP<:AYT5<7P*OXDH'98E/\,I\3/(<O'"[T:DT9]N 2OLU]YCR<
M8-J9'X#J^A-5[!1,2$PHCM;"8(J>13_"U@N5ZN)$<D^2")> F72@.1;Y8 7)
M$ ;A=@)K$1Y$!R6;(DS6,QB$H:CL@7A14<3%LV7;3!$S)FDP]CD#763,RW#?
MX!8>M!PS/V,OACR:H\0EQ_%_\]$C:R<<=\($7\)TI<25$G]+2GR(A[RT)U<<
M[?S8.5W@0.8G_,FA >=KX9+G3;$S;JBEDK95L3XL/Z6/GM Q#;.9T'PF&GZ!
M>X'_AJJ/;*TAPA;]&!N4F[# LCD+]F+ZR@>6^^/7< P)1UZ^':M4C%(Q;TK%
MI&XH,>H'WS?L]?ZA^(E(!["0+([TPOU1VI9J02U"M0C?TB),[H("^SR!=2U\
MNS]JPUK" 6S@C?\T&7>0OG:Z>KE@;T2!>/"C3_RY.=%21RU<GMZ(G>FX)@@F
M( "/$W9A'IT.H MS<C&?)6#($[XI)^5H2EQ.L?-,_+L[CG_^I5-K)"ZBX-"A
MME^U\M_PRD\%>G@YR 3)J@@N6.BOZ M@@2?D/PUGCB#_'-FYIS%'#WHDX!B-
M9W=VS6),%U,:U/HJ=WVEIZ!@9.!"A98ET8?;1A#FCFB!U$)#^[A'.!N51W$R
M>125@[#)20:3!<+&! '%>,*1RTKB^"(FU5\Q8)6#H5X^I9=/#KOF=(P?R;'W
M5*9YB5BM; JN'?*'\8K'EI:6CDS+VPXW*FB8YO.^,M:_1#5Q<C)!?/+)Q820
M9$K'E\'P4S*?(U_H$%(5MN_'N<4+X;$0GV02_-+T$7;'RVYM_?D,/J C<<W,
M[[B#W,-DV(\F+IN1"! P:-1[O8@N=<.G^$5- E4V*LO'4NS=V,D;NY%<C/2S
MS""^P1YS1.\H*R,GO\--T(6% >%_YD/B1'ITC+GZ_JHP GA%7'3QBZ$PM"F*
M)(!?,5#[Q835]4B%E\WU:5[6"U(=S8A(J$&_V]AZ@F46T!ET9]BOOL5#K^)K
M>I_3+ZZK^ 46.M G[G/$H91OO$9N67C5U/@_U^-=^:P=44N0F,;,"C"4,G+V
MF6!R&P)DF L&NQ#3,IP1;D'F=N? Z%A=$-3%Z]+P @ZP:V"D.DYV'-ZP-!Y"
M,#GAZW^@P-E$](5IB=!0S(FQGP0^<DB"Y9GS*9JNBVPW;-\-N8!XO1/\%.'H
M?=-V_;G'T"+" '<&,<S*(&J1Y%A3_ 8IFCNBPX"%FT;KB^% &/Z$C#$V'T9I
ML>L)?B?BY"7B+%N,F;'#%'-H8/2A9JLB,A[S F%AH<4'"KK285#-+*?(&,.C
M4>6N6''H;0Y.#%+CA,Z?Q+>A%RCIYPW/!XQ#H"T3WJ3PR*#%<3KIE.XTL9<A
ML9&8B#MB'J!G3*DSFO)0FF3<RXC?NWH4]I@01SEU#VQ-09_@BPFY!0;F:MD?
M,ZP^1LX'PQ_O0!18X4U>G-*(_%[8(":6B9B?_-(!:PJYR>HPJ[HML&@@)DWA
M=*:M*C1<AEU6E,&[F&1);V&SUH3_8A\B)R?D%?N,;3WP+PO60,6_Y'O8*K-?
M"3<*:>$-1:[1=[K',MC4C" <7VC1$F[2DG\#)>G"GN@$Z^S>ZVBGP=U%Q'*B
M;4N$Z0JZ6",W;HU]?5&'72@VE:\=(&S.5.K%[1,KX_P!-IG$Y0;L)']0 _?S
M,+@P86C[/A6@3_&'WRR.V60M6@QLR_5%N&BT>[!"+F!&(,J3\T1%,64MH??M
MN$F1=<-J#6/-9&$YS:+!XC>B+G(<-AL;):'%$E7!3A:;CGBQSEP0YH''ZH<R
MNWO!4%AO(JS:6X<_CKI[+KKSN?_YM[/Z6=K7R_S,:4<T]T.?@=%HVV(%L??P
M=^%3Q=]CWW3LGRWJ _WK^[E_\6@8LP]8]\B_'7]/S/# &0WCZ+38+/F.EW$@
M,O>P#C_9KOGG[__Z+W\-VPEMI_\'EE-H.(62^WHI#FC6Z+>S+VB CWZVZLU^
M3^^?,0L3&KRCX]_.O@_\6Z?>_]FL_T3#[@R$T^+?8.7SGS^&G\_@L&&"D6[[
MOYU=-,]^[W=[G7J]'M-39!P[C[M1SQFWWOC9U''<W=QQO_C6!\>R?SN#-4'/
MR/MU@V"ZX ;^=QUSV3 Z*]GW<VA2![8*%R;WR7+GOOW*"_32T1]L$?D>O!=)
M\>#%\@MP7&^UZVLYOCCX?9#;74UNDI8H>F,'2B]*)+6WZ\+8^ZC7+HIFHP1I
M//;*;S:/*X,[Z[>$];"4IG8Y:J2MIRA;'.FF=*Q1AP>?F]44K)RY%;J@N5H7
M'&9Z.GJWMU[WY0Q_+Q2O-@OVK^@;H'"[NU++BF]-7!O,//]*F-\9PEIK=K"#
M3.5%I]7OMU+4+0YU4T+6R.2^9TCOUC/:8C4)B96X0L[:>6;<P16?WNVTZLOT
M1KYH%21'+WW9;$+)XOC7[*V'F8YF0^\OW8@*#[UU;-,4A+?0J.]"W__"D+.[
M9;W[L\[.+[U[-S'T;SQ%"@^%_+HH&O9W#D5]ZXDO<.P'M_)">HK1F-6W^Z%Q
M[]I-[W0;J<G<C,KL=@DDGMI,=K*J>C\T[GTF.YU.>^U,#CF6^U?JH(,0QCH8
M32W'\@./)2%<O<Q84N("#[('K"72?)"):W2:O?0&7(B(?9"=W1:6D+WWN<R>
M_H]'<?9 MD38#S+1W4;66#P:V0L[4C[9$D[T+2]Z[#Q>.R8<%;YAR?<L>=VL
MC7#,Y7NA-_N=9HK*G#%O3-*"H!YI:=8;C<;>B5DP%HZXZBZ:]5[FA+,/DK+'
MM&.MJ'9#;V]"S T-5I#16]C\C[IRVNU66B.F1KL!&=GS66FK95L"%G;BHZZ0
M3B-C@FQ+QH(B+FM5+"7@RO#PTM/_3KTA%GG'6SH3-J+/6&H=0\JR)!4\S.UE
M9G["6O[)AI6DL %35*_I">K6$+$3O04/=KM.X5)2Z[5ZYSB4%CS<'7QF&^VC
MT-LO>- [X,SJ^E:4%G";]M?<M-Q1#-JDH[!73L_<Q_:'(4&\;8Q3<!T,/CC<
M8?VBV6SIW?I^7<?]?=[2;,^Q SB=095[U/#I9\K_O796WB)D.=.O%]R7#C+7
MS5:_T4\1NR$Y>^5$P0/P_MVJ"_Z;';@ N_NEX4^^\W#ZT:?7'SX=73N1*3S
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M:>P>!P)=8/V-6.(AQ+1C>,'YQ7MN&S8'2/1=/:*KZT?UYD7]LGFVDDZ(+0>
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M6*HN<%,E9U&B$>QV_>Y_4$L#!!0    ( (<Z<DYBE7VI'@D  *YW   4
M<&QX+3(P,3@P.3,P7V-A;"YX;6SM76V/XC@2_G[2_0>._9SF;>>V:6WOJJ=?
M1BWU#(B>V3WI=!J9I !K@LW9AH8]W7\_.\ T =MQ@,4)?9^:#JY*/?64RX[+
M#C__.A_'E1DPCBFYKC8NZM4*D)!&F ROJU,Q""ZKO_[RU[_\_+<@N$,"?68H
M_,8K/81)G[Y4?JNT+NJ5H/+R\G(1R:]%\O5%2,?R(B651BOXB%@X"IKU1KOR
MS_KE5:-]U:S_J_*?[L?_!H%2'&/RK8\X5*0AA%]71T),KFHUI7'>9_$%9<-:
MLUYOU=8-J\N65W..4ZU?6NNVC=H_/CX]AR,8HP 3+A )7Z64&IU<H]UNUY)O
M95..KW@B_T1#)!+79-I5,;90_P7K9H&Z%#2:0:MQ,>=15?F T1AZ,*@DM[\2
MBPE<5SD>3V)E=G)MQ&!P79W$<^7)RWJ[55?"/]Q2$@'A$,D/G,98<@#1>Q0K
MQ,\C ,&K%:7\2^\QA6#"J$ QGBNF:JI!S453[?BV/LN8@3$0P3N#S@18XNS#
MC#:I_).MOT5\]!#3E^,9OZ'Q,-L?R4QJI P#OP.!<.QLHTXRL25$<3B-$]<^
MR3NG;(*Y  DM6ENE-!T>?4FNH&'J3K'JG92EX:]NE'3! >+]I!].>3!$:%)3
M?JE!+/CZ2N*IH-Y8=<<?5I>_WG">Q/Q2<XSZ$"?W^[K=H'9BP^Y@@(ET#A#Y
M072EBY:6/%"F_EE=YY\H":>,2?8L&/;0M<W^#4LCE]E^?4/Y<8?Z=&)<M:CQ
MZ7B<: NPC/ZU_(#1L=[GJQO2@]%,N32/3M2M45RM4!8!DZ-@2XZ"+X"'(R'_
M.3W%749EWA(+9;6X(=']OZ=XHI+")["Q:1<K,'%VPPT<_>B7HR6BV\PNMM6N
MP"QL66IP>\.OV]68*"-$_5%1,D.Q&BMOQ"UB;"'GK+^A> H6.ASE"T#35FAM
ML^4(1,_B3Y[[3AC2J;2V!R%(R_LQR([NT)6L8L6GS&Z_GJE+OTQUQ B8:ZK3
M-2X^*SJK]5RT_7*QGHLO[+. =+/B^S]MKV'4J6M<7]MZ!GD3CR5/&/5QC(5\
M()/9_UG0\-N(QM))7(T"8F$)C&S14T?TAD5N=GN.9U?G;X=X"H$^PIN>$_V&
MB=F)7M>X*,0X<)"1YIN>I[CK:4(7+=0<X3-#$;A/CK1212''<8*DQ6 8&3SW
MFRV3D\E$;K+24N4D*XW!0);G&90<Q6? !);FWD'?X8G#)% 2BDSF&_*>;I)U
M6G94^4C\CL7H=LH%'0-;8UTX<>4@7A[F',#H>6RU?OJQ79SIA--"M*%]4=AR
MF%1DKRHW/:^Z;&4#)UXL,D7A9A='1AIT8,KS^K^U][ORYJ:A5"RZ03)PZKE>
MT 6BMEC(Y\9DIM2E7# 0F"7%7GE578#Q)*8+=6&CAL7SYM*CWZD\,7)TZ(98
M>E> 5=F\86$3*@_#-A0&LO[NEZQ<:W3&5;D"D)-KR4O7TC!=U2VW^%K;U6^_
M*42-LPL,T^B1A P0EQ.9Y=_<I4Z3FE-W"U7ZDI9U&9UA2=S[Q1=)Q2-1U0 N
M,!G>A +/LI:&\RCQVHWVH72[2^4!:^AJGI_PNR@9=_EG>A-*+S P;ORP36]R
M*/'*>?X(WYG.Y(#J\,P9>"E:IH/[D?0D>H9#F6R5=ZR%S"S1DM.;#="A5N2#
MU'5<JHUUC(8 $7^0_DGF9OD2>&Y-):<\-UY#!+0]1X#!$P^8(!(>.'IKE9SK
MZ*T%:WKJ?-?RO4;?@\DJ@N7\.+VL9B':*E7$'FV)XVU>K=@,T["F[_R]D7K<
M6;1*E9Q%*S93F<5O5S2 7IUX.2P%:Y6<:PK6@C5Q?ME\Y[M,Z@;A#O.0$GEM
M"M'F*2CK<L$!>HN8 "Q]0;>=^@#TQ:PYN+OE=@E*7G.*E4,5ESQ8#H5?S*JC
M1"4S*1W#$^49Y&^V*PF7M@C7\+N)4$^7[[+""#%XCY+UZ_$$"$\@V4H+!H$S
MY,\$M9!'+.Y@PB#$6?2EFYTA:6F A3R!\4"9O#E9[K\*%Y\9DJ$5*AL_($Q4
MLOA"Y PTQG^\5J(T5.93<X94YW. PY$0+P_1MKT&JZT%]W.5?6Q%NEQ:SC 4
M<N$_]I'4G1<ER M?UR'8(3?C9(/SPU15EI/%^0F$HC.X3W:0 /34+?F7"95?
MK4W64'T,I6?$_#'<80B$_=?5M)'P.@?LD.6BD K5U#+?)RJTZROYQ,^,77?@
M#J]?\)':[\=]B*0O[H#AF<0Y@]> W?W.?AQS#UUG% X'>,$0&^\\QX9,6#*$
M_TC@=@;?EYAOY<!E?5N,5>P,&;<#-I"[]S.U/G]S/E4G=3N#Y(%0%5T?B0#Y
M2:SJL#T8(A8E9N5/[\?2?D;D']4OAACQ?(IB=].&=6-ZKOTM&9K.*%#V]D$Q
M3X'NPMA]UT>N2-")OPGZ=< =CBL68VO;QMOR<K&=DGL3-*<0.QS#+P:_6T>>
M;T@DK[ I1&XOLMA7X9N("#=7&$*E6;3TGRQFO9Y-V3<^;&K>1%38'&#<)>?]
M]//]8+!<Q)J'(T2&T$,".D2_A<6V=)!+3>FWY^2#:]B@H]MQ483#1!O!?^)@
M_, HY[*C#K!MF2K5ZO3GG;GDO0=R3F!_>6.ZG=>(U[AU]\1RRMSL;03!_R/V
MT(THIS23$KH>[Y9V9)?[+#*^Q_-=E^]LBS$;?^SUO".>D]ZT.IL@LXA??K)B
M37M.6HNCH#67'8.7,/-0M98H.5-K&,5\[_6;KHWEY?;/*7OYZ)UIV!D#L[9U
M\<<WK=D.6PT.KU3U@(.$-+J3<\683E9O*[DG0TQ AL?W[*WO3KDU>*7"$DJ;
M9:1<@ JZ16R-01J^ 2-[$I(AYX6^/<-T][B<%=J1=^CJ-W@QI-Z43Z(>X'%_
MROCRB6=9<8"HPZPUF]P:RLA6;I#9VW5]]+]GB*7.X0<@,N7$:DDY&F."N6#)
M>)O=$5T5%#VAYL7CL-'2!Y]E7"?*P<[^ZT4G'=,2\VS3O]<F9?'\J\5ZI^MF
MWR=8H]/\^EII?G/"AY$]]/(1"3FVH9A+2U1?XL!F&46W;&&O8:RCP/@;&A80
M[I'M@[K?*?OV2))C^#P_=S;I\I!G0U'(,XC?+7]0DX@11!\HC?*S9Y,N#WLV
M%.Z_PJ4;5;[_PNPO_P-02P,$%     @ ASIR3J_=N$[Q*0  L(\" !0   !P
M;'@M,C Q.# Y,S!?9&5F+GAM;.U=^V_C.)+^_8#['_IZ?\XD?B1Q!CN[<%Y]
M ;J3(,G,W ,'09$86SNRY*&D=#*'^]^O2/EM/B72I#,++':ZW1157WT4R2I6
M%?_Z][=)^ND5X2+)LY\^=WXX^OP)95$>)]GHI\]5^7(P^/SWO_WKO_SUWPX.
M+L,R?,)A]%OQZ2%,LN?\^Z=?/O5^./IT\.G[]^\_Q/#/)?WG'Z)\ C_FV:=.
M[^!;B*/Q0?>H<_;IOX\&/W;.?NP>_<^G_[W_]G\'!Z3C-,E^>PX+] D$R8J?
M/H_+<OKCX2'I\>T9IS_D>'38/3KJ'<X;?JY;_OA6)&NMO_?F;3N'__'MZV,T
M1I/P(,F*,LRBY5.D&]9SG;.SLT/ZK]"T2'XLZ/-?\R@LJ6JD<GWBMB!_.Y@W
M.R _'72Z![W.#V]%O) +VL3EXC6K'1P?UO_XF:@+YREZ0"^?J*0_EN]3]-/G
M(IE,4X*0_C;&Z.6GS]/TC2A]<'36.R+O^<M%GL4H*U ,?RCR- &Z4'P>ID0Y
MCV.$RN+S)]+YSP\W:V"G."_#-'DCI!Z2!H<J/1V:E_41AA>:H*PL[E[NI@A3
M7MH)S>MR9]+?AQA^&J,RB<+4 I2-_BWCNAB'V0@5-]GC&-X[SM,8YI6KWZND
M?+\(IPG N$0O293 !/-N#*S>2SW2@!WN6TA@6S=A,;Y.\^_F/MF5'MO)?ATF
M^)<PK= W%!85IOT_A<\I4I95U$,[V1Z3498 8V%6#J,HK[(2EN9[4 =P6,BG
MXDM4ADFJC,/4VW:-^0;V+!.T&!S64?/>MVO<S$]_ZT.WK@Y-,7:MI96IPKHJ
M6.^RB/<!37,,KQUF\; 8QO^H"OB+29#B%UA$=AMBLHMY12;1;'?:#L%-]@JC
M/L?0M::8K"<MK&)C]#4)GY.4K/_Y9)IG\..O84';P=P-@_<N@T;U?#:<@IQA
M--:$8N'%YC71=#BI]=5Z[P0F>)G ?N$V+YL/?7D_[>1\0#!F*U2PC0U-814[
M:SG#E'GTVQ,.LR*,:+^-9Q5Y1U32$$=S86=_7.U[8=8G67D8)Y/#69O#,$T_
M2]%Q' QS_P#Q+!Q3U+2W-N+ GV%A Y@',7H)J[0T*!RC;T.BYI,PR>Q(.NNZ
ME:"TCX,)FCPC;%+*]7[;B#@&:7!4/:.#!72#@C)[;R-NEI=#H]_-O$,J%(S.
M)$O(M_X5NEI["7HK$6S]XOEKB#3MG6;4&YI':V]*B?\QQTP\%,M+6#Q30%5Q
M, K#Z2&9_@Y16A;S7^B$>'#4F3D<_S+[.5C,NP /W< ?B_E;TO 9I?3= ;]Q
MT#^:*<J%S-2V5I&7-@QZ@RU2AWA=:AA4\_YFXTMKUG[!^41)9;-WYE)YZ\'Y
M8Y1G)8RWJY3^,PQP-")_6/Y[FL.H^NESB2M02%6 V/F4 "0NG1S'"/_TN>.0
MJ8LT+&!EI^OG\"U1&F2;SP2],RO\">8[ 9\K%(FY9,)@,]3=/4.KTEVN+9T,
M:K8;!WT[WQ1O/1<0PM0SFQL.#C8IO7TD)5C?55DC9WU?:)&=)2 V2_W=LS0L
M"EBPA\\%.>\L!0RM-PSZ'3NLL':6+1<DAN1L]1^[4O]%A<GQA3(+&^V#?M<E
M&0S]BHA@"<_FX\3!I!46XV$6D_^0DZ;7,"76_+"\ !/Y/<E&U'TBFL=4G@_Z
M=O8 6GRQ:.!,9<J8V#2>.OBL:F]I\8 B! (3)Q(J9XA%7Y?@L>#X:)](DT)A
M<S78/5=WY1CA-7@"AK8;!\=.5R)=7C@ V&R<[9Z-N2__'8:+@(?59L&Q!\N/
M.@-;HG,,30<^ =6O8&/\]/9)_=NR<_3OP-(GY[L9BL]1!G\H[],PJZ6]SC'Y
MR^SWXC;/(BE'VGT%QWWW/"KLXIH!XY#LP%EPC_,IPN4[$;:$?0W9TTSI49AP
MQA,]%AP?[P5U4@P<EAQX#VI,TCDP.#[9"\VO2,O1L0/;?WZJG: "!@-U5:Q%
MV2G8HZI=!'VGBY26OT +$X=-!ZZ$%;&7<Z\>A=O/!7VGWY<6%5(V.? X%#KP
M/MS7'DF 2LV$^QRD1&521VK K^0'-)FF^3OY864%+I@H1:N9V3<%)TX_;SG'
MG/70@A8XH\F!$^0BSZ@"?DW*\455E/D$X44@D](H4>PA.'%J #9E7P<=AU4'
M[I*5P*A+]%RJ\LA^)CAQZCQIP9P #X<K!\X4.JOH3LW\AX(3IQ9B4[8D@#BG
MR [<+RLRJI_(\!\*^K[096#OQ,+&8<Z!XV9;4"W&@A.GOGV)FE6YH2@XG+@(
MREB?I.6\L!\(CIT>EC7B1H"$PX\+#\OLA.@^?"?'0R0I(HIPA>)&TV"#WH*^
M4Z]9(V:;PN30[B+@8QT!79S53T893P7'EJ*G%%UP#1E1XG<+)X='%Y$CZY(^
MX3!&VCRN/A4<GWY8'K=P<GAT$7$BLD*5%DWIXT&O=]H_^T!?J19H#M4.'#*Z
MEB#'9O)EU33JD:6P.%0Y\+*LR*A&4'#R@1SE% R'# =NE(M\,DE*FE='XM!R
MF@:+LDA,CN"IX,3I4F> +!DX3A2XDSR737@"SK8;!R=.URW-S!>F]!PNW+I)
MF .OQ4%O<.+43#=ZP$NQ<%B;.U(.UW/J=I1EQZGRM&?I=IV!@\U7TWR[SL#.
M?DLWX8XJC3?O;$O\SY2[999.9V!G;]8FYZXF24PG&\B'R;KK#/Q-NZ.:YFR]
M.$@^3.(=H/$_\TZ;(/NY=P4N5TB"OVT2!#^1$,RXBLH[_(CP:Q(ASJ3&:TJ\
M&L<=.X?VAJ<S*01;27@Z/- -8"U;P?U6A.UK.)8"8*0SF53)7$X$2&QEXSDA
MQO549H$AV53F8'<]$_G;FIG&CJ)?MJOA.(D<5/L0V.L+&X,W^71? 0C8C4M4
M4E(X3]30G,2PM*%'AL:;5+MYU3 !,_,FL+[ZYEX1V*/K4ON37G>1%^7=RTPZ
MH>=XI5W0.7,:'*2G>H;H_J37/: " 7J23'X)$J8YS3VZ>IN2[U7X%0B> Y!.
MHX]U/PTI%!.9<EO% ^&'X L.Z^."!Y1,GBM<U)[$.D,<Q7=XF2O.($.S!\#B
M6\8/@Y9&H$PDR3$)F@^.E9%!DO2R$4! .,E&LW'"3E34[ &P. U/52=(&Y0_
M&7:/*(4^1U]0AG"8DJB'> *J)L=[I-ZF?.I3ZP!@.PT*T'17:V#R)[UN=MR2
MC>HROU_S0K1Q8[0&0$Y#!/1(X@+P)UN.!N?=YED^%U7^.?$> 6A.(P(TN1&B
M\"<!;4O.>BSI\%,_ <!\BP+0H6<5A#^)9%> .8Y) 7P,NQLR\WX!79 /_2[;
M_C=Q<03MOD 9>V30-H3G3R+:58@S&(C%/<+T,IWSL$@B8H,D:54NPQ)8S(J?
M#+I'>V1]*8'Q)Q_M5Y2,QN2^BE>82$;HMB*ZN'NAHM]5);D-CEQNITYFLPY!
M+7M@RIG Z$]"V_;R(=_<<)\!<'ODPI+ \"?!#>9Y)5M@K1V \*URJHB+;=$E
M"6P^Q<6M7PJW\^T5J1N!T.P08K[>$+DG9#A3$8=I.KN5DSAMHWR4)7^@&):G
M)(^)*[?XJA!A9_A-0+.#'0JYXS2N4G3W8@:.-,K/QOM =79,?&&PH!7^.:X;
M>UK;[X#%C4OTOLY@2T(6!4^!4NQX)/2B?"SRS1Q@4HUX$_W(D50:<"=\#C"Z
MCHF4,J!%W"HL;P(DK5'G.M;(-H<>WE\@/%"51KXH/!UT.TZ-)X4/J\%1\RHV
M;RY#4#L8*J2L:O4#.G!JD#7FMP%*;ZY9F&T4P'!C[B/DO@ZU#@"U4^_D#G?F
M.@H11XVZM^!U+G[?M]RWKHNCGK8YN-VN;TY^JD;.O,B1WQM;L6DF8K?C1R:B
M4/?;$ALT[!V8>0M$L_EG?O]SH9J-R'H.%.-?1F)-EIA6/AAOC+L-$:5&';,]
M8+(4#Z*?F\C7.>>0DP_(&ZO-&$F^6-SFV9+9V@[L,U)T),_H^BJUP;;: B:G
M$1^"SX+-# >!/S94'">U%/=A$M]DLZVQE!GA<[!5<NKMT&9) 8TW27(/J S)
MU3GS,!0%]Q3K 4#EU&.AS9$(AH&T.68L/?UN;XJB0O%E18+$:X.:WE6X4I[U
M-B_1U5M$#4X&$0U[ FB]7L^WB%+&OKTM/@.Y=#KL47] 880^85<U/M]"3O7X
M4P/H3W*> HR"^LA6(#VB")I*BO2UZQ@TM0?CP"16?_(%&P98=7V++!80QA#=
MGYORZF&S$C0I^LHVVY(I9G]XX(COT7UX\3^JHB[X^)1S-KT4Q/.FZ_\!P7ZM
M2,KY*40])<Q.&D@#V9W6ME\-JO8M$U$P4G:C#1,IC.R=%?-XZ $5)4XB>@Y#
M*BQ]#W%<P-QT]W*=XQ>4E!5FKK$M>P2LON4M\C99;4&:2&0T36@]Z9FGM>X7
M</N6[VB>W%6H_F1&RDTZHUMIM7Y!27M@$1N$ZD\BILJ:1;,66^X":!]DYW1T
MYEN20\L5?1V9/TF<*K)OW$9$+TU8C.!K%)*)K"7Q*J\(NL?'/;=G .;'A19P
M23[H?@7>.$VN:1V%TW.R*C>,^^C9,8^TXSYZW%-,EL3[G=!!MWM/\!9)G,=:
M.P!NQYYI%=?1X]]FMBV\/X$W[&!)C,D41>>K\_=EF_N07M%, 2U193&YK/DV
MG"!IA(&-UX%&74>1,!@6.,"LX/<F,NB#C"A?0EZ<#RT/LU%68D9@?W2'Z51<
M&XWSFA-J,3.\IP&W=\=1_&V!,B ?0YQJU\ZP*L<Y)A'Y:L1M/@7XO#-YE AC
M Q%'/WE@P83%^#K-O^_=G3C=OHORA$TMDKZ=? !MBX1_42]+XOVV2,S>B=/M
MVSF=;66I]+E%O25 O+%:VMZ]TCUV=9.$HJ8YZP8'B3=[?P.\^++O-DB0ASOH
M6U22-?P>YZ\)[ W.WW^&N?@F6Y0C'49E\EI?W2>_E%Z_,]"A=R?2_$6N*3YO
MMML-([R.G486-=4ZE\--:!ZE&*R<@)! E2Q*4K0F\5-N[G.U\3I0O=,H!+.#
MQ9Z&O$F28'N+M/UL\"4Y#2JSQY2.DZW6@C=7$UVB*491(F-TM1DY//TS\;B-
MW9O[BJYSC))1=E%A3 Z GW (HRPB<LVK(?^<812F$F>93C>@ :>S]Z[9U]>-
M/PD<][4!,\QB&BQSGP-<5":8;F?/40;\*=SUH]$+*,!I0-FN!X>V:DQD<K!O
M$EI4/Q].\@KP7U?$D7M#8B:G*"J7Y0(?2#'FXN<I":><B\H).&W7*2!V>C"R
MJ\%@2E/6;IE:XKW+.(&2)!.-%W:L^CB@<'JNLDN^]73B3\Z*VQLFNB=.,]EW
MO3HT5) _=V7!7 9C^8]9);3K) M!8]F(ED 3.0T$CP%$IW'(NQX#<EU82T,A
MH?+P-C2[::& G>Q-5B+X4SF+Z'A HQ#'5!S]5<%,[Z #IX7,=KIHF%29/ZDM
MH"DP@ ITB>K_KNAF%J*LX&A4[P2T^Z>R,70UXT^.R[;D,)2II#0H'[0(^L)?
MD_ Y2<4%$#5[@B_$Z7&$+F6JQ"N ]B</9EO\8111VTAXJ:W.XP#9J4?9%L\\
MI/[<7K8M\PTL4AF\39RN*'P.0#IU+-NB<PNB/_>9\<<>[$C(P"-%K*,(5RB>
M3S2Z!*MT"&IQZE2V_2'+L?MSSQE#%[/;,R/J R^;#@1^-Z "IULZ6_3+$'MU
M<9KBEI7L09*L@M^6MWH9B?=A=0QJ<NI"-AY7TEH7DKO>=AF_IP;E,BFB&@V*
ME49,JWY!24Y]T&8'C %5<,:+UV&$1J:3H-<;=(^=^IM=S1X+Z!SR'4057KV\
MU*=@LVJ'#V&)[C*"!_9$Y#\DI?TU3(E7173DH-%-T#WUKK@)/VY4'QF'7 <.
M0,[(7#B[300("SH#M7J7SZ4=("S%QZ';2<WD:>VM+M9\TZ38AH!7P5,PGIW:
M_4TI81,L!<IATH&+3AVXD0\6X/L8^-N09UW<'-H=..] Y BAN+@&#:E_P(*G
M:#D=MU7JS7*K@I632.7 B<?!3MR.A:D$'4%GH$CO$N"UUU\I/@[=#AQTL[-B
M4@$K@DTA1H %C(#RG=1C*&&[2+:*4TY8GWXG,'LYC=AH2ACGR];$S:'=@8MN
MV[VX+(=)%*3EBUU_%* Z#<(P2[$:6@ZQ#AQI\R%YG>/5=8<ZCQDJ4/BH%7L"
M1?B8M=?RR]8"SQD%_KC'] : >B< W^G1N5GN=7%S:'=QP7(UG=95+\)T7BGE
M)GO)\:0NR23?L"GV /M6[PK "FJ%Z(#BL.DD%&X>SI?$XN#IC99!=^#V:@8=
M??.6708B#C4.O%9L5VI=0GISQR YG5+M!N::/3*,])%QR'7@R&++/H1% >-W
MF/]E]VDH/0^@]\C/K &)PZ,#S]1\ZB$Q$_#'Y?J=Q0Q/#CGW3/.BPDAAF6S;
M=>#X,%&?_?9H.25H'+BXB.=M&1,_<\F1+1Z(6]'BE#3MKB,8 *I=P,+EU!@V
M0QU[6.CI@$-_^V35^7)RDZV$1-5VF[(CJU$_@,OI)M@&MRT4P2%X/ORMUXZ\
M#A-,UZ%O('R%EW7G]J]6I(/%LG&I2#N'K=J5(KFG+PQY_UDG<J6FG)U#U%9E
M(OF5IH4P/DR1R)ZEO:&)&I'\TL)L'!^F0F3O: \*1.JQXV%Y2+*G7-E BF>U
M[<:!I2O([$QG'/F]J=ZX+I_2I0B\1P);MRPKSVD<9:LPLP'#F_*-9OGQ97HS
M191L=G/@-EZ8*,.B0&4!-M2*A34S6^*[[(%<-(AK2PZ,.SS_ZWE8) 5YGKK1
MGU TSI+?*U30>>8)MK+G(/MO O9W\OZ@Y]3CH64<[$XAXAJ-UHWCQV24)2])
M1"SW.HV07'F9I^2RMX)YZ\)YF)+R$H]C!(JY1&68I!J&-/LJ6Y$0(EM9_>&@
MUSL]T3MQUQ>59R*K/4A%M'0C-M-L;J"];:>0!BZOS.L"EROS,_QM<VZ&GP(2
MTC.;-3A;3D:K&J]#\UF7EC5.18!L&=*Z7'!W,\QVM?BN+F03Z5.H^0WA;=G+
M.]&]ZRVD&1+LF\5*9#Q&* MQDM]C])KD59&^/Z!I3DY8OJUM@3:XD3U6@W02
M2B >^=L$*4.Q93%K+QZ+:DY"B@1/U"NPDPVT+CLJ*+PQE6?[>X4["M8:UD"<
MY).UWK5)$'EC%-?RU26Q2V6&-MK7L-S6$F?K640*#X0W!?U9-<*HZ+?POT4I
M$I$C7:F#&KC;0GQ"0CA.=3UPWA3Z7_%Q#+.8G@FLW06O\!&J=D'!]YW$.AF;
M0+6Q^E.S?U5T/5)7,;DMM*RM?CF+F^!,%-(W3ICZBLA_J$;H-$I)I'<I4SPX
M)JK;VULA%U4T+QJMCYN/UP/;:8*- B7J2R07GS^5[;?Q:GU^-2*GN]'&C G0
M^%-+?D7(Y49+;Z;<?JY6C-/,F5:3I0"1B;+P.Y@O&YL4C!XH=K=WQ*EQTV#B
M9*#TIX([$[7N-UGC<FH1MF%/C,F?HNIJU5=72XT2#&X3O5O-D0OY_2EMOFW1
M"*C8;EPC<C+/&;.P!:@D5<H]#)RH;VY8A*'L5>C$J5[A,!>A$Z='=F8? Z$3
M5'OK(UP3UY\H=.*T8^<,TG#H1$V+\/!K%=#^ADZ<=BSE(S<-G:#Z%&I^0_C]
M#9T \3T-G= DX>.'3IPN"NK[<3A/1_XV0<I0/E;HQ&G7B6FBRXX*"ENA$TK$
MW.,\KJ+R#C\B_)I$2+"TLYI2$)9.XW>SO@M1V0J=T*&&GH75LA7"!8?;OH;C
M,EY2J&0N)P(DMN(FG!#CPX[ ,$.R[8&36(B(6/!+B;G+C^0)"K'O;',@_SAX
MOC$Q&G]B&1[0*\HJH:-RWJ26?@_"]A@> RX6?X(4%K>$+"\I%9#":$TQ'3OY
M5HSQ(X+E3WC"VDVR I+6VM4XG)0G,T8/&Y _$0:/*(4^1U]0!L,H)7?YQ1-0
M,SG/(/>W7[U-R;0L.@E0ZH B=W.F;8Q*3:3^1"E<A3@#P4G90WI'-TD7C4#^
MRR2MRN4I!.MJ(O&3%.O R>FH,595(4I"%SP\ %H<_9 [6^C]2\5--KOZ\1)D
M@P>SZ'VOSH4&>C=!N3@7&ECR7QLX%QILYY]IXOH3G0L-+%W]8MAO-)![]E8!
M[>^YT,"6P[OIN1#5I^*1Q(#OXMZ'<R$0WP<O4'L2/OZYT,"SDP<Z\IN="PWX
MQP_[>BXTL%1OPS [*BB\2:E=;'/KB*V+?#+-,[+K5:U%R7J.P#P[VHO($,8.
M0 ^B-QFX&U)*BX@QV]>P7,60Z&F>8Y$*87F3DVN2+=>["]NT>7C@]$#L_@S%
M<_^']+R)_0 %V'&:8B3^7GBG&D(P_IPV-7:<#VR5(#+IEV-X),2 _#E\,A N
M/^CM0;B\@"(!*LG)DX?>TKN7^3T&^U5E\*RO90RY<(F>];QUB5+M-76)4EQ_
M(I?H6=].!K]A@ZBF1<4E2@'MKTOTS%:83U.7*-6GHC?NC!_5LP\N41#?M=%B
MAH2/[Q(]Z_OE$J4COYE+E$+Y6"[1,S<5173944'AC4NTL=%XYN8ZW=9[-C$@
M;QR<VY>X"\LK")C3[*E6Q1Z$7PFX;0K9&X<IYS[O10!GF\O0&9T$O7Z_U]D#
M)Y#X>]9%ZXV#56V\TCJ-K3]TV@NHX/C(3?7*'7_DZW ESEJWOJ;Y'HZ$BQ;U
MS@'%>^1@@J_J1&NEW+V#B8AH)U:KM8-IIKUF#J89KC^-@XG@W0,'TYP6N8-I
M!FA?'4Q$?*\<3#-]*ODV9L+OJX.)BN^E@TF;!$\<3(8=%P2:3VZEV7C7=%S,
M4#CU*%GS_!%P3@(3="E2AN*-@VF'U3,)=">WQ+3>YS6%ZHV[:C-(!E103:HT
MI!8,R1\2$2Q_N ;L?7JGD%L-E#[?O'@;XCJ)<7\LTX'?F6"G=G;.;2W20=,,
M,(+'I25:S+52H.B'4?X*WTM2SV3PA\T)#'X*OJ)1F%X!DO*=8X0R6@6G_A<+
M.MW:0_" &#(\M55?B\$U>3:;!*>NBO_P%+>MWBUY#1F6.]"M:RNRL9*-&H[,
M!>!^MDJ>)_G3&.%PBJHRB0IRA(AA TYO4^8:(7H=!&=.RHPPQ^[V J")PY:]
MJ!^$6ST7Z/>*!.R_PO\]P?MD63_L)P)+M<3M3OPJH+RQ&1E"2G-&N,\$MJI.
MJ&?X"'2NS-(*&&^L/M,\N5Y_[! F6YP<Q!<0^>Y>AF#)92/1X8NP?6"IA/]N
M)D(^)&_" E:$(T7R;D&>Y2]/\*<BC(B4\H0LS9Z"4TN%Z)2G3#X[;#:; /0G
M<\LET;[,N?89E\W#>JEA3"MA.*&^MON7Y ^$AR.,D/#H2/9(<.;T&LLF']6V
MP2 %:*+T().-<QS^D:1J-##;!@,GQPEF]<]'9J*T(-M8UAC_['$Q<.+K-ZMX
M/C(3]?Z8BK].\@A7?P@5OM8FZ'9[QV=.KYPSHVPV*A.7"#(5?3&&+6;R\Z/:
M&.>T#KK'Q[WN!YAB9/A,W/0GH.'J38\(1OM:U \PZ<@16KO*3RVVAB 2A?K-
M_ST8[*-UN0W!VJU]ZNH6ARXM6P0#5V;?MMHX:ET15'+-GF>*=6UFZ6M89BYU
MVQO*2IK^!HJ:5!.AKM?:!&=.EE36&-W6\;:D'.WN* #[6_@FU^YJF^#,R2JI
MJ-TM23G:W5%(]059-A">AKA\OPTGHH6/U30X];^L''L-Y*+A\+&S,.MIA:-Q
M6*#%[FA34DGXM>+SP9FEB%^EI92K?<:<KX6(P][.XK)WQYX/Z[4E&J4+^ZZB
MN>=1SU]0/L+A= SS3"J8(;GM@U,[2Y+]:5(,B4//CB[4>ZQC]58E$WY=W/;!
MP)(76VDN%*N808D0!H>2'1G/)BGQ88(SR8UT5FML<<_C[>B'C=\)3:?SOQ"6
M3E=8FOT<G#\P*%G^8^#&Y2H?W^LZWQ"8HU@')^.+@3//AU$MX+S:/ACXGT(J
M".3B0N+$FSHXUYZ+]G-63%$$4%$LCP_B/1.<N0Y*X*N<0Y$0"H<F%_5)#=/D
M>FFQP9=L>>FU]RCHAXW A!&3NZ>25_2(H@K3\B97;U%:Q2B^!GV02L=526-R
M[UZVKJ]Z9W<@F4LMOC48V(E\WLV,;%LQG('GX"9 MJ!"^UOUT>#,4AZN\BQO
MFT:=P;.A%\X(<'!/H-T1X,L"XNU0D*Y&#A(L+O(,UL^RS@!Y2(K?SM_/41:-
M)R'^3;*DR!X-!ON<<J&$CL.CFX3]#7'GPDH_;=FCP9GK5 PE+E1I9(#CT.@@
M-\,NC;[,T';YE$ZS6CXE9@33[,22)M[56=)W+Y?H%:7YM';B%V7QE%_DKPC#
MLO*?*.2%-NEW%'1LW7UDK*(".P>]*50.B5K^*W:\*ZPB\.)P1"+88Q@P7\(J
M&L/;86R1<*XGC$B9!U+58YB^A"1_<@10$0Z9]V6W[1+0.HD;;TUL>]"<]%\'
MOB_8&4[RC-Y[<A_B.TR=$?$O85JA^?Y0. 5+GP; OE=@WF99&Q^'4 =>LI;&
MP'!"U&3/KU+W#TISDCQN9% 8U !GV+3/*;G(4^ NKTO@K(3L/L#ZDU5$VBFY
M+Z@@$A'XBQF-,\\W[@]P^EZDFSW)MT3,8;9]TLIC-9VFY&ZX24(+W]UD9.=
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M6._8)Z*0SO%"YD#2![:YFN_+-K=K):;;FHNMJDJMM>/<ZHE#OCV0HIQ'>:#
MG34X*[[4;3!K]9@<CJ11B::S1U1]H !VIS]4N,A!0E.U7"HR_X\W+P&1@9V@
M+/$SU&2/D^,X\B&J)LN[P OO@Q"G61Q)0]3^V#LRWC/Z0VO5A4U#D%OA#D<1
M)7]$/H#*+Z#R$T,Q^',AH_($@\!+%Q?1(V[HJ]9025I^% E3-9V\*R@B(4%2
MH@C"@$V)HMWI@SVM9%E(L8CF.%MYA+=V"U5)86N]JI2:6Z+F8=,B@C?0$"48
MP!ZG0=?7EJ&6^MUHY=FJ_YNG=/EP>"GR&D=VVT,&[[Y'9)128.OH-&X60;EE
M8GVW012D+]C_$,=^2G0%/Y#BY%4X;;:BMOK(E8DV_)-/.=4(%72($M*'!&&P
M"F(W#PEVT^JDRC.T=OMXE3'&^$>KC 'FP&:6WN=[CPPAF:W:FXR"V(7%J'11
M& PA0R>ZH=E+&YU D5W1>!#6HD67U%BTT')@*[_&R1^SB.[CINV-147MPEJ4
MVBC,!>A@!SJG')K!M%*KT&6?Q&2]GP[#:/0PDUJ-'F/VS.;6"Y*/7GC U\?3
MC[\$."'=\G*\@VT7S24,4P86C<=8)RZ2(:T1;3Y")P+)38RSM3!\$-&*,C8M
MJ!WBFD;4#FX.[.@>>RE9;\%J+.4EU-XW:<G'A549:BC'8Q6.DALHUJW+AE).
MK*P-'J7&U@:,#FQN%NT/64JM_T?M,S=**A?V))1>Y<T9P0A1$O2CM"R)=2.Z
MF"9.+$>.*JF=R"'5/=</$@L?XB#*;H-77.X)3F(23B990,_*,RQ_WJD+$ULY
M@6UUX_($@0&B'!"PJ.Q HPH31+E<SDZ4:Y]>%/WAW0_O-5I8RX+L!,A:9F0G
M-'9_CJ*PSG&:'G9[^M857!B]33 Q6#)V.,V67B8]MFU!;^L9BQ8:*2*6"C6[
M&0STJ&" * ?;<\JYZE$]MJ!'0EHX>[^C+>1J;WLXP9O1NQ]G#LP5'9B@ !B,
M$/).K- A95F3K^03D&7E1>1?:98<^LOP$&D %P V&?8_QB%1/@RR8UMO(.7@
MT!_(M3+T" 4#5'(8EDLPU[!L,22'H,&=SB78 %U7IV ^-/G*$K:F_2#=DT"*
MT(_H;F\9RA%_L4O1&TCL (?@D>X>T6-O^-GW$A\2Q(+\9F%"_$<20)OO1C07
MQ$// 82):19O_D#[)-BXNI%*;_$]@ "*]6FUD<VR=U79N#@;_HCH7UTM,M7R
ME4.+WCRN;KYS6GJ/&V6NUAXWQ+U.:&MB+BUF+];<X525RVLX+T'KH4Q!$LE/
M4R<X+O0&+DJE3B!I@A#=/-,[/+I.*I+.)NO'(/;I=%!&BR.(*^'$$[+VO2<6
MO00IO9G)1B9&3V36.61T"B'1)IUSOGV(?HONHYMU] OYS^I;F#]V7L;F$?S%
MV^U#,O-\^_#^M[^_?__CS;?56W(@ /EGG #[K;>AQZUQA.D].<(!MB=V<92]
MI".:@)B]!*0IF9=\[]A3XJ%J*KX)7@,?1W[7V+9!/X#(MJE1V[BVH!]F5*O3
M[K< A_Z0?(H2:*;![.50=FXHJQN/$ZS\O&&:^YB]%U!W\Q*'/@EOP2N JZ 7
M&,(CK'/AFCA.P5=M@X@$KI"37+HR$O@2KP5Y#X2Y(+^3QL$T/LO#8T;V;<KB
MH>\<Q;J5(R.Z*[XF']2D$LA)+,;!"KDE:Y?\?CIIBZ#Q ([8=7W?C$=U'>\6
M-=HS<Q618^1(#XYEV!G T;%^#$SPTU,5QOI9P7_B)):?%\ A28MC,'-F3H[#
M6NBJ/18#7NJS,7K Y.H@N5?E__'[OW_W?X0:OO^'P1P!GJ'?8(\"VQJG_$C0
MB64:%5(9HH5:K:-<"'6#G[)3N'P3I)LPABE 4ZY;3VVWFK*!-H*"RJ>! ;(1
MJJPS*Z2.:RJ;CI.@K++I(-G#'4@R.ZUL;KV-OCBCG,0BPA1R-V$%3=&LLG\%
MK0=0#U'7]4W\Z/K=%6BJQ]/TB21?>2FW"Q-GP-+HIH5:+>-CA!@+QY=YNX^B
M&I$F0^@*HTOL8[;KQ/:T-=LE)L3.,"G118O%DFZ$\IU]]_LIYL.D!I]JC(8"
M.NUNBQGY8( GW8$Q@MX MF/:#%<[^/6T17-+1M1X3?3^3\H=FHZ\;)U&==24
M.YDB?-HN_M[_R>'F15^*4S6&L7=Q%FIKQUG.(6MTM#4\Z-J=\9A@D%V6BXC]
MTC/2A)QTEJ8'[+_7S'UM&%F>!5OI*)P/2PXC=.)1FR49&\3XN)X7VP^J:(9L
M/Z*N@K6)ER1P9-QR^Z-)YBPXX^1O@O NCIZO:-84VUO[D,1N[_N;]+\ZZA)W
MOBOGMTB"YR#R0O@MD\C<WPEIG;DXL29:KU:0Y0 ;Q@Z;T?BH79=B<#I']DN<
MUQ5+H40%+!8(CAL[Q.N7)#X\O\PQ%+/PDN/M(?)E^65G\+,4X9^CL:!$6\Z+
M%5[)N=5") K/G"$Z<424I:O(^.Q1KT;'PQARDPBYSZ&'*I4;+WV!!--M&']F
M#R#E&:)YJ3YX38O\LT!%)145_A2>)D(?(%+F=1$N#"W1"2U0WCI%_H&^-0(?
M@8Q35U<<#D\I_LN!"#J%:C?:V_B2]C8O/D@DYM\D*=HAVG 0E]65W<U=.U#U
M=?=JI]O@KSA1[NK4F]BJ9UJ7BTL;IW]VO@TAZKU:A5)!UYV13!62)L^TM*$F
M48IO:"T)2B!C<_#H7YV/G;P[ZZDM%^U+L[05@S[-&[&"I(@U<S.'3'?[,#YB
M3&]U+>B&M78>4=!8G$M4DG,)XWE;Q"ZOL=;.:[FTT2 7.8O1GDCSXN4OGF$:
M[T)][;BX=#F$J5*+JN9TJ864Y8NCUZ2#H4PZO"U'K;WRF-WUL6R2%Y(>?_82
M_RZ(\"S#.]4Y<A_,;5]4/;<OA!=<KYZ !%79UAYX?#JB:KNB!#IECCX!>T3Y
MNXT(>X.*\-9J+SBQ;#A/>IF?FC)/O^R#Q"O/2G7VT\\W;)M13SW3NS6-4/F5
M_"S>N4WUB2*A:?4)H>Y+A*Y&_H&TR&Z\#)]21F5KBSZ_8&M1TFNOB*LK7*O-
MY3HWE[Q=??*AGT'PG4HVLK-E4?\0JJVG!HH?HX68!1PQ=[JIXLBKN]VTTN[T
M< C%T3/%D0\XV@*.H!*3TV(I7?K*]!;O)4)B\V]_#1%SBYZ\0 @@OK\_DES@
M=QX?V(!J;R%Y6YQ^Y69?KT-EV_";7__:39_K31?&WZA*]S_._,60M>( Q'C]
M2EV J#ZE+0<@_O;7:OZ2GK1H_)(BM?]C;%^%U8M:O@JH7X'=L\WYE"Z2TEF^
M%4)3!R]AZ:JO?0VVK>RM"UCSHC!?]D7Z*A7]Y@#2.R\(N=X,5H^WK\!$Z?]]
M)*XEB)Z9!JJ\TWX_\S48I;A_+F"-;,,P_])0]M9[1E1OIJ> TX!L+FWE.7[%
MP?,+B?+'KSCQGO'T"[R"G9J5);8EQ9 LMM?>[6+0:??YM9 &Y>*@0AYQ+>=!
MV7W_J&[M%OJ'M#VOL0ZR$"^VLXC6HSQXNG<<)>TM6J),8BZY&MI!BE'9<@ U
M I3]W42>LK,=8N37('M9XI#:0?H2[-?Q-,J"3/]L86M.+G&EU9*_R5$VAG0W
MUGP0U0$Z#J$6D&;CUSG-@#C'S2$+7K$R#9EK9>FXGY>.K_:;MW">A"SIR>J)
M^26[T>34VZ [\U3+M.U1LQI<B^V6S+V).M==VMHVV#AIY: KF@X'?>*N%J)0
MV,],_CM"Q/Y%?H!@]U_^/U!+ P04    " "'.G)./"L6;QXO   J^0( %
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M/M9M@1@;9?JH"-#5/7%<F^3N*-#/\=(Z :!J$O,:(,YN@2,NX:"N1ENQC7(
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MTPQ(#WG-.;3NV$OG?3Q9^P!3)6,V'?!+A@\9B(H4,>4'AW.2DM?8X %;BU9
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MXU8WQ/E79KIU35LO:&$_U*"6V^X*9P9I?^/B\ ;8+1'-]-3;-1"T_+6I[NI
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M)LOD[>I.C2\WU8W7Q\V^B]FSSDF Q-YRSW>6YZ1@1H2UVY#S$\'@/GTD[/6
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M,C Q.# Y,S N>'-D4$L! A0#%     @ ASIR3F*5?:D>"0  KG<  !0
M         ( !R+X  '!L>"TR,#$X,#DS,%]C86PN>&UL4$L! A0#%     @
MASIR3J_=N$[Q*0  L(\" !0              ( !&,@  '!L>"TR,#$X,#DS
M,%]D968N>&UL4$L! A0#%     @ ASIR3JA]'+@:.P  ,O," !0
M     ( !._(  '!L>"TR,#$X,#DS,%]L86(N>&UL4$L! A0#%     @ ASIR
M3CPK%F\>+P  *OD" !0              ( !ART! '!L>"TR,#$X,#DS,%]P
<<F4N>&UL4$L%!@     &  8 A $  -=< 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
